Purdue University

Purdue e-Pubs
Open Access Dissertations

Theses and Dissertations

Fall 2014

Nano-engineered polymers in drug delivery:
Potential approaches for attenuation of secondary
injury after spinal cord trauma
Wen Gao
Purdue University

Follow this and additional works at: https://docs.lib.purdue.edu/open_access_dissertations
Part of the Biology Commons, Nanoscience and Nanotechnology Commons, and the
Neuroscience and Neurobiology Commons
Recommended Citation
Gao, Wen, "Nano-engineered polymers in drug delivery: Potential approaches for attenuation of secondary injury after spinal cord
trauma" (2014). Open Access Dissertations. 457.
https://docs.lib.purdue.edu/open_access_dissertations/457

This document has been made available through Purdue e-Pubs, a service of the Purdue University Libraries. Please contact epubs@purdue.edu for
additional information.

Graduate School Form 30
(Updated 1112012014)

PT]RI}TIE UNTVERSITY
GRADUATE SCHOOL
Thesis/Dissertation Acceptance
This is to certifu that the thesis/dissertation prepared

By Wen Gao
Entitled

NANO-ENGINEERED POLYMERS IN DRUG DELIYERY: POTENTIAL APPROACHES FOR
ATTENUATION OF SECONDARY INJI.ITY AFTER SPINAL CORD TRAUMA

For the degree

of

Doctor of Philosophy

ls approved by the final examining committee:
Richard B.

Borgens

Jianming Li

Stephen R.

Byrn

Linjie Pan

Youngnam Cho

-

To the best of my knowledge and as understood by the student in the Thesis/Dissertation Agreement,

Publication Delay, and Certification/Disclaimer (Graduate School Form 32), this thesis/dissertation
adheres to

the provisions of Purdue University's "Policy on Integrity in Reseatch"

and the use

copyrighted material.
Richard B. Borgens

Approved by Major Professor(s):

Approved by: Laurie A. Jaeger
Head

ofthe Departrnent Graduate Progtam

t2/08/2014

of

1

NANO-ENGINEERED POLYMERS IN DRUG DELIVERY:
POTENTIAL APPROACHES FOR ATTENUATION OF SECONDARY INJURY
AFTER SPINAL CORD TRAUMA

A Dissertation
Submitted to the Faculty
of
Purdue University
by
Wen Gao

In Partial Fulfillment of the
Requirements for the Degree
of
Doctor of Philosophy

December 2014
Purdue University
West Lafayette, Indiana

ii

To my lovely parents and husband,
With all the love and support there could possibly be.

iii

ACKNOWLEDGMENTS

I gratefully appreciate the greatest opportunity that Dr. Richard Borgens offered to me.
His encouragement and support allow me to become an independent thinker and
researcher. Also, I would like to thank Dr. Jianming Li for the guidance and great help
during my graduate study and Dr. Youngnam Cho for the inspiration of my earlier
experiment design. I also want to thank John Cirillo for all the technical assistance on
generator design, Michel Schweinsberg for the amazing figures, and especially Judy
Grimmer and Jennifer Danaher for their continuous help. At last, I want to give my
appreciation to Purdue University Birck Nanotechnology Center and many their
engineering staff and staff scientists as well as Chia-Ping Huang from Life Science
Microscopy Facility.

iv

TABLE OF CONTENTS

Page
LIST OF TABLES ............................................................................................................. ix
LIST OF FIGURES ............................................................................................................ x
ABSTRACT...................................................................................................................... xii
CHAPTER 1. SPINAL CORD INJURY AND ITS POTENTIAL TREATMENTS AT
A GLANCE................ ........................................................................................................ 1
1.1

Spinal Cord Injury and Animal Models in Experimental Study ............................... 1

1.2

Secondary Injury in Spinal Cord Trauma ................................................................. 3

1.3

Possible Treatments for Secondary Injury ................................................................ 6

1.4

Biomaterials in Spinal Cord Injury Studies............................................................. 11

1.5

Goal of Current Study ............................................................................................. 13

CHAPTER 2. POLYPYRROLE DRUG RELEASE VIA NON-INVASIVE
ELECTROMAGNETIC STIMULATION ...................................................................... 14
2.1

Introduction ............................................................................................................. 14
2.1.1

Overview of Conductive Polymers in Neuroscience Study .......................... 14

2.1.2

Electrochemistry for Polypyrrole .................................................................. 16

2.1.2.1 Electropolymerization of Polypyrrole ...................................................... 16
2.1.2.2 Doping and Releasing Processes of Polypyrrole ...................................... 18
2.1.2.3 The Effects of Different Parameters During Eletropolymerization .......... 20

2.2

2.1.3

Conductive Polymer Based Drug Delivery System....................................... 22

2.1.4

Synthesis Techniques for 3D Nanostructure ................................................. 24

Method and Materials .............................................................................................. 25
2.2.1

Template Preparation for Polypyrrole Polymerization .................................. 25

2.2.2

Fabrication of Dexamethasone Doped Polypyrrole Carriers ......................... 25

v
Page
2.2.3

Morphology of Polypyrrole Nanowires Imaged by Scanning and

Transmission Electron Microscopy ........................................................................... 27

2.3

2.4

2.2.4

Electromagnetic Stimulation ......................................................................... 28

2.2.5

Drug Release .................................................................................................. 30

2.2.6

On-Demand Dexamethasone Release............................................................ 31

2.2.7

Temperature Effect on Drug Release ............................................................ 31

2.2.8

XPS Analysis ................................................................................................. 31

2.2.9

Statistical Analysis......................................................................................... 32

Results ..................................................................................................................... 32
2.3.1

Stucture of Polypyrrole Nanowires ............................................................... 32

2.3.2

Comparisons of Drug release......................................................................... 34

2.3.3

The Influence of Temperature Elevation on Drug Release ........................... 37

2.3.4

XPS Confirmation of Dexamethasone Release ............................................. 38

Discussion ............................................................................................................... 40

CHAPTER 3. DESIGN AND SELECTION OF ELECTROMAGNETIC FIELD
GENERATOR ................................................................................................................ 44
3.1

3.2

3.3

3.4

Introduction ............................................................................................................. 44
3.1.1

Time-Varying Electromagnetic Fields .......................................................... 44

3.1.2

Electrochemical Techniques Used for Polypyrrole Based Drug Release ...... 46

3.1.3

Electromagnetic Field in Biological and Medical Studies ............................ 51

Methods and Materials ............................................................................................ 53
3.2.1

Configuration of the Electromagnetic Field Stimulator ................................ 53

3.2.2

Electromagnetic Field Measurements............................................................ 54

3.2.3

Antenna Gain Equations ................................................................................ 55

Results ..................................................................................................................... 57
3.3.1

Electromagnetic Field Characteristics ........................................................... 57

3.3.2

Drug Release by Square Waveform Stimulation … ...................................... 59

3.3.3

Drug Release Using Sawtooth Waveform ..................................................... 60

Discussion ............................................................................................................... 62

vi
Page
CHAPTER 4. ATTENUATION OF SECONDARY INJURY BY
ELECTROMAGNETIC RESPONSIVE POLYPYRROLE DRUG DELIVERY ........... 64
4.1

Introduction ............................................................................................................. 64
4.1.1

Cellular, Molecular, and Biochemical Cascades in Spinal Cord Injury ........ 64

4.1.1.1 ROS and RNS ........................................................................................... 64
4.1.1.2 ROS and RNS Associated Mitogen-activated Protein Kinases Signaling
Pathways...................................................................................................................66

4.2

4.3

4.4

4.1.2

Evidence of Neuronal Recovery by Inhibition of iNOS and ROS ................ 68

4.1.3

Glial Cells in Spinal Cord Injury ................................................................... 71

4.1.4

In Vivo Applications...................................................................................... 73

Materials and Methods ............................................................................................ 75
4.2.1

ROS Production in Challenged and Treated Microglial Cells....................... 75

4.2.2

Immunofluorescence Labeling Assay............................................................ 77

4.2.3

Surgical and Treatment Procedures ............................................................... 77

4.2.4

Whole Animal Bioluminescent Imaging ....................................................... 79

4.2.5

Statistical Analysis......................................................................................... 79

Results ..................................................................................................................... 80
4.3.1

ROS Detection ............................................................................................... 80

4.3.2

iNOS Suppression by Dexamethasone Release ............................................. 82

4.3.3

Selection of Animal Injury Model ................................................................. 85

4.3.4

Neuroinflammation Attenuation by Drug Loaded Polypyrrole Implant ....... 87

Discussion ............................................................................................................... 92

CHAPTER 5. SYNTHESIS AND CHARACTERISTICS OF SIRNAS CONJUGATED
CHITOSAN NANOPARTICLES .................................................................................... 99
5.1

Introduction ............................................................................................................. 99
5.1.1

Evolution of Post-transcriptional Gene Silencing ......................................... 99

5.1.2

Pros and Cons of SiRNAs Therapeutic Strategies ....................................... 101

5.1.3

SiRNAs Inhibition in Spinal Cord Trauma ................................................. 103

5.1.4

SiRNAs Delivery Strategies ........................................................................ 104

vii
Page
5.1.5
5.2

5.3

5.4

Types and Modification of Chitosan for SiRNAs Delivery ........................ 107

Material and Methods ............................................................................................ 109
5.2.1

Synthesis of SiRNAs Conjugated Chitosan Nanoparticles ......................... 109

5.2.2

Transmission Electron Microscopy ............................................................. 111

5.2.3

Size and Surface Charge of Nanoparticles ................................................ 111

5.2.4

Gel Retardation Assay ................................................................................. 111

5.2.5

Toxicity Studies ........................................................................................... 112

Results ................................................................................................................... 112
5.3.1

Chitosan Nanoparticles Morphology ........................................................... 112

5.3.2

Particle Size and Surface Charge ................................................................. 115

5.3.3

Binding Affinity Between SiRNAs and Chitosan Nanoparticles ................ 117

5.3.4

Low Cytotoxicity of Chitosan Nanoparticles .............................................. 118

Discussion ............................................................................................................. 121

CHAPTER 6. PREVENTING CELL DEATH AFTER SPINAL CORD INJURY VIA
TARGETED SIRNAS DELIVERY ............................................................................... 127
6.1

6.2

Introduction ........................................................................................................... 127
6.1.1

Macrophages Polarization and Their Role in Spinal Cord Injury ............... 127

6.1.2

Route of Administration for SiRNAs Delivery ........................................... 129

6.1.3

Nanoparticles Targeting Strategies to Macrophages via Fc Receptor ......... 130

6.1.4

Targeting Macrophages in Spinal Cord ....................................................... 135

Materials and Methods .......................................................................................... 136
6.2.1

Cell Culture.................................................................................................. 136

6.2.2

Light Microscopic Studies on M1 and M2 Macrophages Morphology ...... 137

6.2.3

In Vitro Experiment ..................................................................................... 137

6.2.4

Transfection Efficiency ............................................................................... 138

6.2.5

Western Blot Analysis of Gene Silencing ................................................... 138

6.2.6

NO Assay ..................................................................................................... 139

6.2.7

In Vivo Experiment ..................................................................................... 140

6.2.8

Western Blot Analysis for Spinal Cord Extracts ......................................... 140

viii
Page
6.2.10 Statistical Analysis....................................................................................... 141
6.3

6.4

Results ................................................................................................................... 142
6.3.1

Divergent Morphologies of M1 and M2 Macrophages ............................... 142

6.3.2

Efficient Transfection of SiRNA Conjugated Chitosan Nanoparticles ....... 143

6.3.3

Protein Knockdown ..................................................................................... 146

6.3.4

NO Recudtion .............................................................................................. 150

6.3.5

Inhibition of Apoptosis Pathway After Spinal Cord Injury ......................... 152

Discussion ............................................................................................................. 154

CHAPTER 7. FUTURE STUDIES .............................................................................. 163
BIBLIOGRAPHY ........................................................................................................... 167
VITA................................ ............................................................................................... 193

ix

LIST OF TABLES

Table ..............................................................................................................................Page
1.1

Spinal cord stimulators development in clinical trails ........................................... 10

3.1

Polypyrrole based drug release .............................................................................. 47

4.1

iNOS inhibitors and their neuroprotective results ................................................. 70

4.2

Glial responses after SCI ....................................................................................... 72

5.1

Size distribution and surface charge of different siRNAs conjugated chitosan

nanoparticles ................................................................................................................... 116
6.1

Summary of human and mouse Fc Receptors...................................................... 134

x

LIST OF FIGURES

Figure .............................................................................................................................Page
2.1

Polymerization of Ppy............................................................................................. 17

2.2

Neutral, Polaron, and Bipolaron state of Ppy ......................................................... 17

2.3

Redox reaction and overoxidation of Ppy............................................................... 20

2.4

PpyNWs fabrication processes ............................................................................... 27

2.5

Stimulation scheme for the application of EMFs ................................................... 29

2.6

Scanning electron micrograph of PpyNWs............................................................. 33

2.7

Transmission electron micrograph of PpyNWs with inclusion of AuNps ............. 34

2.8

DEX release using various Ppy platforms and stimulation methods ...................... 35

2.9

DEX release profiles of flat Ppy as a function of temperature and its comparison to

that of with and without EMF stimulation ........................................................................ 37
2.10 XPS spectra for surface analysis of DEX presence on Ppy templates before and
after EMF stimulation ....................................................................................................... 39
2.11 High magnification of TEM image depicts the successful fabrication of PpyNWs
through entire film ............................................................................................................ 41
3.1

Ampere's Law and Faraday's Law .......................................................................... 45

3.2

Illustration of Cyclic Voltammetry and Potential Step techniques ......................... 50

3.3

Schematic figure for three-way square waveform generator .................................. 56

3.4

Schematic figure for sawtooth generator ................................................................ 57

3.5

The input signal generated by asymmetric square waveform ................................. 58

3.6

Illustration of input signals in the case of pulse train (left) and symmetric

waveform (right). .............................................................................................................. 59
3.7

Comparison of DEX release from flat Ppy – AuNps film using pulse train,

asymmetric, and symmetric waveforms ........................................................................... 60

xi
Figure .............................................................................................................................Page
3.8

Illustrations of the input signal of magnetic field (right) and electrical field (left)

for sawtooth waveform ..................................................................................................... 61
3.9

DEX release comparison between EMF stimulator with sawtooth waveform (blue)

and with pulsed square waveform configuration (green) ................................................. 61
4.1

Composite fluorescence signals and quantitative measurement of ROS ................ 81

4.2

Confocal images of the iNOS expression after LPS induction and DEX treatment in

BV-2 cells ......................................................................................................................... 84
4.3

Illustration of spinal cord injury procedures and EMF stimulation set-up ............. 86

4.4

Luciferin and luciferase reaction based bioluminescence imaging ........................ 88

4.5

Bioluminescent images of mice in control, Ppy control, and Ppy treatment groups

........................................................................................................................................... 90
4.6

Quantitative data of GFAP expression based on bioluminescent results ............... 91

5.1

Transmission electron microscopy images of different siRNAs conjugated chitosan

Nanoparticles .................................................................................................................. 114
5.2

Gel retardation assay indicating the integrity of Chitosan Nanoparticles............. 118

5.3

Morphology images of macrophages after treatment of siRNAs and different

siRNA conjugated chitosan Nanoparticles ..................................................................... 120
6.1

Macrophage morphology of inactivated macrophages (control), activated M2

macrophages, and activated M1 macrophages................................................................ 143
6.2

Illustration of transfection efficiency of siRNAs and siRNA conjugated Ab-

chitosan Nanoparticles .................................................................................................... 145
6.3

Screening of siRNAs for silencing of iNOS mRNA expression .......................... 147

6.4

Knockdown of iNOS protein activity ................................................................... 149

6.5

NO production of macrophages ........................................................................... 151

6.6

NO production using scrambled siRNAs .............................................................. 151

6.7

Different proteins expression level after SCI with and without treatment of

different chitosan Nanoparticles carried siRNAs ........................................................... 153
7.1

SEM image of single cell on Ppy nanotube structure ............................................ 164

7.2

SEM images of cell adhesion on flat Ppy and PpyNWs ........................................ 165

xii

ABSTRACT

Gao, Wen. Ph.D., Purdue University, December 2014. Nano-engineered Polymers in
Drug Delivery: Potential Approaches for Attenuation of Secondary Injury After Spinal
Cord Trauma. Major Professor: Dr. Richard B. Borgens.

Secondary injury elicits a complex series of pathophysiological events after the primary
spinal cord trauma and even after its implantation treatment for neural functional
recovery. These secondary injuries include an up-regulation of glial cells associated
reactive oxygen species, nitrogen species, and reactive astrogliosis, and they can result in
various levels of cellular and tissue damage. The inhibition of them has been proved to
lead to functional recovery of the spinal cord. In this study, we concentrated on
developing polymers and nano-techniques based drug delivery strategies to eliminate
these secondary injuries.
To maintain and improve the performance of the implants during treatment, we exploited
the polypyrrole as a suitable material to carry and locally release the drug at the injured
spinal cord based on its conductive characteristics.

We focused on the geometric

modulation of implants materials on a nano-size scale and developed a polypyrrole
nanowire platform that can served as a high capacity drug reservoir and can release drugs
in a relatively longer time. Most importantly, we introduced the electromagnetic
responsive feature of polypyrrole for drug delivery. This valuable technique can help us

xiii
to achieve a non-invasive and remotely controlled drug release in deep tissues and avoid
the physical contacts commonly required during traditional electrical stimulation. We
used dexamethasone as a drug cargo, since this drug is commonly used for antiinflammation treatment and has been successfully delivered from polypyrrole using
conventional electrical stimulation methods in earlier studies. According to the results,
we showed successful and long lasting polypyrrole mediated drug release under
electromagnetic stimulation and the released drugs remained bioactivity and can be used
for the treatment of secondary injury.
We also introduced a gene silencing strategies by delivering siRNA conjugated chitosan
nanoparticles to the spinal cord lesion. These siRNAs can specifically knockdown
inducible nitric oxide synthase and subsequently eliminate nitric oxide induced secondary
injury. This drug delivery system were designed to discriminate different macrophages
which have divergent effects to spinal cord recovery and to target the specific proinflammatory

macrophages

(M1

macrophages)

instead

of

anti-inflammatory

macrophages (M2 macrophages). The targeting effect allowed us more efficiently
destruct the negatively impacted mRNA in targeted cells to improve therapeutic effects
after spinal cord injury.
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CHAPTER ONE
SPINAL CORD INJURY AND ITS POTENTIAL TREATMENTS AT A GLANCE

1.1

Spinal Cord Injury and Animal Models in Experimental Study

Spinal cord injury (SCI) results in a temporary/permanent motor and sensory impairment,
also can be destructive to other organs, such as bone fracture, abnormal bladder and bowl
movement, and cardioresperiation and cardiovascular risk. It is not only physically but
also spiritually affecting the livelihood of injured patients. Main causes of spinal cord
injury usually lies in the motor vehicle accidence, falls, violence, recreational sports, and
some are diseases related. There are approximately 2.5 million patients who are suffering
from the chronic paralysis. Apart from this, estimated 130,000 newly injured individuals
occurred each year worldwide and approximately 12,000 from United State. Spinal cord
injuries symptoms can vary depend on the type and the level of the injury. SCI usually
can categorize into 1) complete and incomplete type of the injury based on functional
behavior and 2) tetraplegia and paraplegia based on if the level of the injury is above or
below the first thoracic spinal nerve. A complete injury refers to the complete sensation
and movement loss at the lowest sacral segments of both sides of the body. The
individuals with incomplete injury is characterized by some functions below the level of
the injury including the lowest sacral segments. In this case, individuals might have one
side of body function in a better condition than other.
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The database in regarding to the injury conditions after hospital discharges since 2010
shown that there are 40.6% of incomplete tetraplegia, 18.7% of incomplete paraplegia,
18.0% of complete paraplegia, and 11.6% of complete tetraplegia, and only less than 1%
of patients shown a complete neurological recovery. [1] In the laboratory researches,
many animal SCI models were developed based on the experimental needs to mimic the
condition of the human injury. SCI models can be categorized to contusion, laceration,
compression, and chemical mediated injury. Contusion model usually conducted by the
various impactor devices, such as Multicenter Animal Spinal Cord Injury Study
(MASCIS) contustion model, Infinite Horizon (IH) contusion model, and the Ohio State
University (OSU) Electromagnetic Spinal Cord Injury Device (ESCID) contusion model.
The MASCIS impactor is a device using a rod to drop onto certain level of the spinal
cord and tracks the trajectory of the falling rod. Therefore, the same velocity,
compression distance, and falling rate can be duplicated in each of the experiment in
order to achieve same desired injury. Other impactors also can results in reproducible
injury outcomes. IH contusion model is also a force based device which can displace the
exposed spinal cord to induce the injury. The impactor produced from OSU is based on a
slightly different technique. The main components of this device are sensitive
electromagnetic shaker and interactive software which can control the force, slope,
duration, and amplitude of peak displacement applied to the cord. Laceration injury is
also frequently used in many SCI researches although it is rarely observed in the clinical
case of human SCI. It includes partial spinal cord laceration injuries, such as focal
myelotomy, dorsal or lateral hemisection, and complete laceration injuries, such as
complete transaction, resection, and aspiration lesions. The ascending and descending
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axonal pathways can be sucessfully disconnected using these methods. The most
common human SCI is combination of acute impact followed by the persistent or
transient compression to spinal cord. Many compression models using aneurysm clip or
calibrated forceps are also developed showing a reliable, reproducible injury model
especially with economical benefits. [2] These injury methods can successfully initiate
certain level of locomotors and sensory loss such that we can investigate 1) the
therapeutic efficiency of pharmaceutical agents and 2) intraspinal circuit improvement
after grafting neural tissues or implanting biomaterial based guidance channels. The
chemical-mediated injuries models can be induced by N-methyl-D-aspartate receptor
(NMDA) agonists to study its associated secondary injury cascade, but may not fully
express all the condition that may be encountered in the case of human SCI.
Therefore, our proposing therapeutic approaches developed for SCI can based on the
condition of compression technique initiated incomplete injuries to recreate the similar
injury conditions in human SCI.

1.2

Secondary Injury in Spinal Cord Trauma

The primary injury is usually considered as the initial mechanical damadge. It can
implicit a complicated cascade of the pathophysiological events in a spatial and temporal
manner mainly due to vascular and biochemical effects, and this is considered as the
secondary injury.

These changes results in a propagating detrimental cycles and

jeopardize the potential neuronal recovery after primary injury.
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The secondary injury is mainly characterized by apoptotic and necrotic cell death
associated events. SCI triggers the resting and infiltration of immune cells to release free
radicals. It eventually leads to lipid peroxidation, oxidative stress, and excessive
production of nitrous oxide causing cell death. These immune cells also can produce
different cytokines and protease, such as tumor necrosis factor- α (TNF-α), interleukin
(IL)-1β, IL-6, caspase, and calpain at the injured sites. These can also initiate and regulate
the cell death through different signaling pathways. [3,4] The inflammation combining
with deleterious effects of ischemia and hemorrhage by SCI can lead to a progressive scar
formation and central cavitations (enlarged scar-encapsulated cavity). Also, excessive
intracellular level of Ca2+ immediately occurred after the induction of SCI could leads to
mitochondrial damadge. [5] It also further degrade local axoplasm and results in the
membrane breakdown. Not only the direct mechanical invasion but also the production of
free radical, inflammatory cytokines, and protease can cause destroy or deteriate the
integrity of the plasma membrane. It subsequently results in increased membrane
permeability and ionic and molecules homeostasis. Moreover, oligodendrocytes/myelin
assoicated neurite growth-inhibitory factor, such as Nogo-A, Rho-A, myelin-associated
glycoprotein (MAG), and oligodendrocyte myelin glycoprotein (OMgp), and astrocytes /
oligodendrocytes precursor produced various inhibitory proteoglycans, such as
chondroitin sulfate proteoglycans (CSPG), brevican, ND-2, and DSD-1, are all showed
also deleteriously effects to the axonal regeneration and neuronal recovery after trauma.
Glutamatergic excitotoxicity excreted after injury can directly or indirectly via reactive
oxygen species (ROS) or nitrogen species (RNS) damage the cord tissue, especially to
vulnerable neuron and oligodendrocytes which containing many glutamate receptors.
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Therefore, this excitotoxicity is most responsible for the demyelination of the axons. In
addition, decreased sympathetic tone and parasympathetic myocardial effects after acute
injury can cause various systematic changes. Vasoconstriction of spasm in blood vessel
and irregulation of blood flow can potentially results in a ischemic environment.
Systematic effects of hypotension and hypothermia induced neurogenic shock,
conduction block, and spial shock were also the primary features during the secondary
phases [6].
Immune system mediated secondary injury draw most of our attentions due to the
controversial role of immune cells and its regulatory proteins in SCI and their potential
developments. These included major types of immune cells which are microglia,
monocytes, and neutrophils. The resident microglia and some innate immune cells exist
in healthy environment of the central nervous system (CNS). After injury, neutrophils
firstly response to the intrusion and immigrate to the site of injury, then, perivascular
monocytes infiltrate into the damaged region and differentiate into macrophages.
Activated resident microglia and infiltration macrophages, as well as neutrophils secrete
various proinflamatory cytokines and neurotoxins and can lead to the exacerbation of the
spinal cord. These secondary injuries begin with hours and last for several weeks to
months after the initial physical injury, it allowed us to have time windows to apply the
protential treatment to enhance neuroprotection and restore the neuronal function after
SCI.
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1.3

Possible Treatments for Secondary Injury

Overall, the possible treatment approaches for sencondary injury can be accomplished by
inhibiting the inflammatory responses and neural death, regulating the inhibitory factors
on demyelination and scar formation, applying neuroregeration factors to spout neuron
growth and spinal tracts, as well as cell or tissue based transplantation.

Many

pharmaceutical agents for SCI treatment had undergone the clinical practice since 1980’s.
Inhibition of inflammation responses and oxidative stress was extensively developed .
NASCIS II and Japan MPSS trial based on the earlier treatment (within 8 hours post-SCI)
of glucocorticosteroid Methylprednisolone Sodium Succinate (MPSS) unveiled the
improved neurological and sensor recovery. Other pharmacological compounds with
antioxidant properties and neuroprotective functions were also developed

including

lazaroid, cyclosporine A, and EPC-K1. [7]
Maryland GM-1 (Monosialotetrahexosylganglioside, a major component of the cell
membrane)

trial also achieved the similar outcomes and indicated an improved

neurological recovery after injury, but Sygen GM-1trail which is combination of MPSS
and GM-1treatment did not shown the beneficial outcomes. These strategies are focused
on controlling cell membrane disruption induced cell death in secondary injury. Other
approaches were also revealed similar therapeutic potentials toward delayed cell death for
SCI treatment, for example, inhibiting proteases caspases via enforcing the anti-apoptotic
protein Bcl-2 expression and reducing proteases calpains by suppressing the cytoskeletal
degradation of damaged cells. [8]
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Glutamate receptor antagonists (NMDA blocker MK-801 and AMPA/KA receptor
antagonist NBQX) have also been shown to have neuroprotective function after SCI.
[9,10,11] However, the trial based on the treatment of NMDA antagonists Gacyclidine
(GK-11) for suppressing glutamate excitotoxicity did not shown any clinical
improvement. Since the overactivation of these receptors were responsible for abnormal
action potentialsand, they can further results in a large amount of transmitter substances
and accompanied with electrolytic shifts, and eventually lead to the cell death or spinal
shock after SCI. These changes usually indicated by an increased intracellular Na+ and
Ca+ and extracellular K+. Balancing the action potentials by inhibiting the voltagedependent channels could also be the potential approaches to limit the neural dysfunction
and its damages. Sodium channel blocker Tetrodotoxin have shown a functional recovery
after SCI, but riluzole did not have a significant clinical improvement. Calcium blocker
Nimodipine can reduce SCI initiated ischemia. [12] 4-aminopyridine (4-AP), as
potassium channel blocker, aims to restore the conduction properties of demyelinated
axons. It has been shown promising outcomes for motor and sensory improvement as
well as voluntary bowel controls. [13,14]
Many investigations also focused on enhancing the axonal regeneration and neurite
promoting by either applying exogenous neurotrophic factors or limiting the inhibitory
factors and unpermissive extracellular matrix that responsible for inhibition of neurite
outgrowth. Nerve growth factors (NGF), [15] neurotrophin -3, [16] and 4/5 (NT-3, NT4/5), brain-derived neurotrophic factor (BDNF), [17] glial cell line-derived neurotrophic
factor (GDNF), cilliary neuronotrophic factor (CNTF), and basic fibroblast growth factor
(BFGF) were the most common neurotrophic factors used for sprouting and regeneration
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in different cell type and locations. Many growth inhibitory signals occurred in SCI has
been proved to associated with the Rho singaling pathway and Rho associated protein
kinase (ROCK). The activation of Rho signaling pathway can disrupt or collapse the
cytoskeleton structure of the nerve fiber growth cone. ROCK-inhibitor Y-27632, fasudil
(HA-1077) , the protein p21CIP1/WAF1, or genetic deletion of the ROCK isoform were
various approaches developed to eliminate the ROCK production and to promote
corticospinal tract regeneration and locomotors improvement. A growing strength on
targeting protein kinases are developed as treatment in many preclinical studies. Apart
from Y-27632, SB203580 and TDZD-8, as potential therapeutics to inhibit p38α-MAPK
and glycogen synthase kinase 3 (GSK-3), were also investigated in clinical study for SCI.
[18] Moreover, directly targeting Rho pathways using Rho specific siRNAs, C3
transferase treatment, and Rho pathway antagonists Cethrin also addressed the similar
results. Many myelin/ oligodendrocyte -derived growth-inhibitory proteins (Nogo-66,
amino-Nogo, MAG, and OMgp)

were also received the attention during the SCI

treatment since they can activate Rho signalling to inhibit the neurite growth. The
blockage of other

Rho activator, for example CSPG, versican, and NG2 via

chondroitinase ABC, ibuprofen, and indomethacin treatment can also promote neural
regeneration. Suppression of the inhibitory protein activity of NoGo by using IN-1
antibody or siRNAs strategies has been shown to support the outgrowth of axonal tracts.
[19] However, genetic deletion of myelin-associated glycoprotein (MAG) did not shown
the significant regeneration of retinal ganglion cell fibers and corticospinal tract.
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Some naturalling occurred molecular, such as cyclic adenosine 3'5'-monophosphate
(cAMP), [20] inosine, [21] purine nucleoside, [22] and hypoxanthine derivative
leteprinim (AIT-082) were also showned their neuroprotective capability.
In many pre-clinical cases, the strategies using various stem cells, such as neural stem
cells, schwann cells, embryonic stem cells, olfactory ensheathing cells, and bone- marrow
mesenchymal stem cells were developed in SCI study as well. These cells were either
implanted or transplanted to the spinal cord for tissue sparing, axonal regeneration,
remyelination, and functional recoverys and showed improvments at various level.
However, only few investigate the the inflammation responses after SCI and treatment.
Computer-controlled functional electrical stimulation (FES) for SCI also extensively
developed for strengthening the motor and sensory function of upper and lower
extremities and limiting associated dysfunction and issues following with SCI.

In

addition, these stimulator combined with other physical therapy approaches has also been
shown the potentials on improvement of bone health, bladder and bowel movement,
reducing neurophathic pain, cardioresparistion and cardiovascular dysfunation which are
intimately related with post-SCI . Several stimulator and its application is summarized in
the Table1.1.
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Table 1.1 Spinal cord stimulators development in clinical trails.
Device

Sponsor

Indication

Status

Compex Motion or
HEWHS stimulator

Toronto Rehabilitation
Institute

Focus on study of upper limb intervention for tetraplegic
patient to generate the palmer functions and the lateral grasp.

Phase
III

FES cycling (RT300-SL )
/FES Stepping (RT-600)

Hugo W. Moser
Research Institute at
Kennedy Krieger, Inc.

Low level electrical currents is applied to the leg and buttock
muscles to initiate muscles contract and produce the motion of
the legs. Also, to improve CNS growth factors release and
reduce the inflammatory at spinal cord.
/To increase motor,
pin prick, and light touch score.

Phase
II/III;
/Phase
I/II;

FIRSTHAND System

Department of
Veterans Affairs (VA)

Somatosensory stimulation to generate functional movements,
such as enhancing pinch strength and upper extremity acitivity.

Phase I/
II

IST-16 (16 channel
implanted stimulatortelemeter)

Case Western Reserve
University; NIH; VA

Surgical implant multiple contact peripheral nerve electrodes to
to excite muscles in order to move paralyzed muscles, facilitate
standing duration, stepping, and balance.

Transcranial Direct
Current Stimulator

Beth Israel Deaconess
Medical Center

Relieve migraine pain.

Ness H200

University of
Pittsburgh

To aid movement and stimulate the nerves that supply
paralyzed muscles, to improve the arm function.

Home-based ankle
continuous passive
motion machine

Chang Gung University To study the effect of fast continuous passive motion on the
reversing adaptation of human paralyzed muscle after SCI.

Neural Prosthetic
System 2 (NPS2)

Richard A. Andersen,
PhD

Phase
II

Brain- controlled medical device, any movement plans can be
sent to specific region of brain and execute the actual
movements.
10
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1.4

Biomaterials in Spinal Cord Injury Studies

Many biocompatible natural and synthesic materials based plantforms were developed
not only as a nerve guidance channels or structure surports, but also can be used for drug
delivery tools for SCI repair. Due to the complexity of spinal cord bioenvironment, the
spinal-blood barriers cause the challenge for nanoparticle (Np) based systematic delivery.
Therefore, more therapeutic investments are focused on using implantable platforms for
long lasting medication therapy in SCI studies. [23] The platforms mainly include
hydrogels, electrospuned fiber mesh, and porous scaffolds and can be made of either
degradable or non-degradable materials. The most common degradable natural materials
used in spinal cord are collagen, hyaluronic acid, chitosan, agrose, fibrin, fibroin, and
poly (β-hydroxybutyrate), and degradable synthetic materials are poly (lactide) and
glycolide (poly (glycolide-co-lactide)) (PLA-PGLA), poly (ε- caprolactone) (PCL). They
are characterized by less cytotoxic effects and well supporting to the cell adhesion and
connection. They also featured of a lower risk of nerve compression if their degradation
rate is at similar pace of the regenration of

the nerves. However, unpredicted

inflammation initiated by the debris of these materials could jeopardize the theraupeutic
effects. When the integrity of the matrices is highly demanded, non-degradable synthetic
materials, such as poly (2-hydroxyethyl methacrylate) (PHEMA), poly (3,4ethylenedioxythiophene)

(PEDOT),

and

poly[N-(2-hyroxypropyl

methacrylamide)(PHPMA) are more appropriated to use when safety of these materials
were established. The special properties of synthetic material are that they can be simply
modified and utilized varying to the application requirements. One special electrical
sensitive polymers were also received many attentions. Polymer poly(tetrafluoroethylene)
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(PTFE), polyvinylidene fluoride (PVDF), PEDOT, and polypyrrole (Ppy) are commonly
investigated because they are compatible to neural tissues and can enhance the neural
growth and drug release when expose to electrical stimulation. [24] See more details in
chapter 2.1.1.
The nanoparticles mediated systemical drug delivery were also developed althrough
under the challenge of spinal-blood barriers. Delivery strategies by enhancing drug
targeting showed promising

outcomes to solve this issue. Ferulic acid and glycol

chitosan synthesized Nps can be delivered to lesioned spinal cord through systemical
administration and result in neuroprotection. [25] The direct injection of nanoparticle
suspension into the injury site of spinal cord can also be used to bypass the spinal-blood
barriers and efficiently deliver the drugs. Directly inject glial cell line-derived
neurotrophic factor loaded PLGA Nps to the damadged spinal cord can promote neural
survival and functional recovery.[26] In addition, some material itself in a nanoscales,
such as self-assembled monomethoxy poly(ethylene glycol) -poly(D,L-lactic acid)
diblock copolymer and poly(ethylene glycol), also showed beneficial results to reduce
lesion and inflammation, or repair damadged nerve membrane. [27,28] During this
nanoparticle administration, the size, shape, and surface charge of the nanoparticles can
significant influence its drug delivery outcomes.

13
1.5

Goal of Current Study

Broad and brief review of existing issues and solutions of SCI described above allow us
to have a general understanding during SCI, especially for secondary injury studies. Our
goal and primary contribution in this work is to focuse on exploiting the potential
approaches based on polymer materials drug delivery strategies to eliminate the noxious
molecules initiated by various glial cells after SCI. We included microglial cells and
macrophages in vitro study, and reactive astrocytes in vivo study. First, we modulated the
Ppy platform based on structure and synthesis to optimize the local drug delivery by
maximizing the drug loading capacities of Ppy. Especially, we are firstly introduce the
non-invasive electromagnetic generator to initiate the chemical and mechanical
alternation of conductive polymer Ppy for remotely controlled drug release (details
described in Chapter 2, 3, and 4). Second, we developed a chitosan Nps associated
siRNA gene silencing strategies with specific targeting effects to pro-inflammation
macrophages (M1). This targeting strategy is the first time to discriminate different
macrophages subsets during drug delivery for neuroinflammation inhibition efficiency
after SCI (details described in Chapter 5 and 6).
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CHAPTER TWO
POLYPYRROLE DRUG RELEASE
VIA NON-INVASIVE ELECTROMAGNETIC STIMULATION

2.1
2.1.1

Introduction

Overview of Conductive Polymers in Neuroscience Study

Conducting polymers characterized by high electronic conductivity, electrochromism,
charge storage capacity, and electrochemically controllable ion exchange capacities have
been exploited in various engineering applications such as high-power supercapacitors,
[29]

batteries, [30] fuel cell, [31] anti-corrosion coatings, antistatic coatings, [32]

shielding interferences, [33] sensors, actuators, and synthetic receptor. [34] In
neuroscience study, many conductive polymers, for example, polyaniline, polythiophene,
especially PEDOT and Ppy are primarily used for nerve guidance conduits due to their
biocompatibility and high conductivity properties. Ppy, as the archetype of electronically
conducing organic polymers, have especially been exploited due to: 1) the fabrication of
Ppy is simple and can be accomplished in both aqueous and non-aqueous conditions; 2)
Redox activity of Ppy can be protentially used for various application, especially for drug
delivery of our interests; 3) Ppy in the oxidized state is inherently stable for long storage
times as long as the material is keep away from oxygen and humidity; 4) Most
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importantly, different nature of Ppy dopant or counterions can influence Ppy
characteristics and further expanded or improved its applications.
Conductive Ppy has especially been used as a substrate to support the interaction and
connection of nerve cells in many studies. [35] (Polycaprolactone (PCL) fumarate
synthesized with Ppy enhanced cell attachment, proliferation, and neurite extension. [36]
This result also supported by Paul Geoge et al where neurons and glial cells become
enveloped and grew through the implants of polystyrene sulfonate (PSS) or sodium
dodecylbenzenesulfonate (NaDBS) doped Ppy. [37] Neurites outgrowths from PC-12
cells have also been observed when NGF electrically released from its originally
conjugated Ppy scaffold. [38] Electrical stimulation to Ppy films in PC-12 cells, Dorsal
Root Ganglia, and Schwann cells culture results in a significant increased neurite lengths
compared to the ones without stimulation.[39,40] In vivo studies, Ppy implants showed
its connection to the spinal cord tissue without increased inflammation responses; [41]
and

also suggest motor recovery and improved somatosensory evoked potential

conduction after implantation of Iodine doped Ppy into transected rats spinal cord. [42]
In neurology, many medical devices have been developed to record electrophysiological
activity in neural circuit and/or to support nerve conductance by neurostimulation.
Developing biocompatible electrodes are very important because these electrod
component in many of these devices can result in invasion to the tissues during recording
and stimulation. Conducting polymer coating as neural tissue-electrode interface has been
a promising tool to offer effective long-term performance of electrode implants. They are
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featured of relatively high charge storage densities but low impedance, therefore, can
optimize the electrode-tissue communication.

2.1.2
2.1.2.1

Electrochemistry for Polypyrrole
Electropolymerization of Polypyrrole

The proposed mechanism of Ppy polymerization starts with a slow neutral monomer
oxidation to form a pyrrole cation radical. The reaction then followed by the coupling of
radical cations that generate different resonance forms, fast deprotonation, and
aromatization process to form a dimer. The chain growth then propagates by preferential
coupling with monomers and/or dimmers and continues until the charge on the polymer’s
backbone is incorporated with counterions. These counterions can maintain
electroneutrality of the polymers when positive charges accrue along the polymer
backbones. This electropolymerization process is based on the radical-radical coupling
mechanism and illustrated in Figure 2.1. [43]
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Figure 2.1 Polymerization of Ppy.

Figure 2.2 Neutral, Polaron, and Bipolaron state of Ppy.
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2.1.2.2

Doping and Releasing Processes of Polypyrrole

How does the Ppy conducting organic polymer become conductive? First, we need to
understand that how hundreds of inorganic substances can become conductive. This is
through a process called electronic doping: the substances can be conducted by addition
of impurities, that can be accomplished by giving electrons to or accepting electrons from
the nonconducting form of the substances. Conductivity in the conducing organic
polymer Ppy is related to the configuration of alternative single and double bond along
the polymer backbone (See Figure 2.2). Every bond contains “s” bond and every double
bond contains “p” bond. The introduction of voltage potentials and dopant ions to the Ppy
allows the displacement of the weakly bonded electrons in between the stronger double
bonds, resulting in the conductivity of this material. Therefore, we can say, Ppy need to
be “oxidatively” or “reductively” doped in order to be conductive.
In our study, we conducted drug incorporation experiment based on the characteristics of
Ppy oxidation as it is the most common mechanism in many drug delivery studies. The
oxidation process develops cation along with the polypyrrole backbone, and
concomitantly yields a local deformation which due to a geometrical change in every four
pyrrole units. These processes constitute a “polaron” (Figure 2.2 B) and combinations of
polarons pair can form “bipolarons” (Figure 2.2 C) during further oxidation process with
higher charging levels. Polarons and bipolarons are the dominant charge carriers by
transport charges along the segment of conducting polymer chain. The conductivity of
Ppy can be reflected not only by charge migration but also the hopping charges of the
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carriers from chain to chain. In sum, the mobility of charge carriers and the amount of
charges in polymer chain are important for Ppy become conductive. [44,45,46]
Here, I need to point out that redox activity of conductive polymers Ppy not only involve
mass and resistance charges but also electron transitions, and Ppy electrochemistry
processes can be accomplished by only involving electrons. During oxidation of Ppy,
when certain level of positive potential is applied, electrons are removed from the
backbone of the Ppy, thus negatively charged dopants or couterions are taken up and can
be incorporated to the Ppy structure. These dopants compensated with the positive
charged sites on the polymer backbone and reach electroneutrality of Ppy. On the other
hand, when a negative potential is applied and reducing it, the anions or anionic
molecules can be expelled (or “undoping”) as there is a loss of electrostatic attraction to
the Ppy. (See Figure 2.3 A) Apart from the expulsion of these anions, reduction process
can also involve the incorporation of cations. Therefore, both negative or positive
charged drugs can be ingress or expulsed to compensate the resulting charges along the
polymer chains. In our case, a anionic drug DEX can synthesize with Ppy at the oxidated
state and released at the reduced state of Ppy.
Additionally, the oxidation-reduction action of Ppy can provoke mechanical effects such
as swelling and de-swelling of the conductive polymer materials along with the ionic or
small molecules fluxing in or out of the polymer structures. [47]
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Figure 2.3

Redox reaction and overoxidation of Ppy. Redox reaction of Ppy for

conjugation and releasing of Anionic (A) and Cationic (B) molecules and overoxidation
of Ppy (C).

2.1.2.3

The Effects of Different Parameters During Eletropolymerization

The electrochemical approach for making electroactive materials depends on many
parameters. For example, applied potentials, current densities, substrates, dopant, doping
level, solvent, electrolyte, concentration of polymers, electrodes, even temperature and
pH can influence the outcomes of polymerization of polypyrrole.
Doping level represents the average positive charge per pyrrole ring. In general, the
oxidation level of Ppy is at 0.25-0.32 per pyrrole unit which is one anion for every 3 to 4
pyrrole units, which can be influenced anion types and its charges. [48] However, at high
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doping levels which might be caused by the application of an excessive level of anodic
electrode potential, Ppy can be overoxidized due to trace water or other nucleophiles,
such as OH- attack causing irreversible changes in the polymer’s chemical structure. (See
Figure 2.3 C) This interruption of Ppy structure could lower the intrinsic conductivity of
the polymer and make Ppy loose the capability of electrochemical activity. Thus, Ppy
would not be able to release the drugs as described in 2.1.2.2. Since conductivity of Ppy
at high doping levels is dramatically decreased, we control the level of potential at range
of 0.8-1mV during Ppy synthesis, and -0.1mV for Ppy drug releasing.
The substrates of where Ppy will be deposited during electropolymerization also
determine the characteristics of Ppy. Many materials can be used as the substrates, such
as glassy carbon, gold, indium-tin oxide coated glass, platinium, titanium, and aluminum.
[49] Some substrate materials works less efficient than others, for example, when Ti, Fe,
and Al are used as substrate, it results in a increased oxidation potential of pyrrole. In our
experiment, we select the indium-tin oxide coated glass as substrate for flat Ppy due to its
strong structure support and its conductivity. Also, since gold materials feature of high
conductivity and non-toxicity , evaporated gold base was used as substrate for Ppy
nanowire synthesis.
The resulting electrochemical properties of Ppy is also depend strongly on the synthesis
medium where polymer prepared during electropolymerization. One study indicated that
interaction of counterions melanin in Ppy and various components in the synthesis
medium. It also indicated that medium containing sulfate, phosphate, or chloride can be
responsible for ion dynamics in Ppy films.[50]
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The dopant used for Ppy electropolymerisation can highly influence the characteristics of
Ppy film and have been widely discussed in different literatures.

In summary, the

counterions should be chemically inert, very soluable in the monomer contained synthesis
solution, and electrochemically more stable during oxidation-reduction process than the
monomer itself (in our case is pyrrole). Curtin et al indicate that the anion preference of
Ppy is I->Cl->Br->ClO4- , [51] which could arise from the buffer salts, such as I2, BF4,
FeCl3, and perchlorates. Much of research also reported aromatic sulfonate variants are
good candidate as dopant for Ppy polymerization, especially for application as neural
interfaces. These include PSS, sodium benzenesulfonates (BS), and para-toluenesulfonate
(pTS) dopants. Moreover, various biological dopants, such as laminin peptide sequences,
neurotrophins, hyaluronic acid, fibronectin fragments, human serum albumin, and
polysaccharides, can also be immobilized into the Ppy to enhance cell proliferation and
differentiation in biomaterial tissue engineering studies. [52]

2.1.3

Conductive Polymer Based Drug Delivery System

To successfully delivery the drugs using a Ppy platform, the characteristics of the drugs
themselves are also critical for the application. To design an efficient drug delivery
system, the size of the dopants can influence the incoroporation of the drug into Ppy or
their release from Ppy. Matrix Maria Hepel1et al reported that melanin (a bulky
molecule) is irreversible after incorporation into polypyrrole, whereas the small chloride
ions can be easily released from polypyrrole after conjugation. [50] However, one study
described that despite the fact that nicoside has a lower molecular weight compared to
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naproxen, it cannot be released during the potential cycling of Ppy. This result indicates
that size is not the only parameter that should be considered during the selection of the
drugs for Ppy based drug delivery system.[23]
The charge of the drug molecules is usually associated with its pKa value and it is
especially important to Ppy mediated drug delivery. This drug delivery system is not only
able to release the anionic drugs, but also can successfully achieve the delivery of
cationic and neutral drugs. As described previously, anions are incorporated into the
polymer to balance out positive charges initiated during oxidation. When immoblised
larger sized anionic dopants (e.g. melanin, PSS, pTS) with Ppy, cations or cationic drugs
can be incorporated into Ppy, but during reduction instead of oxidation, and then released
during oxidation. The study of chlorpromazine conjugated Ppy/melanin films has
provided more insight. The mass of chlorpromazine in Ppy was increased during
reduction and decreased in concomitant with the oxidation when evaluated by
electrochemical quartz crystal microbalance, indicating the egrass and release of cationic
drug, chlorpromazine. [50] Many studies of dopamine release used immobilized PSS
with Ppy and also successfully accomplished the cationic small molecules delivery.
Similar mechanisms also applied to incorporation and releas of NT-3and BDGF with
immobilized molelcules pTS in Ppy. The detailed mechanism of cationic drug delivery is
the same as that of anionic drugs by using electrostatic forces with slight differences as
shown in Figure 2.3 A and B. Novel strategies have also been developed to help
incorporation of neutral drugs, such as N-methylphenothiazine by using anionic dopant βcyclodextrins prepared Ppy films and achieved by encapsulation drugs into the
hydrophobic interior of β-cyclodextrins. [53]

24
2.1.4

Synthesis Techniques for 3D Nanostructure

Compared to 2D structure, 3D structured polymers showed promising results to load
larger amounts of therapeutic agents, especially useful in the treatment of chronic
medical conditions. Many polymer nanostructures are well developed, such as nanowires,
nanotubes, opal structures, and inverted opal structures. The template method is
considered to be the most convenient for nanostructure development. For example,
porous polycarbonate and porous anodic alumina membrane are typically used as
templates for nanowire growth. The formation of pores in the template is related to either
1) dissolution of the oxide to form pores

or 2) self-organized anodization which

generally performed by different strong acidic electrolytes. Unlike PANI nanotubes
which formed along with phenazine-based aniline oligomers spontaneously produced
internal template, Ppy nanotubular growth need an external template. It could be
generated using coating on hard template method, that is, placing insoluble inorganic
nanofibres, such as manganese (IV) oxide, titanium (IV) oxide into the synthesis
solutions during oxidation process, then dissolving the template to form nanotubes. [54]
Its formation also can based on the self-assembling of some dyes, such as MO, acid blue
AS, rhodamine B, Prussian blue, or methylene blue. The surfactant characteristics which
combine both hydrophilic and hydrophobic moieties in these dyes, allows them to form
supramolecular structures. Other 3D geometric structure of Ppy are also exploited, for
example, Luo and Cui synthesize Ppy over polystyrene beads deposited electrode, and
formed a 3D structured polymer porous film after removal the beads. [55]
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In our study, polypyrrole nanowires (PpyNWs) were manufactured based on the simple
template technique using anodic alumina membrane. The modulation of the geometric
structures of Ppy to nanowire shape can maximized the drug incorporation and can
release drugs in relatively longer time.

2.2
2.2.1

Method and Materials

Template Preparation for Polypyrrole Polymerization

Indium tin oxide (ITO) glass slides with 5-15 ohms resistivity (Delta Technologies, CO)
were used for fabrication of flat Ppy. They were washed with acetone, ethanol, and then
Milli-Q water by incubating glasses with each solution for 30 mins at an ultrasonic bath.
For PpyNWs experiments, anopore inorganic aluminum oxide membrane (AAO) with
0.2μm pore size and 60μm thickness (Whatman) were used. The AAO templates were
coated with gold at thickness of 100 nm on one side using a Varian E-beam Evaporator.
Then, they were stored in a dry oven prior to use.

2.2.2

Fabrication of Dexamethasone Doped Polypyrrole Carriers

One synthesis solution was prepared by mixing 0.2M pyrrole (Py, Sigma), 0.025M
dexamethasone 21-phosphate disodium salt (DEX, Sigma), 0.05 M 10 nm NanoXact
spherical gold nanoparticles (AuNps, NanoComposix, CA) together. For comparison,
0.2M

pyrrole,

0.025M

DEX,

0.1M

Poly

(3,4-ethylenedioxythiophene)-

poly(styrenesulfonate) (PSS, Sigma) was also prepared by gental mixing. Prepared AAO
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templates were subsequently incubated into each of solution mixtures for 30 minutes
before PpyNWs electropolymerization. This procedure allow the Pyrrole monomers,
drugs, and other systheis components (either AuNps or PSS) diffuse into the pores of the
template. Cleaned ITO slides or AAO templates were connected to the working electrode
from a CH Instrument model 604 electrochemical workstation with a platinum counter
electrode and a Ag/AgCl reference electrode placed in the synthesis solution. The
electropolymerization of DEX doped Ppy was then performed using a constant potential
at 1V. This constant potential is cotrolled by potentiostat device in the electrochemical
workstation, it will be briefly called potentiostat stimulation in the later content.
Following polymerization, the final films were rinsed thoroughly with Milli-Q water. At
end, the AAO templates will be removed by incubation in 3M sodium hydroxide. The
whole synthesis procedure is indicated in Figure 2.4.
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Figure 2.4 PpyNWs fabrication processes. The figure at far left is an illustration of the
AAO template. Next step showed one-side gold coated template. The third step
demonstrate the diffusion of pyrrole monomer, AuNps or PSS, and DEX into the porous
column of the template. The fourth step is formation of DEX doped Ppy after
electropolymerization process. The far right figure indicate the removal of AAO
templates and free standing PpyNWs structure.

2.2.3

Morphology of Polypyrrole Nanowires

Imaged by Scanning and Transmission Electron Microscopy
Ppy samples were prepared by first sputter coating with platinum for 60 seconds. SEM
images were taken with a FEI NOVA nano SEM field emission scanning using ET and
TLD at high vacuum at an accelerating voltage of 5 kilovolts. TEM images were taken
using a FEI/Philips CM-10 Transmission Electron Microscope, operated at 100 kilovolts;
A 200µm condenser aperture; and 70µm objective aperture. TEM images were captured
by a SIA L3-C digital camera.
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2.2.4

Electromagnetic Stimulation

The set up of electromagnetic stimulation was illustrated in Figure 2.5. More details are
described in CHAPTER THREE: Method and Materials and Results sections.
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Figure 2.5 Stimulation scheme for the application of EMFs. (A) The top illustration
shows the setup of EMF generator during the stimulation. The stimulator is connected to
a circular wire-wound coil. A standard cuvette containing DEX doped Ppy film was
placed in the center of the coil. Left inset describes the dimensions of the coil, where
Height(H) is 1.2cm, Length(L) is 3.8cm, and Width(W) is 3.0cm. The recordings in B are
probe measurements of the magnetic fields (MF) and electric fields (EF) at the center of
the coil, with ~ 36 Gauss and ~ 4000V/m respectively. The insets demonstrate the
idealized waveforms for both MF and EF based on the input square pulse stimulation
regime.
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2.2.5

Drug Release

Both potentiostat electrical stimulation and EMF stimulation were used to release DEX
and these two methods are described in more details in CHAPTER THREE. In former
cases, the procedure is similar to the electropolymerization process with three electrodes.
The stimulation is potentiostat device controlled constant potentials and the DEX
conjugated Ppy films was linked to a working electrode and emerged in PBS solution.
Then, a constant voltage of - 0.1V was applied for five hours using electrochemical
workstation. The DEX conjugated Ppy platforms were also stimulated by EMF generator
illustrated as Figure 2.5 which depicts the experimental set-up and the essential
components of the EMF stimulation system. Before conducting the drug releasing, the
Ppy samples were placed into PBS contained cuvette and this cuvette was then positioned
in the center of the coil without any physical contact. The coil was energized with an
asymmetrical square wave pulses and remotely trigger drug release from Ppy. The
supernatants were subsequently collected after 1, 3, and 5 hours of stimulation.
In addition, different Ppy compositions used for polymer synthesis were also tested and
compared. All experiment were last for 16 days with EMF stimulation. The sample
solutions were collected at 1, 3, 5, 7, 10, 13, and 16 days after continuous EMF
stimulation.
All collected aliquot samples were analyzed by a UV-Vis Spectrometer at 242nm
wavelength. A calibration curve of DEX (y(OD)=23.8x-0.04) was used to calculate the
amount of released drugs.
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2.2.6

On-Demand Dexamethasone Release

To determine the controlabiliy of EMF stimulation to Ppy drug release, “on and off”
experiments were performed on PpyNWs with AuNps components. The recordings were
begun after 10 hours of stimulation by the EMF to avoid the robust release at first couple
of hours. Pulsed EMF stimulation was turned on for 2 hours and turn off for 2 hours. This
regimen was continued for four cycles for each sample.

2.2.7

Temperature Effects on Drug Release

To test if the release of DEX might be influenced by the heating during the stimulation,
we placed the DEX doped flat polypyrrole templates within a incubator at 37℃. This
temperature was slightly higher than the ambient temperature in the vicinity of the active
coil, which was measured to be about 30℃.

2.2.8

XPS Analysis

Ppy samples about 0.5-1.0cm2 were prepared and submitted for XPS analysis. The
surface chemical composition of the samples was analyzed by X-ray photoelectron
spectroscopy (XPS) using a Kratos Axix Ultra DLD spectrometer. The spectra were
collected using monochromatic Al Kα radiation (1486.6 eV). The survey and high
resolution spectra were obtained at the constant Pass Energy mode with the pass energy
of 160 eV and 20 eV respectively (survey 1 eV/step; high resolution spectra 0.05
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eV/step). A built-in Kratos charge neutralizer was used. Data analysis was performed
with CasaXPS software version 2.3.12.

2.2.9

Statistical Analysis

All data are shown with standard error of the mean ( + SEM). Independent Student’s ttest and one way ANOVA followed by Tukey Post Hoc test were used to determine
statistical significance. Significance was determined by a P-value < 0.05.

2.3 Results
2.3.1 Structure of Polypyrrole Nanowires
Nanowire architecture was imaged by SEM and TEM and illustrated in Figure 2.6 and
2.7. Since polymers thickness can be easily controlled during electropolymerization, the
growth of (or length of) PpyNWs can be vary with the deposition time during synthesis.
1300-1400 seconds of deposition time can achieve approximately 10μm long PpyNWs
(Figure 2.6 A) while shorter lengths were completed in a faster deposition times. The
commonly used deposition time in our study is at 200-300 sec and it can form PpyNWs
structure as showed in Figure 2.6 B. All the PpyNWs showed as free-standing vertically
aligned conformation. For PpyNWs with AuNps composition, the distribution of the
AuNps within the polymer bulk were indicated in Figure 2.7 A and B.
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Figure 2.6

Scanning Electron Micrograph of PpyNWs. (A) Scanning Electron

Micrograph showing a top view of polypyrrole nanowires (200nm diameter and ~10μm
length) with longer deposition time. (B) A similar micrograph where showed a 200nm
diameter and ~ 500nm long PpyNWs synthesized in a shorter time.
A=10μm; in B= 2μm,

Scale bar in
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Figure 2.7

Transmission electron micrograph of PpyNWs with inclusion of gold

nanopartilces. (A) Transmission electron micrograph of PpyNWs. The dark regions are
the accumlation of AuNps in the Ppy. (B) showed details of gold nanopartilces in each
individual PpyNWs. These wires range from approximately 500nm to 2000 nm in length,
and ~200 nm in diameter. Scale bar in A=2 μm; and in B = 0.2 μm.

2.3.2

Comparisons of Drug Release

Drug release profile of the PpyNWs compare to conventional flat Ppy films are shown in
Figure 2.8 A, B, and C.

35

Figure 2.8. DEX release using various Ppy platforms and stimulation methods. (A) The
DEX release using either constant potentials (protentiostat stimulation) or EMF
stimulation from both flat Ppy film and PpyNWs. The releasing time were tested for five
hours. (B) Comparison of DEX release with different synthesis compositions (AuNps vs.
PSS dopant). All experiments were applied with EMF stimulation for 16 days. (C) Active
(EMF stimulation) vs. Passive (no stimulation) for both flat Ppy films and PpyNWs. (D)
"on" and "off" EMF experiment to test the DEX release from PpyNWs-AuNps when
response to the stimulation. Higher concentrations of DEX were generated with EMF
stimulation whereas a smaller amount of DEX was detected at the absent of EMF
stimulation. * p < 0.05; ** p < 0.01; and *** p < 0.001.
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Figure 2.8 A reveals the results of DEX release over a five hour period of stimulation.
For flat Ppy, potentiostat mediated stimulation was not significantly different from that of
EMF stimulation. Although there is no statistical difference beween EMF stimulation and
potentiostat mediated stimulation in the case of PpyNWs, there was more apparent DEX
release when using EMF stimulation. Also, upon the exposure to EMF stimulation, there
was a statistically significant increase in the DEX release of PpyNWs compared to flat
Ppy film (*p < 0.05).
AuNps embedded Ppy either in flat Ppy films or PpyNWs also showed increased DEX
release when compare to the PSS doped Ppy films.

At 1, 7, and 16 days, these

differences were by almost double for both Ppy platforms (*p < 0.05 between PpyNWs
and **p < 0.01 between Flat Ppy). Also, the results of flat Ppys only showed marginal
release of DEX (<0.5mg/cm2) from flat Ppy films. In contrast, PpyNWs showed a very
significant enhancement of DEX release. (At day 1 and 16, **p < 0.01, and at day 7,
***p < 0.001 between AuNPs; At day 7 and 16, **p < 0.01 between PSS study; Figure
2.8 B). The groups without EMF showed relatively small amount of DEX diffusion, and
it was below 0.11 mg/cm2 for PpyNWs and 0.3mg/cm2 for flat Ppy films on the last day
of recording. This reveals a extrodinary DEX release occurred after EMF stimulation
compared to without EMF stimulation. (At day 1, **p< 0.01, and at day 7 and 16, ***p <
0.001 between PpyNWs; At day1, *p < 0.05, and at day 7 and 16, ** p < 0.01 between
Flat Ppy films; Figure 2.8 C). Further "on" and "off" switching stimulation performed by
EMF was used to test the control of DEX release as shown in Figure 2.8 D. In such cases,
DEX release fell off precipitously at absence of EMF stimulation, and was regained when
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EMF coupling was applied. Such consistency over several cycles demonstrated the
protentials to controlled drug release using this drug delivery strategies.

Figure 2.9

DEX release profiles of flat Ppy as a function of temperature and its

comparison to that of with and without EMF stimulation. *p< 0.05, ** p < 0.01.

2.3.3

The Influence of Temperature Elevation on Drug Release

According to the results from Figure 2.9, there is some increased level of DEX passive
release under the elevation of temperature (37oC) compare to the samples at room
temperture without EMF stimulation. However, no statistical difference was observed
until 13th day whereas the significant statistical difference occurred from day 1 when
using EMF stimulation compared to without stimulation . Therefore, we conclude that the

38
DEX release result from increased temperture did not reach the levels of active EMF
stimulation during the entire experiment, and are not the driving force for DEX release.

2.3.4

XPS Confirmation of Dexamethasone Release

X-ray photoelectron Spectroscopy (XPS) was used to verify the existence of DEX after
loading with Ppy and the escape of these loaded DEX after EMF stimulation (See Figure
2.10). XPS surface analysis was conducted on the PpyNWs before and after (16 days)
EMF stimulation. High-resolution spectra of F 1s (fluorine) and P 2p (phosphorous)
elements in the DEX molecule can reveal the elemental components in PpyNWs before
and after stimulation. It can denote the presence and absence of DEX upon exposure to
the EMF. These two elements were vanished after EMF stimulation indicating the DEX
release after EMF stimulation. For PpyNWs-AuNps, the pre-stimulation F 1s and P 2p
atomic percentages were 1.53% and 1.54%, respectively while the post-stimulations
results were 0.00% and 0.17%. For PpyNWs-PSS, the pre-stimulation F 1s and P 2p
atomic percentages were 0.60% and 1.31%, respectively while the post-stimulations
results were 0.00% and 0.15%.
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Figure 2.10. XPS spectra for surface analysis of DEX presence on Ppy templates before
and after EMF stimulation. (A) Elements identification on the surface of DEX doped
PpyNW-AuNps before (Green) and after (Red) EMF stimulation. Characteristic peaks are
shown in this spectrograph. (B) Same recording for DEX doped PpyNWs-PSS before
(Green) and after (Red) 16 days of EMF stimulation. Below A and B are expanded views.
These show details of signature fluorine and phosphorous elements indicating DEX
molecule. Note that apparent elemental signatures were observed before EMF stimulation
and vanished after EMF stimulation, indicative of DEX release from the surface of
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PPyfilms. The very bottom graph shows the molecular structure of DEX, with fluorine
(F) and phosphorous (P) highlighted in red.

2.4

Discussion

In this study, we investigate the potential of polymer implantation for local drug delivery
strategies based on the nature of implantation. We focused on the Ppy mediated drug
delivery system from three aspects: structure, synthesis, and releasing profile in order to
non-invasively administrate the drugs over a relative long-term. A geometrical
modification of Ppy to 3D structure increased both surface areas and overall volume of
the Ppy, and enhanced the possible payload capacity of these carriers. It has been proved
that dramatically increased NGF were indicated in a inverted opal structure ( porous) of
Ppy compare to the flat Ppy. [56] In addition, the template assistanted manufacture of
PpyNWs is simple and highly reproducible. A large area of PpyNWs film showed
consistancy of vertical nanowires through entire film (See Figure 2.11). The embedded
AuNps enhanced the strength of Ppy structure and improved its electrochemical activity
with increased DEX release. Most important, we are the first to introduce Ppy responses
to non-invasive electromagnetic fields and its potential use for drug delivery. This
approach was designed to optimize the performance of many medical devices and
implants which require relatively long-term and stable amount of drug administration to
very local sites.
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Figure 2.11 High magnification of TEM image depicts the successful fabrication of
PpyNWs through entire film. Scale bar is 50μm.
The mechanism of DEX release from Ppy when it responsed to EMF exposure could be
the result of single or multiple phenomenon. As we mentioned in the Introduction, Ppy
films undergo a reduction when sufficient negative potential is applied, therefore, anionic
drugs DEX can be expulsed to the surrounding solutions. The other potential cycling
methods, such as cyclic voltometry and bipolar (pulsed) current stimulation (See details
in 3.1.2), applying both cathodic and aniodic current which is similar to EMF stimulation
have been reported and indicated that they can also successfully release drugs out of Ppy
matrix.[57,58,59,60] Ppy conducting polymers swell during oxidation along with the
entry of counterions into the polymers and results in a mechanical change and volume
enlargement of the polymer. Conversely, Ppy shrinks during the expulsion of counterions
at the reduction process. This electromechanical property is commonly used as the basis
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of actuator, such as polymer based artificial muscles, and also existed during drug
incorporation and releasing. In our case, the Ppy with high conductivity has more mobile
charge carriers that can interact with the EMF. The switching of the polarity of the EMF
produces a very short-lived, but bipolar electric field. This transitory alternative electrical
field potentially provide the conditions for undoping of the anionic drugs from the Ppy at
the concomitant of polymer de-swelling. According to the results, drug release amount
dramatically increased at the first day of release and was reduced after 5 days. This is
possibly due to doped Ppy fims possess high conductivity and mechanical strength, but
this decrease during the undoping process.
We are not excluded the possibility of the anions in aqueous solutions might move into
the interstices of the Ppy polymer coil and exchange small sized anions or anionic drugs
out of the Ppy films during the potential sweeping. This effect has been used to develop
electrically switchable ion-exchanger for purification of water. [61] Bipolar current or
heating can cause the movement or relative rapid movement of ions in the solution,
providing the potential exchanges between anions. In this situation, certain anions in
aqueous solution such as Cl- with a stronger electrostatic interaction might be more
vulnerable to exchange with other anions. This ion exchange action of Ppy could
potentially play a role during DEX release.
pH values can also be responsible for the ion exchange abilities of Ppy. During the low
pH, protonation of the nitrogen increase the capacity of ion exchange, in contrast,
deprotonation in a higher pH environment can result in reduced or even devanished
electronic conductivity and eventually lead to the expulsion of anions. [62,63] This is not
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likely the reason in our case since all the solutions in which Ppy placed remain a neutral
pH value. However, the possible disruption to the weak electrostatic interaction between
DEX and polymer because of a changing EMF field should be under the consideration.
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CHAPTER THREE
DESIGN AND SELECTION OF ELECTROMAGNETIC FIELD GENERATOR

3.1

Introduction

3.1.1 Time-Varying Electromagnetic Fields
A time-changing electric field can produce a magnetic field, and conversely, a timechanging magnetic field can produce an electric field. The former statement is the
experimental basis of Ampere’s law and the latter for Faraday’s law in a time-varying
conditions. Ampere’s Law (See Figure 3.1) indicates that a magnetic field is produced by
a changing electric field and a current. For time-varying magnetic field, it includes
conduction current (for static (dc) conditions) and the displacement current. It means that
either true conduction current density J (A/m2) or by a time-varying of electric flux
density D (C/m2) through the enclosed surface can generate magenetomotive force (H).
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Ampere’s Law :
∮c H . dl = ∫s J . ds + d/dt ∫s D . ds
Faraday’s Law:

∮c E . dl = - d/dt ∫s B . ds

Figure 3.1 Ampere's Law and Faraday's Law.

In the equation of faraday’s law (See Figure 3.1), left side indicates that a voltage is
induced in the closed loop considered as electromotive force. Right side is the timechanging magnetic flux penetrating the surface whose perimeter refer as contour. Here
needs to be clarified is that Faraday’s law gives the same results for different surfaces as
long as the contour size does not change, that is, only those magnetic field lines that
penetrate the contour of surface contributes to flux. In sum, the faraday’s law refers to
time-varying magnetic flux (the average of magnetic field over the area of the loop) that
penetrates a surface bounded by contour will induce an electromagnetic force (emf)
which is very similar to a voltage source in that contour. The minus sign in Faraday’s law
is related to Lenz’s law providing that the direction of that induced emf will produce a
current in contour whose magnetic field will oppose changes in the original magnetic
field.
In our study, we based on this physics pheomenon of electromagnetic induction and
custermized a electromagnetic generator where an alternating current flowing through the
coil at a certain frequency and generates an oscillating magnetic field around the coil.
When the coil is closely positioned to an electrically conductive material, it also induced
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a current known as eddy current in the conductive materials. We hypothesized that this
current can initiate the drug release from conductive polymer Ppy.

3.1.2

Electrochemical Techniques Used for Polypyrrole Based Drug Release

The most frequently used electrochemical techniques in the Ppy based drug releasing
system are summarized in the Table 3.1 with released compound and stimulation
conditions
.
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Table 3.1. Polypyrrole based drug release.
Dopant

Released Compound

Stimulation Condition

Ref

(anion+/cation-)
Galvanostatic:
(DEX)(-)

Galvanic Mg alloy

[64]

Glutamate (-)
Sulfosalicylic acid (-)
Fluorescein (-)
ATP(-)
Salicylate and
Naproxene (-)
Hexacyanoferrate (-)
DEX (-)

-1.0V vs SCE
-0.5,-0.8,-1V
-2V
-0.6V
-0.7,-0.4V

[65]
[66]
[55]
[67]
[68]

-0.4,<-0.6V
<-0.6V

[69]
[70]

+3V
+0.5V

[71]
[72]

-0.8~+0.9V/+1.4V

[73,74]

ATP (-)
Acetylsalicylate or
salicylate (-)
Ppy/ pTS
NT-3
Biphasic Pulsed Potential or Current:

+0.6~-0.6V
-1V

[75,76]
[77]

-0.8~+1.0V

[78]

Ppy/ pTS

NT-3 and BDNF(+)

+/-0.5 and +/-20 mA at
5 Hz; -0.6~+0.6V at
5Hz; +/-1mA/cm2;

[58-60,
78,79]

ATP(-)

-0.6~+0.6V

[80]

-0.8~+0.2V

[50]

+0.4~+0.6V

[81]

Cathodic Potential:
Ppy/Cl
Ppy

Anodic Potential:

Ppy/biotin/streptavidin NGF
Poly(N-methylpyrrole) Dopamine (+)
/PSS
Cyclic Voltometry:
DEX (-)

Stepped Potentials:
Ppy/pTS

Ppy/melamin and
Chlorpromazine (+)
Ppy/Cl
Poly(N-methylpyrrole) Dimethyldopamine (+)
/PSS
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The potentiostat is an electronic device controlling constant potential difference between
the working and reference electrodes. Chemically, it refers to the flow of required
electrons in order to maintain voltage potentials at a fixed level. In some of controlledpotential techniques, such as cathodic potential and anodic potential listed in Table 3.1,
bulk electrolysis coulometry is usually the most common and desirable method used to
achieve the constant potential. On the other hand, a galvanostat is a device to measure
and control the constant current flowing through the system, instead of the constant
potential.
Cyclic voltammetry is a potential cycling technique by changing the potentials of
stationary working electrode linearly with time from no reaction occurred to potentials
where reduction or oxidation of a analyst occurred. It scans potential negatively
(reduction process) before reaching to the switching potential, and the scan reversed
where scan potential positively (oxidation process), the voltage then swept back to
original point. (shown in Figure 3.2 A and B) During this potential sweeping, the current
is measured by potentiostat device and display to a cyclic voltammogram plotted as
current vs. potential (See Figure 3.2 B). As the summary Table 3.1 shows, there also are
many investigations on the potential step techniques for Ppy drug delivery. In the
potential step measurement, the applied voltage is instantaneously jumped from one level
to another, and corresponding current were measured as a function of time. It could
include either single potential step (Figure 3.2 C and D) or double potential step (Figure
3.2 E and F). The former one is related to only the potential with forward step, and latter
case is with addition of the potential that returned to a final value following a time period.
Many stimulation methods, such as galvanostatic, cathodic potential, and cyclic
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voltammetry, have been successfully used to release DEX from Ppy plantforms. (Bolded
in Table 3.1) ()These can provide as useful reference to understand the mechanism of
DEX release.
In our study, we focus on a special stimulation technique: pulsed current stimulation.
The electrical field induced by our electromagnetic field generator (See Figure 2.5)
shares a similar pattern to that of biphasic pulsed current. The pattern of this bipolar
current is similar to double potential step shown in Figure 3.2F) with an alternative
polarity of potentials and current. The exact illustration was indicated at Rachael T.
Richardson et al. [58]
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Figure 3.2 Illustration of Cyclic Voltammetry and Potential Step techniques.
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This biphasic pulsed current generator with +/- 0.5mA current amplitude and frequency
of 5Hz has shown a successful NT-3 release for 7 days. [78] The same generator with +/1mA and frequency at 250 Hz has also indicated the potential application to produce a
long- term releasing profile by Ppy conductive polymer. [58,59,60] The most significant
drawback of biphasic pulsed current stimulation is that it requires the direct contact of the
electrode with the drug-doped polymer. This is not required in our EMF method. Our
electromagnetic generator was designed to simulate the drug release without any physical
contact to avoid any potential invasion to tissues during clinical application.

3.1.4 Electromagnetic Field in Biological and Medical Studies.
The inductive coupling of pulsed EMF technique has revealed an emerging and
substantial clinical application in tissue repair, dominantly in orthopedic application and
wound healing. A large number of studies had shown the physiological efficiency of
electromagnetic-based clinical devices.

The majority of these investigations used

extremely low frequency electromagnetic device exposure. Moreover, these devices have
been shown to be physiologically effective usually up to 20 Gauss peak time-changing
magnetic fields and up to a 150mV/cm for peak induced electric field at the treatment
sites. For example, some studies have suggested that the combined application of
alternating and static magnetic fields wigh low frequences might alter the binding
kinetics and result in the changes of ion or ligand movement in the binding site. [82]
Pulsed EMF also has shown the potentials to exert an anti-inflammatory action, alleviate
pain in arthritis and degenerative joint injuries. [83]

52
Not only extremely low frequency electromagnetic devices used in biological study,
pulsed radio frequency devices were also exploited in some application. The induced
electric field from a pulsed radio frequency devices at orders of magnitude larger, which
is approximately between 10 and 40 MHz. Among many biological therapeutic strategies,
cancer treatment commonly associated with radiofrequence devices because it can raise
the local body or tissue temperature to a desired level (effective temperature range would
be 42-45oC) to cause hyperthermia and destroy the tumors.

The application of

electromagnetic field in drug delivery system was commonly conducted with magnetic
nanoparticles, or many temperature- sensitive materials. [84] These earlier studies did not
investigate the response of conductive polymers to EMF, therefore, in our work, we
concentrated on the action of Ppy EMF exposure and its potential applications.
Concerns regarding the safety of EMF exposure to human body were also arised as the
developing the EMF associated medical application. The available data from IITRI(US),
IAF(Canada) and MKI(Japan) showed no evidence regarding to EMF related general
toxicity, including epidemiologic studies for occupational EMF exposures and
experimental studies for both animals and humans. In teratology studies, there has no
results indicating decreased in fertility in male or female animals that receiving EMF
exposures. The possible role of EMF in immunotoxicity studies and carcinogenesis have
also been thoroughly investigated. The results of these studies reveal that there are no
observable deficits in lymphoid organ cellularity or histology and T or B cell function
after exposed to the EMF field. There are few studies indicated the significant
suppression of NK cell function, but only in female mice, not in the case of male mice or
female and male rats. In some biochemical based experiment, extremely low frequency
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magnetic field (60Hz, 50 Gauss) combining with 100μm H2O2 showed a decreased
number of viable cells after 24 hours exposure time, however, there is no Bax and Bcl-2
protein level or activation of

caspase-3 apotosis signaling were observed. [85]

Combination of other noxious element (such as H2O2, FeCl2, or UVA) together with a
long-term EMF exposure could generate ROS, [86,87] but not for a short time exposure.
Zmyslony and others tested the effects of EMF with radiofrequence to the production of
ROS and showed that the 15mins of radiofrequence exposure did not alter the production
of ROS.[88]

3.2
3.2.1

Methods and Materials

Configuration of the Electromagnetic Field Stimulator

Multiple factors must be considered when designing the EMF stimulation system and
pulse conditions. These parameters include waveform shape, pulse duration, pulse
magnitude, duty cycle, etc. Three-way switchable magnetic field stimulator was custom
made for the purpose of this study. This device is an integrated system with asymmetric,
symmetric, and pulse train three different waveform conformations (Illustrated in Figure
3.5 and 3.6), and a professional electronics schematic is provided in Figure 3.3. We
chose square waveform to maximize the induced electric fields within the Ppy since that
is the hypothesized stimulus for drug release. The coil was made of AWG 16 copper wire
with 15 turns, and its geometry of the coil was build at the size of 3.0cm (W) x 3.8cm (L)
x 1.2cm (H) ( See Figure 2.5). The coil was then stimulated with a pulsing regime using a
custom made circuit. Each input pulse was only “on” long enough to saturate the coil
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(pulse width at 500ns), and then turned off for the duration required to completely unload
the coil (~10μS) (See Figure 3.6). Therefore, the duty cycle was approximately 4.8%, and
other two stimulation patterns are also maintained a ~5% duty cycle. For comparison,
sawtooth waveform shown in Figure 3.8 is also studied. This generator can be designed
by various ways, in our case, it composes of NPN and PNP transistors show in Figure
3.4.

3.2.2

Electromagnetic Field Measurements

Using the waveform patterns shown in Figure 3.5 as the input signal, the real time
magnetic and electric field output from the stimulation coil were measured using high
frequency EMC 100B (magnetic) and 100D (electric) probes (Beehive Electronics, CA).
Probes were connected to a Tektronics TDS 2012B oscilloscope and terminated with a
50Ω resistor. For data collection, each probe was positioned and oriented in the
stimulation coil center for maximum expected reading. This value was taken to be the
output probe value and converted to dBm. The recorded data points from the oscilloscope
were imported into MS Excel in which the Fast Fourier Transform (FFT) of the
waveforms was calculated. From the FFTs, the fundamental frequency, along with the
output dBm power value was used with the antenna gain equation provided for each
probe to estimate AC field magnitudes.
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3.2.3

Antenna Gain Equations

The antenna gain equations used to convert EMF probe voltage into the corresponding
magnetic and electric fields are as described:
For magnetic field (100B) probe:
Pout = 42.2 + 20log(B) + 20log(F)
Where
B is the magnetic flux density, in tesla
F is the frequency of the received signal, in megahertz
Pout is the probe output power into 50 ohms, in dBm
For electric field (100D) probe:
Pout = -113.2 + 20log(E) + 20log(F),
Where
E is the electric field strength, in volts/meter
F is the frequency of the received signal, in Megahertz
Pout is the probe output power into 50 ohms, in dBm

Figure 3.3 Schematic figure for three-way square wavefrom generator.
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Figure 3.4 Schematic figure for sawtooth generator.

3.3
3.3.1

Results

Electromagnetic Field Characteristics.

The real-time magnetic and electric field output waveforms at the coil center were
plotted in Figure 2.5. The measurements revealed that the magnetic field output was
similar to the input field, with some oscillation noise present in the square waveform.
FFT decomposition of the measured signal showed the fundamental frequency of the
magnetic field was to be 3.2MHz. This converts to average peak amplitude of 36 Gauss
when using the antenna gain equation. Moreover, the amplitude of the magnetic field did
not vary by more than 20% within the coil. The highest field amplitudes were in the x-y
plane at the center level of z-axis. Along the z-axis, there was a small drop-off in
intensity as the probe was moved away from the coil center. Overall, the magnetic field
surrounding outside the coils has weaker signals at a order of cubic decay. Therefore, all
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Ppy drug release experiments were applied within the coil and exposed to peak magnetic
fields roughly within the range of 25-40 Gauss.
Similarly, the raw electric field data is also depicted in Figure 2.5. Note that the measured
electric field corresponded to the measured magnetic field, as expected by Faraday’s law.
The electric field waveform exhibited oscillatory behavior with sharp peaks primarily
concentrated at the “ramp-up” and “switch off” phases of the EMF. The peak E-field of
was measured at 4700V/m with a fundamental frequency of 65MHz. Thus, the estimated
electric field magnitude in which the Ppy film positioned is in the 3000-5000V/m range.
The time-averaged EMF values are lower when considering the duty cycle, and would be
less than 5% of these values. The distance dependence of the electric field from the coil
center is similar to that of the magnetic field.

Figure 3.5 The input signal generated by asymmetric waveform stimulation. 500ns pulse
duration were spaced 10µs apart. These pulses were in the positive direction for 200ms
and then alternated to the reverse polarity for 10ms.
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3.3.2

Drug Release by Square Waveform Stimulation

The geometry of the signal can highly influence how effective they create the biological,
chemical, or physical responses. In our study, to compare the efficiency of drug releasing,
the releasing profile of DEX conjugated flat Ppy – AuNps films using train waveform
and symmetric waveform were also performed (See Figure 3.6). In both cases, pulses of
duration were spaced 10µs apart which is the same as that of asymmetric waveform. The
difference is that there is no reversed stimulation in the case of train waveform. For
symmetric waveform, the pulses are in the positive direction for 200ms and then
alternated to the reverse polarity for another 200 ms. EMF measurements for these two
waveforms were conducted as the study of asymmetric waveform. To define the most
effective electromagnetic fields, we compared the DEX release using these two square
waveform configurations to the results of asymmetric waveform. (See Figure 3.7).

Figure 3.6 Illustration of input signals in the case of pulse train (left) and symmetric
waveform (right). There is no reversed stimulation for pulse train waveform. The pulses
in symmetric waveform have same stimulation duration (200ms) in both positive and
negative direction.
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Figure 3.7 Comparison of DEX release from flat Ppy–AuNps films using pulse train,
asymmetric, and symmetric waveforms.

According to the results, there is no statisitcal difference between these three cases. It
could due to the magnitude of peak magnetic field and electrical field of these two
waveforms were similar to that of asymmetric waveform.

3.3.2

Drug Release Using Sawtooth Waveform

To optimize the drug release, we also developed an electromagnetic field generator that
could produce a sawtooth waveform. The sawtooth waveform can be considered as an
extreme case of asymmetric triangle waveform. The magnetic field produced on the
wave's ramp and collapses on the wave’s cliff (Shown in Figure 3.8 left) where induced
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the maximum level of electrical field. Since the magnitude of saw tooth pattern increase
very sharply, it can produce a strong electromotive forces (Figure 3.8 right), but the
polarization of electric field cannot be determined using sawtooth potential.[89]

Figure 3.8 Illustrations of the input signal of magnetic field (right) and electrical field (left)
for sawtooth waveform.

Figure 3.9 DEX release comparision between EMF stimulator with sawtooth waveform
(blue) and with pulsed square waveform configuration (green).
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Increased amount of DEX release was clearly observed using sawtooth wave stimulator
from day 1 to the end of the experiment (See Figure 3.9). However, there was no
statistical significant difference between the square wave and the sawtooth wave at any
point of the experiment. At day 16, the p value for statistical analysis was calculated as
0.06 using independent student t-test with assumption of normal distribution.

A

increased trend of the DEX released using sawtooth waveform was observed compared to
that of the square waveform. It kept a the constant increasing level during the testing,
indicating the excessive DEX release of each sample under sawtooth wave based
stimulation.

3.4

Discussion

Since the cells usually are at a condition of highly conducting ionic medium, it has been
proven that they can response to the electrical field and their biological effects are greatly
influenced by ion displacement in the body. In general, this ion displacement occurred
due to the peak voltage value also represented as the electromotive forces. This
electromotive forces can be initiate at abrupt "falling " time in a given pulsed signal,
depending on the electrical characteristics of the coil employed, the shape or waveform of
the electromagnetic signals, and how fast the rising and falling time changes. Among
various waveforms, both sawtooth and square signals are far more abrupt than the simple
sine waveform. The advantage of sawtooth pulse form is that it simultaneously contains
various individual sine vibrations with broadest frequency and amplitude. These can
composed of the similar frequency and amplitude of oscillating wave from cell
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membrane. In this case, cell membrane can respond to the resonate frequency which
similar to the cell’s natural frequency. This waveform is first introduced by Dr.
C.A.L.Bassett and proved by FDA for the treatment of non-union fractures and assist
spinal fusion operations. This is based on Faradays’ law we described earlier, that is:
changes in the electromagnetic signals can induce an electrical current, and the maximum
current induces when the magnetic flux changes most abruptly. Since the intensity of
electric field is dissipating from the center of the coil in our case, the higher level of
induced electrical field generated from alternating magnetic field may compensate the
negative impacts of the distance. In this case, the actual penetration capability of the
induced current can be critical for this drug delivery system to be used in clinical
applications, and it usually refers to the standard depth of penetration equation. This
penetration involves with several parameters. The penetration decreases when eddy
current at a higher frequences travelling through a materials with high conductivity and
permeability. Since redox properity of Ppy requires highr conductivity in order to release
the drugs, we need to adjust the stimulator to larger coil size and lower pulse frequences
in order to achieve an increased penetration of both magnetic field and current flow.
Therefore, we would not be limited during in vivo application because of the larger tissue
depth.
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CHAPTER FOUR
ATTENUATION OF SECONDARY INJURY
BY ELECTROMAGNETIC RESPONSIVE POLYPYRROLE DRUG DELIVERY

4. 1
4.1.1

Introduction

Cellular, Molecular, and Biochemical Cascades in Spinal Cord Injury
4.1.1.1

ROS and RNS

Collected evidences have identified that the activation and accumulation of resident
microglia and infiltrating macrophages after spinal cord trauma can cause inflammatory
and immune responses which can amplify the destruction. Macrophage and microglial
cells can be activated by different endotoxins or cytokines, such as TNF-α,
lipopolysaccharide (LPS, a component of the wall of Gram-negative bacteria), and a
combination of interferon γ (IFN-γ) and LPS, or H2O2. Then, they can trigger various
inhibitory molecules, such as IL-1β, TNF-α, nuclear factor-kappa B (NF-κB), nitric oxide
(NO), and ROS which initiates a cascade of neuropathological events and results in the
cellular death via necrotic or apoptotic pathways. In our study, we focused on the RNS
and ROS production due to the suppressive ability of DEX to them (See details at 4.1.2)
and their detrimental effects to SCI. These can be used to test drug delivery efficiency in
vitro and in vivo studies.
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During the activation of macrophages, inducible nitric oxide synthase (iNOS) utilizes
oxygen and electrons from nicotinamide adenine dinucleotide phosphate (NADPH) to
oxidize the catalytic substrate L-Arginine into NO. NO and superoxide (•O2-) are radical
effectors of the innate immune system that helps to inhibit the growth of invading
microorganisms. Although NO is an anti-bacterial and anti-viral effector and can protect
the brain and spinal cord from certain infectious diseases, excessive levels of NO can also
be toxic to neurons and could cause neuroinflammatory conditions after SCI. Many
studies have suggested that synergistic reaction of NO and superoxide can produce
cytotoxic molecules peroxynitrite (ONOO-) which can readily oxidize nucleic acids,
proteins, and unsaturated lipids [90,91] causing neuronal cell death in SCI. [92,93,94,95]
Furthermore, reactive intermediates of over-expressed iNOS are mutagenic and would
not only lead to DNA impairment but also results in the growth of tumors in CNS.
Suppressing ROS production also critical in SCI because they contribute to lipid
peroxidation by attacking the cellular membranes, especially to polyunsaturated fatty
acid, and many other macromolecules, such as protein and nucleic acid, leading to the
neuron death. ROS usually refers to small molecules •O2-, hydrogen peroxide (H2O2), and
hydroxyl radical (•OH) that are generated during the electron transfer process of
mitochondria as well as the unstable intermediates during the lipids peroxidation. The
hydrogen peroxide is generated from superoxide via superoxide dismutates. Hydrogen
peroxide can either be converted to a strong toxic oxidant hypochlorous acid by
myeloperoxidase (MPO) or converted to highly reactive hydroxyl radical during the
Fenton reaction, or converted to water and oxygen becoming non-toxic when catalyzed
by catalase and glutathione (GSH) peroxidase. Aerobic organisms can reduce molecular
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oxygen (O2) in water to creat energy. During this process, partially reduced oxygen
species are inevitably generated, such as superoxide, which is not detrimental in low
concentrations. However, an abnormally excessive production of various ROS causeing
an imbalance between radical generation and scavenging which will actually cause
damage. This imbalance is represented as oxidative stress and always occurres after SCI.
Since radicals have an unpaired electron, they can become highly reactive with any
macromolecules and damage them by modifying their structures and/or functions.

4.1.1.2

ROS and RNS

Associated Mitogen-activated Protein Kinases Signaling Pathways
It has also been implicated that the cascade of secondary damages in SCI is closely
involved with the regulation of mitogen-activated protein kinases (MAPKs) signaling
pathways. [96] Phosphorylation of MAPKs on a specific activation loop which contains
a characteristic threonine-x-tyrosine motif active three principal subfamilies of MAPKs
signaling pathway: extracellular signal-regulated kinases (ERKs), p38mapks, and c-Jun
NH2-terminal kinases (JNKs) or stress-activated protein kinases (SAPKs). Thus, the
initiation of the subfamily of MAPKs in the study of secondary injury after SCI was
critical. [97,98] They especially play an important role in NO assoicated deterioraton of
neuronal activity in the SCI. [99] Therefore, the inhibition of MAPKs family signaling
pathway implies the physiological importance to neuronal recovery after traumatic injury.
In a microglia-neuron co-culture condition, p38 and JNK inhibitors can partially rescued
neurons from death after LPS challenge. [100] Also, inhibiting ERK1/2 pathway may
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eliminate cortical neuron damage after IL-1 insults. Administration of the specific
inhibitor of MAPK3/MAPK1 (PD98059) significantly improved motor functional
recovery. These evidences demonstrate that the activation of MAPK highly influence the
secondary injury after spinal cord trauma. [96]
The activation of MAPK can be initiated by the ROS related oxidative stress, and ROS
blocking approaches have showed the inactivation of this MAPK signaling
pathway.[101,102] This ROS medicated activation can be due to oxidation of growth
factors, oxidative modification of intracellular kinases, such as thioredoxin, and downregulation of inactive members in MAPK pathways, such as mitogen-activated protein
kinase phosphatase 1 (MKP-1). [102,103,104,105,106,107] There is an abundance of
literatures reporting that the activation of several MAPK families signaling pathways
including ERK1/2, ERK 5, JNK, and p38 can be initiated by H2O2 and then generates
ROS.
The MAPKs have also been shown to be involved in activating many transcription
factors and directing cellular responses to various noxious stimuli, for example,
proinflammatory cytokines. The transcription regulation of iNOS has been reported to
involve with JNK pathway by IFN-γ +TNF-α. [108,109] Further studies have indicated
that the LPS or combination of IFN-γ and LPS stimulated ERK and p38 mapk cascades
of signaling molecules regulate the induction of iNOS in glial cells. [110] Thus, we
designed our experiment using LPS and H2O2 as stimuli to initiate iNOS and ROS via
MAPK signaling pathway.
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Dexamethasone, as a well-known anti-inflammation drug, has shown its successful
regulatory effects on inflammatory responses. It has also been known to antagonize LPSinduced JNK/SAPK pathway via inhibits the production of cytokines, TNF- α, [111] and
partially limit the pro-inflammatory gene expression by inducing the expression of MKP1.[112] Suppression of NF-κB activation by glucocorticoids can result in iNOS down
regulation in some cells line .[113] Further results indicate that the suppression of LPS
activated MAPKs by dexamethasone blocks the iNOS expression and ROS production.
[114] The different concentration of dexamethasone between 0.1 to 10μM has been
proved to inhibit the expression of iNOS in a dose-dependent manner when applied to
primary cultured rat hepatocytes, [115] vascular smooth muscle cells, [116] murine
macrophages, [117,118] and activated microglia. [114] In primary microglia culture, the
NO production can be suppressed to 50% and iNOS protein and mRNA expression can
be downregulated to 70% by administration of DEX. [119] All the supportive evidences
showed a well-established in vitro model for testing the DEX release from Ppy using our
non-invasive EMF stimulator.

4.1.2

Evidence of Neuronal Recovery by Inhibition of iNOS and ROS

The enhanced production of ROS and NO has been reported to associate with neuronal
death after SCI. Among the ROSs, H2O2 and OH. are known detrimental effectors for
oxidative damage. Antioxidants and antioxidant enzyme can inhibit ROS and ameliorate
motor neuron damage and

dysfunction after SCI. [120,121] The potential

pathophysiological role of elevated iNOS level in SCI has been investigated in many
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studies and many experimental models indicate that the inhibition of over-expressed
iNOSs during earlier phase of SCI leads to a modest functional recovery. (See Table 4.1)
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Table 4.1 iNOS inhibitors and their neuroprotective results.
iNOS inhibitor

Charateristics

Results

Ref.

Cyclosporin-A
(CsA)

Protect damage tissue from lipid peroxidation
(initiated by free radicals) and reduce the
formation of RNS, such as peroxynitrile.
Nucleophilic hydrazine compound, selective
inhibitor, more effective at inhibiting the
enzymatic activity of iNOS than eNOS and
nNOS.
Significantly inhibited LPS-induced activation of
JNK and p38 MAPK signaling pathway via NFjB and AP-1.
Non-selective competitive inhibitor of NOS,
associate to the L-Arg binding sites, usually as LArg analogues.
Selective nNOS inhibitor and potent
against iNOS
Oxidized the redox modulatory site of N-methylD-aspartic acid receptor. The production of NO
complicate this receptor medicated neurotoxicity.
iNOS gene deficient.

A significantly better myelination index, motor
recovery, red nuclei neurons survival, and axon
growth.
Decreased lesion volume and significant
recovery of rat hindlimb motor function after
spinal cord injury.

[122]

Aminoguanidine
(AG)
Flavokawain A
Nomega Nitro-Larginine-methyl
ester(L-NAME)
3-bromo-7nitroindazole
Pyrroloquinoline
quinone (PQQ)
NOS knock out
mice
ASOs

iNOS antisense oligonucleotides.

Reduce iNOS expression and many proinflammatory cytokines in macrophages, such
as TNF-α, IL-1β, and IL-6.
Results in reduction of necrotic volume and
damaged cells in the lesioned area.

[124]

Significantly decrease contusion volume after
traumatic brain injury.
Significantly decreased lesion size and increase
axon density and promote the functional
recovery of SCI.
A gradual improvement of motor function and
no observation of delayed neuron damage.
Significantly decreased iNOS positive
immunoreactive cells and retard neuronal cell
death at the injury site.
As the results as ASOs treatment, but less
effective. Negatively regulate the LPS activated
macrophages.

[126]

[125]

[127]
[128]
[129,
130]
[131]
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N-[3(Aminomethyl) Selective iNOS inhibitor.
benzyl] acetamidine
(1400W)

[123]
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4.1.3

Gilal Cells in Spinal Cord Injury

The spatial and temporal glial activation can further complicates and intensifies the
detrimental effects after intial physical damadge at spinal cord, resulting in sequences
sensory and motor repairment. Many previous studies reported a variety of astrocyte and
microglial activation patterns in regards to different injury model, locations, and methods.
[132] The summary is illustrated in Table 4.2.
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Table 4.2 Glial responses after SCI.
Sites Animal Injury Methods
Spinal Contusion Injury

Glial Response After SCI

Ref.

T10

Rat

NYU-MASCIS

Astrocytes: start day2 and
decreased till day30

[133]

T10

Rat

IH Imapctor

Glial:persistent activation for 2hrs3months

[134]

Microglial:1-12wks

[135]

Astrocytes and microglial: start at
day1

[136,
137]

Metal Rod (2mm in
diameter, weight 30g)
Spinal Cord Compression Injury
T12

Rat

T11

Rat

Clip Compression

OSU-ESCID
T8
Mice (Eelectromagnetic
Astrocytes: day2-1month
Device)
Spinal Hemisection/Hemitransection Injury
T13

Rat

Adjustable wire knife,
right lateral hemisection

Micro-scissor, left
lateral hemisection
Micro-scissor, right
T8/9
Rat
dorsalventral
hemisection
Spinal Ishemic Injury
Argon laser beam with
560nm wavelengths
T8
Rat
after rose bengal
injection
8kLux illumination with
T8
Rat
halogen lamp after rose
bengal injection
Argon laser beam with
560nm wavelengths
T8
Rabbit
after rose bengal
injection
Spinal Excitotoxic Injury
T12

T7
Right
striatum

Rat

[138]

Astrocytes and microglial: day7
persistent to 3months

[139]

Microglial: start at day 1;
Astrocytes: day3-over 4wks

[140]

Microglial: day2- over 3wks

[141]

Astrocytes and microglial: start at
day2

[142]

Astrocytes: <1hr-2wks

[143]

Astrocytes and microglial: start at
2hrs

[144]

Rat

NMDA-induced

Astrocytes and microglial: start at
day1

[145]

Rat

Quinolinic Acid
(NMDA Receptor
agonist)

Astrocytes and microglial: start at
day1 and developed from day 7 to
1month

[146]
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4.1.4

In Vivo Applications

In neuroscience study, various prosthetics and medical devices are commonly used to
assist the patient with traumatic injury or other neurodegeneration diseases and
neurologic disorder. Recording/stimulating electrode arrays often accompanied with
these devices either to stimulate the neural connection and muscle movement or to
analyze the encoded information from neuronal tissues. Because these devices can be
invasive to the tissue and causes negative impacts on patients, the local delivery of antiinflammation drug could be an appropriate approach to optimize the conditions. The
local drug delivery generally can be used to achieve high concentration drug
administration at targeted site while minimizing risk of side effects. Many studies have
shown the anti-inflammation treatment of DEX in many implantation cases. DEX
released from nitrocellulose-based coating materials on silicon neural probes can
facilitate a long-term recording without accelerating the glial scar formation around the
recording sites. [147] Other researches also have unveiled the potentials of DEX local
delivery to eliminate the activation of microglia, macrophages (stained by ED-1), and
CSPG expression (stained by CS56) one week after implantation.

In addition, the

number and density of reactive astrocytes evidenced by glial fibrillary acidic protein
(GFAP) staining were also remarkably reduced by DEX release at both 1 week and 4
weeks after probes invasions to brain, indicating local treatment of DEX can reduce
astroglial ovre-responses.[147]
In addition to microglial and macrophages, astrocytes are indispensable component to
modulate the inflammatory processes of neurological disease and neurotrauma.
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Astrocytes produce many inflammatory chemokines, such as KC (also known as
CXCL1), and MIP-2 (CCL2), immediately after injury and responsible for the early
neuroinflammation.. The over-activation of astrocytes was also contribute to the
inhibitory molecules, including of tenascin, semaphoring 3, ephrin-B2, slit proteins, and a
CSPG after SCI. Especially for proteoglycans, it is believed that it creates the
nonpermissive environment for axonal regeneration. Under the presence of these
inhibitory molecules, the axons from peripheral regions are unable to reach to the damage
site of spinal cord and end up to a dystrophic state causing the regeneration failures. [148]
We can say, the neuronal activity are mostly likely to be interrupted or inhibited not only
by mechanical boundary but also by the production of inhibitory molecules induced from
activatived astrocytes. [149,150] Manipulating the environment of the extracellular
matrix and attenuating the production of inhibitory molecules would provide an
opportunity for a successful neuronal recovery.
Astrocytes reactivity and reactive astrogliosis were usually characterized as increases in
GFAP level which occur rapidly after CNS injury, GFAP was generally considered as an
indicator of alternations in astrocyte phenotype. The severity of astrogliosis is classically
determined based on the morphology, numbers, and levels of GFAP and vimentin
expression. [151] Therefore, the massive up regulation of GFAP was associated with the
increased spread of inflammation in response to all CNS injuries and disease. One
previous study described that the proliferation of immunoreactive GFAP expressed
reactive astrocytes increased as the motor neurons in lower spinal cord of mice
progressively deteriorated. [152] Inhibition of over-activated GFAP postive astrocytes
can promote white matter preservation and axonal sparing, allowing an improved
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functional recovery after SCI.[153] The actual role of GFAP was also exploited along
with astrocytes study in CNS. It is believed that GFAP, as intermediate filament in
astrocytes, contributes to the maintenance of myelination and structuration of white
matter,[154] but also glia scar formation with vimentin. One study based on cultured
neonatal astrocytes which are believed to have similar characteristics of reactive
astrocytes unveiled that the inhibitory function of GFAP on neurite growth. The study
using a GFAP null mice models response to direct injuries didn’t suggest the different
degree of scar tissue formation or improved neuron production compared to wild type
mice, but showed the poor scar formation in the case of neurotoxins application,
infection, Alzheimer’s disease, and multiple sclerosis.[155]
Since activation and reactive gliosis indicated by increased GFAP intermediate filament
proteins proliferation, we used a GFAP-luc mice as animal model, which can express
upregulated GFAP signals after SCI, to detect the release of DEX in vivo studies as well
as its therapeutic effects for neuroinflammation treatment.

4.2
4.2.1

Materials and Methods

ROS Production in Challenged and Treated Microglial Cells.

The microgilal BV-2 cells were mainteined in Dulbecco’s modified Eagle’s medium
(Sigma-Aldrich) containing 10% fetal bovine serum, 100 IU/ml penicillin, and 100 μg/ml
streptomycin at 37oC in a humidified incubator with 5% CO2. Cells were harvested by
trypsinizing and reseeded in 12-well plate for 24 hours at cell density of 1*106. They
were then incubated with 1μg/ml Lipopolysaccharides (LPS; Escherichia coli 026:B6
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from Sigma-Aldrich) for 6 hours, and followed by 1μg/ml DEX treatment for 1 hour. In
addition, approximately 30-40 mm2 size of PpyNWs-AuNps films were placed in cell
culture and stimulated for 30 minutes or 1 hour by pulsed EMF after LPS challenge. The
similar procedures were also applied to another group at exception of no stimulation of
EMF. For control groups, cells were only received six hours of LPS challenge. Then all
cells were trypsinized, centrifuged, and resuspended in PBS containing 10μM oxidative
stress indicator (CM-H2DCFDA, Molecular Probes). Suspended cells were then placed
into the incubator for 1 hour, then the production level of ROS was detected using the
fluorescence plate reader. ROS expression was also imaged by a fluorescence microscope
with an X-Cite series 120PCQ fluorescence illumination source (Olympus IX 81
inverted). Moreover, another strong oxidizing reagent, hydrogen peroxide (H2O2) was
used to confirm the LPS results. The experiment was based on the company instruction
for OxiSelect Intracellular ROS assay kit (Cell Biolabs, Inc.) Briefly, BV-2 cells were
seeded in black 96-well plates for 12 hours and then incubated with 1mM DCFH-DA
solution for 1 hour. The medium with 20μM hydrogen peroxide was then placed in each
wells except the ones for control groups and incubated for 30 minutes. DEX treatments
were applied for another 15 minutes after disrecard hydrogen peroxide contained
medium. To evaluate DEX release by EMF stimulation, the PpyNWs-AuNps films
placed in the wells for a 15 minutes stimulation. The fluorescence signals of all samples
was then read using a fluorescence plate reader. In all instances, the coil was placed
below the culture plate during the EMF stimulation.
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4.2.2

Immunofluorescence Labeling Assay.

BV-2 cells were cultured on Poly-D-lysine (Sigma) pre-coated round cover glass (#1.5
thickness, 12 mm) in 12-well plates for 24 hours. After appling LPS, DEX, and released
DEX, BV-2 cells were fixed at room temperature for 30 minutes using 4%
paraformaldehyde solution. Then, the cells were incubated in 1% albumin from bovine
serum blocking buffer for 1 hour, and subsequently incubated in primary antibody
solution containing anti-nitric oxide synthase II antibody (EMD Millipore) (1:400)
overnight at 4 ℃. Next day, diluted Cy3 conjugated goat anti-rabbit IgG antibody
solution (EMD Millipore) (1:100) were applied to cells for 2 hours. Dried cover glasses
were mounted on glass slides using vectashield hardset mounting medium with DAPI
(Vector Lab). These samples were all imaged with a confocal microscope (Leica SP5
/STED /MP System).

4.2.3

Surgical and Treatment Procedures

The demonstration of surgical and treatment procedures are shown in Figure 4.3. All
aspects of animal care and treatment were carried out according to the guidelines of
Purdue Animal Care and Use Committee (PACUC). Female GFAP-luc transgenic mice
were purchased from Taconic. Surgery began when mice reached the age 9-12 weeks old
and their weight was above 22g. Animal anesthesia was applied by intraperitoneal
injection with ketamine 90 mg/kg and xylazine 10 mg/kg. All the mice then received a
bilateral, hemilaminectomy procedure at low thoracic region. The dorsal surface of the
dura mater was exposed at a size of approximately one third of the cord. SCI was induced
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by clamping to exposed cord under stereoscopic illumination. For Ppy control and Ppy
treatment group, the DEX doped polypyrrole films was lifted on a drop of sterile saline
and deposited on the dorsal domain of injured spinal cord. The lesion was surgically
closed in layers, and then skin were closed and sutured. Animals were then moved to
their individual cage and warmed with incandescent lights until recovery. Also, all mice
were received buprenorphine HCl after surgery and the next day.
The control group only received the SCI. Sham-treated animals (Ppy control group)
possessed DEX doped PpyNWs, though the polymer was not exposed to the EMF
stimulation. For Ppy treatment groups, the first treatment of released DEX by EMF
stimulation was conducted within three hours after surgery. During the treatment, the coil
was positioned over the arch of the animal’s back and brought to the surface of the
epicenter of spinal cord lesion site when animal were under isoflurane anesthesia. (See
Figure 4.3) The highest intensity of the EMF was roughly at the center of coil.
Stimulation of EMF was applied 2 hours daily for seven days. The mice were euthanized
and followed by fixation perfusion at seven days after injury. Two animals were
euthanized before 7 days due to the condition of animals self-damaging their rear limbs,
and they were replaced, prior to the end of the experiment.
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4.2.4

Whole Animal Bioluminescent Imaging

At day1, 3, and 7 after spinal cord injury, mice were imaged using Caliper IVIS Lumina
II at the Purdue Multi-scale Imaging Center (MUSIC). One of common luciferase
substrates, D-Luciferin - K+ Salt Bioluminescent Substrate (Perkin Elmer) at 15mg/ml in
DPBS was freshly prepared and all mice received intraperitoneal injection at 10μl/g of
body weight before imaging. All mice underwent imaging during short period of
immobilization under isoflurane anesthesia. Luciferin kinetic study was performed with
peak wavelength at 560nm and the maximum signal was determined between 18-22
minutes after luciferin injection. The quantitative data of luminescent density were
confined at the region of interest (ROI) around spinal cord region and also analyzed with
setting at the range of 9.5e5 to 1.2e7 p/sec/cm2/sr. A automatic ROI measurement
methods is used to identify the bioluminescent emission automatically with fixed
threshold.

4.2.5

Statistical Analysis

All the data are shown with standard error of the mean + SEM. Comparative independent
student’s t test, Tukey's HSC multiple comparisons tests were used for in vitro studies,
and one way ANOVA followed up with three Fisher's LSD post hoc were used for in
vivo study to detect the statistical significance. Statistical significance were determined
by a P-value < 0.05. Prior to conducting the ANOVA, the assumption of normality was
evaluated and the normality test is determined based on the level of skew and kurtosis
less than 2 and 9, respectively.
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4. 3
4.3.1

Results
ROS Detection

ROS production was detected after challenge murine neonatal microglial cells (BV-2)
with two toxins, LPS and H2O2. In one group, cells were received the LPS (Figure 4.1 AG) and in the other, the cells were directly insulted with H2O2 (Figure 4.1 H).
Additionally, the treatment either by direct apply DEX or release DEX via EMF was also
evaluated to determine whether they can reduce ROS generation and rescue damaged
cells.
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Figure 4.1 Composite fluorescence signals and quantitative measurement of ROS. (A)
Control: without LPS insult. (B) BV-2 cells challenged by 1μg/ml LPS, showing intense
ROS production indicated by green fluorescence signals. (C) Introduction of 1μg/ml
DEX treatment after LPS insults (D) After LPS incubation, cells were applied with
combination of DEX doped PpyNWs-AuNps film and EMF stimulation for 30 minutes
(E) for 1 hour stimulation (F) without EMF stimulation. (G) Corresponding graph
describes the quantitation of ROS production in panels (A-F). Values shown as percent
normalized to control. (H) Quantitative data of ROS production after H2O2 insults and
DEX treatment. * P < 0.05, ** P < 0.01.
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CM-H2DCFDA, as ROS indicator, was used to measure the ROS production during this
experiment. BV-2 cells treated with LPS (1μg/ml) exhibited intense green fluorescence,
indicating the enhanced production of oxidative stress (Figure 4.1 B). The addition of
DEX (1μg/ml) after LPS challenge effectively suppressed ROS production during the
inflammatory cascade (Figure 4.1 C). ROS production was nearly undetectable when
applied DEX-doped PpyNWs-AuNps platform with EMF stimulation for 1 hour (Figure
4.1 E). A less suppression of ROS activity occurred when shorter stimulation times
(30mins) were applied (Figure 4.1 D). In contrast, DEX-doped PpyNWs-AuNps film not
subjected to EMF stimulation did not show signs of ROS scavenging. (Figure 4.1 F)
Similarly, more ROS byproducts in BV-2 cells were observed after 20 μg/ml H2O2
exposure. (Figure 4.1H). This increased level of ROS was supressed either by direct
application of 10 μg/ml DEX for 15 mins or with 15 mins of EMF stimulation to the
DEX coupled PpyNWs-AuNps.

4.3.2

iNOS Suppression by Dexamethasone Release

Above findings were further corroporated by the results of iNOS measurements. The
iNOS expressions were demonstrated by labeling of Cy3 (red) fluorescence signal. The
control group does not show any iNOS expression due to absence of LPS challenge.
Microglial cells showed intense fluorescence signals (primarily localized in the
cytoplasm regions) when exposed to a higher concentration of LPS (10μg/ml) (Figure
4.2), showing significant upregulation of iNOS. A less upregulation of iNOS expression
was observed at a reduced LPS concentration while PpyNWs-AuNps not stimulated with
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EMF (Figure 4.2 DEX w/o STI) also showed a similar response. In both cases, there is
apparent iNOS expression occurred, showing the potentials of NO-mediated cell
damadge. In contrast, EMF stimulation of DEX conjugated PpyNWs-AuNps resulted in a
strong suppression of iNOS as directly applied DEX treatment (Figure 4.2 DEX STI 1hr
and DEX 1μg/ml), also indicating a reduced level of nitric oxide. These results addressed
the successful DEX release using EMF stimulation and also indicated the stimulated
DEX remain bioactivityfor iNOS supression. These results are all in agreement with the
ROS results showed in Figure 4.1.
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Figure 4.2 Confocal images of the iNOS expression after LPS induction and DEX
treatment in BV-2 cells. iNOS expression in BV-2 cells is shown as red fluorescence
(CY3 column). Nuclear staining with DAPI is shown as blue signal (DAPI column). The
control group didn't receive any LPS challenge and DEX treatment. The row LPS
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10μg/ml indicate the stimulation of high concentration LPS and high iNOS production.
Row LPS 1μg/ml showed lower concentration of LPS applied to the tested cell
population. DEX doped PpyNWs-AuNps film not stimulated with EMF (DEX w/o STI)
showed a similar response as in LPS 1μg/ml. Row LPS1μg/ml:DEX1μg/ml illustrates the
results when direct DEX treatment applied while row LPS1μg/ml:DEX STI 1hr as
comparison indicating the DEX relase treatment when PpyNWs-AuNps film was
stimulated with EMF for 1 hour.

4.3.3

Selection of Animal Injury Model

GFAP – luc transgenic mice were chosen because they were genetically engineered to
express firefly luciferase under the control of the GFAP promoter, so that they can
express the level of GFAP protein as feature of astrocyte activation and reactive gliosis
when there is alternation of astrocytes occurred in the healthy nerve tissue of CNS. This
GFAP expression can be initiated by any insults, such as directly injury, bacterial
infection, neurodegenerative disease, ischemic defects, and tumors. This technique
combining transgenic mice with bioluminence imaging system can permit multidimensional imaging of GFAP expression and its changing dynamics in the living
animal.
The SCI was induced at low thoracic regions with a compression method illustrated in
Figure 4.3. This is not a robusting injury and intentionally very mild to ensure the low
mortality and not severe behavioral deficits during a week of study. The compression
method has been reported to be able to active the astrocytes starting at day 1 after SCI.
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[156,157] Since we focused on the study of neuroinflammation, not behavior testing, the
compression method has been considered as suitable for this situation.

Figure 4.3 Illustration of SCI procedures and EMF stimulation set-up. A) shows a spinal
cord compression using blunted forceps. The dimensions are exaggerated for explanatory
purposes. The cord was compressed to a depth of approximately 50 % of its diameter.
The degree of lateral compression was also approximately >50% of the cord's diameter,
and arrested by a detente built on the inner face of the forceps. B) The PpyNWs thin
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film was physically placed on the injured site immediately after compression. C)
Experimental setup. This illustration shows the application of the EMF to a spinal cord
injured mouse under anesthesia. a) The background shows the integrated system and
power supply for the generation of the EMF. b) The coil positioned directly over the
spinal cord injury in the mouse.

4.3.4. Neuroinflammation Attenuation by Drug Loaded Polypyrrole Implant
All mice were distributed to three study groups: Control Group: animals only receive
SCI; Ppy Control Group: animals received implantion of DEX doped PpyNWs film,
though they were not exposed to an externally stimulated electromagnetic field; Ppy
Treatment Group (Experimental animals): the identical implantation procedures were
applied as Ppy control group with exception to the EMF exposure. An applied EMF is
required to induce the release of DEX from the PpyNWs.
Figure 4.5 shown the bioluminescent images of three groups of GFAP-luc transgenic
mice at day 1, 3 and 7 after SCI. The data illustrated by bioluminescent imaging system
can provide the level and specific sites of GFAP expression and can compare relative
GFAP intensity between groups. The quantitative data can be expressed via converting
the ROI of the images in relative lights units (CCD camera counts) to a physical units of
radiance (photons/sec/cm2/sr). It means that the total flux of photons or radiance in each
pixel (photons/sec) was integrated over the ROI area and then multiplied by one steradian
(sr). The upregulation of GFAP mRNA or we may say luciferase protein after SCI can be
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visualized after injection of the luciferase substrate D-luciferin due to the reaction shown
as below Figure 4.4.

Figure 4.4 Luciferin and luciferase reaction based bioluminesence imaging.
The image and descriptive statistics of the GFAP expression are reported in Figure 4.5
and 4.6. There was a trend for the intensity of GFAP to become reduced in all groups of
animals. A statistical difference between two control groups during the entire experiment
was not detected. There always had a clear and observable GFAP expression at every
time point in these two control groups. It has also been shown that the EMF induced
DEX release produced a relatively steep decline of GFAP level.. The experimental
groups were always associated with numerically smallest mean level during the detection.
At the first measurement day post-injury, the mean value of GFAP expression was 60%
lower than control values, though this difference did not reach significance given the
wide variability of the means 24 hours after surgical injury (P > 0.05). By day 3, this
radical decline in experimental animals was very significant compare to the control
groups both visually and statistically (P < 0.01). The statistical testing between control
and Ppy treatment groups, between Ppy control and Ppy treatment groups also yielded a
significant effect (P < 0.05) at day 7. Moreover, at post-surgery day 7, 2 of 5
experimental animals did not possess a trace of GFAP. The other animals in this group at
this time point revealed GFAP expression only at the barest level of detection. It has also
been seen that the standard error of the means (SEM) of the experimental group was
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significantly smaller compared to both control and Ppy control groups at day 3 and day 7.
(See Figure 4.6)
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Figure 4.5 Bioluminescent images of mice in control, Ppy control, and Ppy treatment groups. Each row is one individual at 1 day,
3 days, and 7 days post injury. Note that, at day 7, the GFAP signal is at the barest level of detection or completely absent in
treated animals. Clear GFAP signal from ear infections, as internal controls, are observed in all animals at all times. The
90

luminescent intensity given in units of radiance is shown at the scale bar at the far right.
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Figure 4.6 Quantitative data of GFAP expression based on bioluminescent results. GFAP
expression displayed is given as a function of time at post-injury. Note that EMF treated animals show striking and statistically significant reduced values compared to
controls. * P < 0.05; ** P < 0.01.
GFAP signal associated with ear infections was also observed which was present with all
received transgenic mice. (Figure 4.5) It is important to point out that GFAP positive ear
infections in all animals can be provided as “Internal Control”. This Infection was not
reduced or otherwise affected in either control groups or experimental samples. Note that
the level of GFAP expression in ear regions (Figure 4.5) did not indicate the strongest
signals when figure is captured since the kinetic study of this signal is based on the region
of spinal cord. We suggest that the reduction of GFAP level in spinal cord region is
explained by the likelihood of released DEX after EMF exposure. This observation
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provides formal proof that the local release of DEX by smart PpyNWs was restricted to
the spinal cord lesion, where DEX-doped PpyNWs were surgically placed and later
exposed to an EMF.

4.4

Discussion

The functionality of glial cells was extensively investigated in SCI studies. Activated
microglial cells triggers many pro-inflammatory factors, ROS, and RNS, initiating cell
apoptosis cascades. Also, many studies implicate that not only physical barrier of
astrocytes mediated scar formation, but also the inhibitory molecules triggered from
reactive gliosis contributes to the abortive neuronal regeneration after SCI. Thus, glial
cells have been emerged as an attractive target in many CNS related pathological context.
In this study, we used LPS and H2O2 challenged microglial cells (BV-2) in vitro and
spinal cord compression model in vivo to simulate the neuroinflammation conditions and
then detect the releasing profile of anti-inflammation drugs DEX using a novel
application of EMF-sensitive conductive polymer based drug delivery systems under this
neuroinflammation conditions.
Among all the harmful molecules produced from gilal cells, we primarily study the ROS
and RNS production. It has established that NO primarily produced from macrophages
and microglial cells via iNOS expression and act as a neurotoxic agent in spinal cord
injury model, brain ischemia, and hypoxia. However, some researches also shown that
NO may exerted neuroprotective functions and particularly resistant to neurodegeneration
in Huntington’s disease. [158] Therefore, balancing the level of NO production is very
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important and vary based on different neuronal degeneration disease and neurological
deficits. According to many case studies of SCI, the reduction of NO-mediated
neurotoxicity showed potentials to achieve the successful neuronal recovery and avoid
the functional impairments.
Since the possible ROS and NO reduction of DEX, we deliver the DEX from EMF
sensitived conductive polymer Ppy to LPS and H2O2 challenged microglial cells, and test
the successful delivery of DEX according to the cellular responses. The results showed
dramatically suppression of iNOS expression by DEX at 1μg/ml and moderate reduction
to ROS. Many studies also confirmed these outcomes. In the study of hyperglycemia,
DEX has been proven to reduce ROS levels in multiple myeloma cells through regulation
of thioredoxin activity.[159] Low concentrations of DEX in a range of 10nM to 1μM
substantially inhibition of IL-1 beta, IL-6, and TNF-alpha secretion.[160,161] Lina Ruiz
et al also reported that DEX can delay neutrophil apoptosis by inhibiting ROS generation.
[162] In addition, DEX suppresses intracellular ROS production in platelets [163] and
directly blocks LPS-induced ROS production in microglial cells by up regulation of
MKP-1.[114] However, long term administration of DEX can accelerate the oxidation
process in some tissues and imbalances the lipid metabolism. [164] One study has shown
increased ROS levels of differentiated M2 macrophages induced by DEX when applying
DEX for 7 days but not 2 days. [165] Our experiment also addressed similar
phenomenon. DEX failed to reduce or , in some situation, initiated production of ROS
when a higher concentration of DEX (10 μg/ml) was applied to a low concentration of
LPS (1μg/ml) stimulated microglial cells. Also, we challenge the cells with different
concentration of H2O2 range from 5μM to100μM with various concentration of DEX at
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similar range. The results showed that DEX can eliminate low production of ROS, but
not for a high level of ROS. This is indicated by a failure ROS reduction of DEX when
H2O2 at concentration of 50 μM or above were applied to the cells. (data not shown here)
Although a clear explanation to the role of GFAP is still under exploration, it is important
to realize that the GFAP level that not be expressed under normal circumstances indicate
the changes in the function and secretion of the astrocytes and normally due to
neuroinflammation related reative astrogliosis. Many investigations showed that
increased oxidatively damaged proteins can also cause the increased GFAP expression in
different neurodegeneration cases. [166,167,168]

In our SCI study,

a GFAP-luc

transgenic mice combining with bioluminescent imaging technique were used to trace the
spatial and temporal changes of GFAP expression after SCI. We reduced these GFAP
signals by releasing DEX via EMF from local Ppy nanosouce which placed at spinal cord
lesion. The results from our study indicated a significant statistical difference between
treatment and control groups at day 3 and 7, but not the first day after injury although it
showed an apparent numerically reduction of mean value in the treatment group. It
propably due to the various responses of animals to traumatic injury in spinal cord and
treatment. The selection of statistical testing methods is based on the assumption of
normal distribution which determined depend on the skew and kurtosis value. MannWhitney testing as non-parametric test described a significant difference at day 1 (P <
0.01). Moreover, there is an obvious reducing tendency of GFAP expression at post-SCI
in all three groups, but it quite different. 2 out of 5 control animals appeared GFAP
signals at day 1, and decreased at Day 3, but prominent by Day 7, and other control
animals showed a prominent GFAP expression from Day 1 up to Day 3, but vanished at
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day 7. A similar GFAP expression and proliferation pattern after spinal cord compression
injury has been reported using immunohistochemistry testing method. One reports
indicated that the reactive astrocytes displaying GFAP signals by Day 1 and reach to the
peak level at Day 3 post-SCI. [169] Other studies reported an increased GFAP level at the
injured and its adjacent sites at day 1 after traumatic injury. It is then prodominent
between 3 to 7 days and gradually decreased afterwards. [170] However, in the
experimental groups, there was a consistent reduction in GFAP expression after initiation
of SCI and showed similarity as described by Theriault et al. [169]
It is also important to understand the plasicity of these astrocytes in CNS injury. There is
no absolute detrimental role for them, they also can benefit to the injured tissues to
certain level. For example, the proteoglycans produced by astrocytes may be protective
for the surrounding viable tissues by limiting the proporgation of cavity after SCI.
[171,172] It is beyond the scope of this report to critically review the biology of reative
astrogliosis after SCI. Opinions vary significantly in many literatures on the role of
reative astrocytes is detrimental or helpful to biological recovery functions.

We

emphasize that there are more GFAP positive activated astrocytes accumulate at injury
sites as their increased number of hypertrophy and largely increase the glioscars in open
injury. These events are considered to be aspects of neuroinflammation in CNS injury.
We can say with certainty that the corticosteroids drug DEX has performed antiinflammation properties which would be useful after SCI. These beneficial effects would
be many and vary such as reduction of edema, lipid peroxidation, concomitant with cell
survival. Especially, the effects of DEX on astrocytes associated GFAP irradiation have
been extensively reported in earlier papers. [147]
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The glucocorticoid steroids drugs, such as methylprednisolone, have been commonly
used in clinical treatment of brain and spinal cord injury to inhibit post-traumatic lipid
peroxidation and other physiological conditions in traumatic injury for more than 30
years. A survey from USA indicated that corticosteroids are widely usded for
management of traumatic head injury, taking for 64% of treatment centers. However, a
randomized CRASH trail unveiled an increased risk of death under methylprednisolone
treatment compare to the placebo groups. We need to emphasize that corticosteroids,
under debating, but still used in different condition of SCI. Unlike traumatic brain injury,
there are many evidences support that corticosteroids treatment can results in beneficial
outcomes, especially for motor functional recovery which proved in NASCIS-2 clinical
trail. In addition, DEX administration to spinal cord injured cat had proved to have a
remarkably functional recovery by eliminating the potassium loss. [178] This beneficial
effect was considered to relate to the maintenance of cellular structural integrity offered
by the steroid drugs. [179] Our studies also addressed the same results. A LDH (lactate
dehydrogenase) assay, as the indicator of cell membrane integrity, was perform for DEX
treatment to LPS challenged microglial cells. It showed a decreased level of LDH activity
after DEX treatment, indicating the potential protection to cell membrane by DEX. (Data
not shown here) However, some reports have shown that there is no statistical difference
in the trauma score, average length of hospital stay, mortality, [173,174] and neurological
benefit [175] between steroids treatment and without the treatment.
It is noteworthy that the timing and dosages of corticosteroids drugs applied to the
patients with acute spinal cord injury plays an key role and have been studied in many
trials. For example, "patient who receives methylprednisolone within 3 hours of injury
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should be maintained on the treatment regimen for 24 hours. When methylprednisolone is
initiated 3 to 8 hours after injury, patients should be maintained on steroid therapy for 48
hours." [176] "Methylprednisolone sodium succinate (MPSS) has been shown to improve
neurologic outcome and significant recovery in rodent motor function up to one year
post-injury if administered within eight hours of injury and in a dose regimen of: bolus
30mg/kg over 15 minutes, with maintenance infusion of 5.4 mg/kg per hour infused for
23 hours." [177] Therefore, unsuccessful or even detrimental outcomes to patient with
SCI could relate to the difference in administration. In our animal studies, we applied the
treatment within 3 hours after SCI and locally administrate the drugs to injured region. It
could result in a different theraupeutic effects compared to the traditional systemically
drug delivery.
Many clinical results showed improvment after SCI by modulating inflammatory
processes, but the steroid treatment alone is not sufficient enough to get fully recovery for
patient with SCI. A combination approaches, often together with pharmacological
therapeutics and some of non-pharmacological strategies, such as targeted rehabilitation,
individually designed cognitive training and exercise, or multisensory stimulation , could
be a more beneficial therapeutics intervention to the patient with SCI.
According to our study, a local steroids treatment might have different impacts for CNS
treatment compare to the systematic administration which applied to all earlier studies.
The targeting strategies of drug release can simply accomplished by physical placement
by coating the drug loaded materials with implants, and not encumbered by side effects.
Our technique also can be as simple as placement using a biopsy needle. Moreover,
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despite the treatment of corticosteroids drugs DEX are less capable to suppress lipid
peroxidation compared to MPSS in spinal cord studies and steroid treatment alone has its
limitation in spinal cord injury, this Ppy mediated drug delivery strategies are not limited
only for the treatment of SCI. It can broaden the potential application for local treatment
to different diseases, such as rheumatic disorders, decubitus ulcerations, and even early
tumor formations in breast, lung, prostrate. Additionally, this drug delivery system has
been proved that it can successfully conjugated different molecules, such as NT-3, NGF,
BDGF, ATP etc, such that it can be used in various applications. Especially, the
administration of the drugs can be controlled by external stimulation of electromagnetic
field without any physical invasive contact to human tissues. This drug delivery system
opens the door to many known therapies that cannot be easily or safely applied
systemically, but till now, could not be delivered continuously for many days to specific
localized tissues.
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CHAPTER FIVE
SYNTHESIS AND CHARACTERISTICS OF
SIRNAS CONJUGATED CHITOSAN NANOPARTICLES

5.1
5.1.1

Introduction

Evolution of Post-transcriptional Gene Silencing.

In 1990, the first study of post-transcriptional gene silencing was investigated regarding
to the promoter in the gene controlling the color of Petunia flowers. In 1998, Andrew Z.
Fire and Craig C. Mello, who later on were awarded the Nobel Prize in Physiology or
Medicine 2006, discovered a sufficient gene activity silencing by introducing the doublestranded RNA into animal cells. This discovery of RNA interference introduced a
powerful

biological

and

therapeutic tool

in

medicine.

Meanwhile,

Alnylam

Pharmaceuticals (which mainly focuses on the development of RNA interference (RNAi)
based gene therapeutics) first reported data for use of RNAi therapeutics in rodent in
2004 and in primates in 2006. In 2008, RNAi was shown as the potential therapeutics for
the use in human.
The strategies of this post-transcriptional silencing of gene expression was rapidly
developed in only a decade, but has proven its strong and effective therapeutic effects on
genetically oriented disease. Reduction in targeted messenger RNA levels and their
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associated gene activity can be initiated by either microRNA (miRNAs), short hairpin
RNA(shRNAs), synthetic short interfering RNA (siRNAs), or even single-stranded
antisense oligonucleotides (ODNs) and ribozymes. The differences of these mRNA
antisense approaches can result in a very different level of cellular uptake, transfection
efficiency, and toxicity. Their characteristics can also lead to different procedures for
mRNA inhibition. MicroRNAs are considered as an artificial miRNAs and mimics the
primary miRNA stem-loops, shRNAs are processed pre-miRNAs and transcribed as
sense and antisense sequences connected by a loop of unpaired nucleotides. In contrast,
siRNA is a laboratory-made synthetic miRNAs and can be engineered to be perfectly
complementary to targeted sequences. In this endogenous pathway, the effects of both
microRNAs and shRNAs are initiated at the nucleus, Drosha-DGCR8 process primary
miRNAs to pre-miRNAs and followed by the cytoplasm transportation of Exportin-5.
The cleaving of Dicer removes loop region and produces the desired mature miRNAs as
single strand RNAs. RNA induced silencing complex (RISC) along with this single
strand RNAs reach to the targeted specific sequences for silencing and eventually leads to
the knockdown of this protein expression. Synthesized siRNAs can be directly
transfected into cytoplasm, follow by either directly loaded onto RISC or untilize a Dicer
medicated process, and then process the rest of the pathway as that of microRNA and
shRNA.
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5.1.2

Pros and Cons of SiRNAs Therapeutic Strategies

The success of RNAi based strategies has led to many ongoing clinical trials and
developmental pipelines. Of them, siRNAs are shown promising outcomes due to
efficient gene silencing and highly specific inhibition of the target of the interest. Another
key feature is that, unlike microRNAs and shRNAs, the process of siRNAs occurs inside
the cytoplasm instead of the nucleus, therefore it limits the risks of unexpected genome
modification. Since shRNAs are endogenously produced, they have long lasting genesilencing effects whereas the synthetic siRNAs only have short inhibitory effects
(generally last for 3-5 days) because of their constant cell division as well as intracellular
degradation. But siRNAs were proven relatively more stable in the bloodstream
compared to ODNs and ribozymes which only remain stable for up to a few minutes,
even though ODNs and ribozymes more easily pass through cell membrane due to less
negative charges on them compared to siRNAs. The long duration of inhibitory effects
can be used in the condition with highly expressed mRNA levels but could be
detrimental. For example, it can induce inappropriate immune response and interference
with the endogenous miRNA pathways - both can eventually lead to toxic effects.
From a pharmaceutical industrial perspectives, the low cost and easy synthesis of siRNAs
does not need to involve either cellular systems or complicated protein purification
procedures, suggesting the promising advantages over other small molecule drugs.
Moreover, siRNAs have relatively low toxicity compared to organically synthesized
drugs due to their natural nucleotide components. Therefore, siRNAs have promising
potential in treatment of various gene oriented diseases. However, there are many
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remaining challenges ahead and could affect possible clinical application. The primary
biological challenges of siRNAs are described below. [180]
1) Off target effects. The major reasons are due to 3′ UTR or its homologous
sequences are present in siRNAs.
2) Non-specific immune response. Certain siRNAs sequences with 5′-UGUGU-3′ or
5′-GUCCUUCAA-3′ motifs have the potential to initiate the inappropriate
activation of immune systems by producing interferon and interleukin products.
Many researchers have also indicated that the siRNAs with long nucleotides
(>30bp) or at a high concentrations could also cause interferon or interleukin
responses in certain cell lines by reticuloendothelial system (RES).
3) Saturating the RISC. Due to the protein silencing mechanism of siRNA, excessive
amounts of siRNAs might influence the normal activity of cellular miRNA.
4) Low transfection efficiency/ poor cell penetration. siRNAs are unable to passively
diffuse through negatively charged cellular membranes due to their anionic charge
and consequent electrostatic repulsion between them. [181]
5) Poor cellular uptake. Apart from the reason of inability of siRNAs crossing
anionic cell membrane, rapid degradation of siRNAs by nucleases also can limit
the cellular uptake. SiRNAs especially through systematic administration into
bloodstream can easily undergo a degradation caused by relative larger amount of
ribonucleases (RNAses) in the blood, aggregation with serum proteins, or limited
blood stability. The lack of a specific delivery system to the target during siRNA
delivery is also a particular limitation for siRNAs therapeutic strategies.
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6) Lysosomal compartmentalization. Endocytic vesicle can entrapped the siRNAs in
lysosomes which prevents the efficient release siRNA into the cytoplasm.
7) Rapid renal excretion. This is mainly due to the capture of mononuclear
phagocytic cells which leads to a rapid clearance from the circulation.

5.1.3

SiRNAs Inhibition in Spinal Cord Trauma

The exploration of siRNA strategies in central nerve system disease are ongoing and
involved in an broad applications from neurodegenration, cancer glioma, pain syndromes,
to primary and secondary damages. In the case of SCI, various target proteins were
investigated to inhibit using siRNAs strategies. Alnylam/Merck collaboration focused on
the development of RNAi therapeutics targeted to Nogo pathway for SCI treatment.
Since Nogo receptor is important axonal inhibitor, inhibiting its associated pathway could
potentially improve neuronal outgrowth and injury conditions, many other research
groups dedicated to the study on the downstream of signaling pathway, such as RhoA and
ROCK signaling pathways. [182] Although RhoA specific siRNA treatment did not
indicate the recovery of motor function, but controlled tactile hypersensitivity and
significant improved white matter and serotonergic axonal regrowth. Also, the
accumulation of ED1+macrophages is dramatically reduced which limits imflammation.
[183] Pretreatment of ERK2 siRNAs has been reported to improve locomoter
performance, so does ephrinB3 siRNA inhibitory strategies which are based on reversal
signaling of ephrinB3 promote axonal pruning and regeneration as well as synapse
formation. [184]
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Other findings also focus on the reduction of scar tissue formation after injury in order to
reconstruct neuronal growth conditions by delivering siRNAs to the injured sites. For
example, GFAP siRNAs combined with photomechanical wave-driven approach shown a
significant locomotive improvement after SCI.[185] SiRNA targeting to telomerase
reverse transcriptase (TERT) and CSPG were also developed to control astroglial scar
formation and to promote robust axonal regeneration. [186,187] In addition, matrix
metalloproteinase-3 (MMP-3) siRNAs can prevent the increased permeability and
disruption of blood-spinal cord barrier after SCI and lead to the potential for functional
recovery.[188]
Other siRNA applications have been used in other CNS diseases such as stroke or
neurodegneration disease and could be potentially used for SCI treatment. The siRNAs
targeting apoptosis mediated protein, such as CCAAT-enhancer-binding protein
homologous protein (CHOP) and caspase 3, might be used to control cell death after SCI.
Our study focused on the targeting to the macrophage and its initiated pro-inflammatory
molecules which plays a key role in secondary injury after SCI. The hallmark expression
of detrimental macrophages is iNOS expression. Therefore, siRNAs targeting of iNOS as
a treatment strategy was hypothesized to be able to alleviate NO production and improve
injured conditions of spinal cords. More details will be addressed in chapter 6.

5.1.4 SiRNAs Delivery Strategies
The remaining challenges described in chapter 5.1.3 result in a large scale of
development of siRNAs based delivery materials and chemical modifications. Many
studies have proved that these modulations can solve the existing limitation of siRNAs
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and optimize the outcomes of this siRNAs application. Generally, the delivery strategies
usually involved viral vectors and non-viral vectors materials. Despite the viral vectors
based delivery system shown the successful results of gene silencing, the danger of viral
toxicity and relatively strong immune responses from the host still present. Many studies
have indicated the possibility of unexpected inflammatory immune reactions, insertional
mutagenesis, oversaturation of RNAi pathways, and cellular toxicity that were caused by
viral vectors carried siRNAs delivery. These obstacles directed many researchers to
pursue safe carriers for siRNA therapeutics.

Complexes of siRNAs with various

materials, such as polymers, lipids, peptides, antibodies, aptamers and small molecules,
as non-viral vector carriers, have been extensively developed. They have been considered
to be able to protect the siRNA from the RNase-rich in vivo environment and deliver
them to the targeted cells and tissues, showing more efficient silencing outcomes
compare to siRNAs alone.
Over many recorded RNAi based clinical trials and commercial products, lipid
nanoparticles or lipid based transfection reagents have been widely used to assist the
siRNAs crossing the cell membrane. However, they have also been reported to be
responsible for cytotoxicity. According to earlier and current studies, the assisted delivery
of siRNAs favors the cationic polymer because siRNAs are anionic. Therefore positive
charged polymers was vulnerable to synthesis with negative charged phosphate group of
siRNAs. This self-assembly formation of inter-polyelectrolyte complexes with drugs is a
non-covalent electrostatic complex formation, which is a very simple and reliable
approach. Meanwhile, the cationic polymer shares a similar feature as a lipid based
material and can easily carry siRNAs crossing cellular membranes.
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Chitosan, as a linear binary polysaccharide, comprised of beta linked 2-amino-2deoxybeta-D-gluocose(GlcN; D-unit) and N-acetylated analogue (Glc NAc; A-unit). It can be
protonated in slightly acidic conditions, expressing the cationic polymers nature.
Chitosan also can process the properties of low costs as well as biocompatible and
biodegradable which can minimize the side effects and the possible cytotoxicity. It is
currently used as a common dietary supplement and has been classified as generally
recognized as safe (GRAS) by the FDA. It is considered to be a promising carrier for the
delivery of siRNAs and has been extensively investigated. Moreover, a relatively short
transfection time of siRNAs (approximately 4 hours) when assisted with chitosan Nps
also provides the possibility in clinical applications.[189]
Many previous findings exploited siRNAs conjugated chitosan Nps were successfully
used in various disease and medical conditions, but mainly focus on the anti-tumor
effects. Some reports have indicated that the mucoadhesive and permeation features of
chitosan can be used to delivery siRNAs to the respiratory sites by intranasal
administration or drop wise into the trachea to treat pulmonary cancer. [189,190] The
chitosan mediated siRNAs deliverery was also widely developed for other cancer cell
lines, such as hepatocellular carcinoma, [191] colorectal cancer cells, [192] cervix, ovary,
mammary carcinoma, [193,194] and leukemia. [195] A novel strategy using chitosan Nps
to deliver siRNAs to peritoneal macrophages to reduce inflammation in an arthritis model
has also been reported.[196] However, in central nervous system study, the chitosan
mediated siRNAs strategies is still underdeveloped. P-glycoprotein siRNAs conjugated
chitosan complexes were tested to be efficient to penetrate blood-brain barrier by
silencing the efflux pumps P-glycoprotein which involved the maintenance of brain
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barriers.[197] Efficient neurite growth and spinal cord repair has also been reported by
deliverying of Rho siRNAs via chitosan Nps. [198] Most importantly, chitosan can limit
lipid peroxidation and propagated damag at cell membranes in order to

prevent

secondary injury after SCI. [199]
Therefore, chitosan can be developed as a good candidate for siRNA carriers base on the
nature of the materials and the various supportive and successful studies.

5.1.5

Types and Modification of Chitosan for SiRNAs Delivery

The most important characteristic of chitosan is that it can offer a variety of modification
according to the requirement of different applications. The modifications of chitosan can
improve siRNAs delivery by enhancing administration efficiency. Trimethyl chitosan
with cysteine conjugate has shown an enhanced mucoadhesion and permeation, therefore,
it can be successfully used in nasal administration.[200] Encapsulation of (+)-catechin
(C) and (-)-epigallocatechin gallate (EGCg) or crosslinking with hydroxypropyl
methykellulose phthalate (HPMCP) with chitosan Nps has also been proved to increase
the intestinal adhesion, penetration and absorption in order to optimize oral
administrations. Although N-octyl-O- glycol modification of chitosan Nps did not show
significant improvement during intravenous administration, it has been reported to have
good biocompatability without signs of cytotoxicity. [201]
Additionally, modified chitosans were especially helpful for transfection efficiency in
siRNAs delivery. Gaspar et al. synthesized chitosan- histidine-arginine (CH-H-R) based
Nps for plasmid DNA delivery. These demonstratd remarkably higher transfection
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efficiency than unmodified chitosan and without leading to any cytotoxic effect. [202]
The design of trimethylchitosan/siRNA complexes is through quaternization of amine
groups to creat the enhanced protonization of chitosan and help its interaction with
siRNAs. [203] Chitosan grafted with PEI have increased long-term transfection
efficiency and decreased cytotoxicity than PEI alone. Furthermore, the proton-buffering
ability of PEI can catalyze the osmolysis of endosomes and help siRNA nanocomplexes
easier escape into the cytosol than chitosan alone. [201] The optimization of transfection
efficiency can be further supported by the good stability of siRNA conjugated chitosan
Nps. Ionic crosslink sodium tripolyphosphate(TPP) with chitosan Nps suggest a new
strategy to protect the siRNAs in serum contained conditions and shows a more strong
stability with siRNAs. [204] Deoxycholic acid incorporated with chitosan showed good
stability during the delivery process due to hydrophobic property of deoxycholic acids.
[205] At last, from clinical application perspectives, the conjugation of PEG on chitosansiRNAs Nps allowed lyophilization for a longer shelf life and avoid aggregation during
systematic delivery. [206] In summary, the selection of nanocarriers for siRNAs highly
relies on the characteristics of materials and its targeted cells and tissues. Different
modification or copolymerization approaches allow chitosan processing much broader
applications.
Intriguingly, recent work raises promising results of enhanced transfection efficiency and
alleviated side effects when using ligand mediated targeting methods. [207] Our studies
focused on this modification of chitosan with ligand conjugation to achieve specific cell
targeting and improve therapeutic outcomes. Various chitosan salts, such as chitosan
glutamate (CS-Glu) and chitosan hydrochloride (CS-HCl), are also developed for in vitro
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siRNA delivery, because of their high solubility at physiological pH. The different types
of chitosan salts have much less influence on transfection efficiency of functionally
active siRNA in comparison to the molecular weight of chitosan salts and weight ratio or
N/P ratio between siRNAs and chitosans. [208] Chitosan hydrochloride is readily soluble
in water, and its properties as a siRNA carrier was also investigated in our experiment for
conjugating different targeting motifs.

5.2
5.2.1

Material and Methods

Synthesis of SiRNAs Conjugated Chitosan Nanoparticles

Four different Chitosan/siRNA Nps were prepared, three of them conjugated with
targeting ligands.

Low molecular weight chitosan was purchased from sigma and

dissolved in 0.2 M sodium acetate buffer (pH 4.5), and the solution was adjusted to
pH5.5. (indicated as Chi) For antibody conjugated siRNA/chitosan, Purified mouse IgG
solution was mixed with chitosan solution which dissolved in 0.2 M sodium acetate
buffer at a molar ratio of 1:1 and final concentration of chitosan at 200μg/ml. The
crosslinking agents of 0.2 mM 1-Ethyl-3-[3- dimethylaminopropyl]carbodiimide
hydrochloride (EDC) and 0.5 mM N-hydroxysulfosuccinimide (sulfo-NHS) were added
to the mixture, and then stirred for 24 h at 4°C. The next day, the solution were injected
into 10K MWCO slide-A-Lyzer Dialysis Cassettes (Pierce) to remove uninterested
molecules based on the instruction from company for 48 hours. (indicated as Ab-Chi). A
second strategy of Ab conjugation with chitosan Nps is also performed and the water
soluble crosslinking agent Bis[sulfosuccinimidyl] suberate (BS3) were used. A 30 fold
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molar excess of the crosslinker BS3 solution compare to the protein was added to the
sample solutions which containing a morlar ratio 1:1 of IgG solution and chitosan
solution which at final concentration of 200μg/ml. In this case, water soluable chitosan
hydrochloride were used (Novamatrix, Protasan up CL114). This reaction mixture were
then incubated for 30 mins at room temperature and then followed by 7K MWCO zeta
spin desalting columns (Pierce) (indicated as Ab-WSC). Before synthesis of
siRNA/chitosan Nps, different ratio of prepared IgG conjugated chitosan solution (10%,
20%, and 30%) were mixed with either 200μg/ml chitosan solution dissolved in 0.2 M
sodium acetate buffer or 200μg/ml water soluble chitosans. Also, Mannosylated-chitosan
solution were also prepared before synthesis with siRNA. This synthesis procedure was
reported in Tae Hee Kim et al. [209] Briefly, mannopyranosylphenylisothiocyanate
(Sigma-Aldrich) was dissolved in 1ml DMSO and then added to 60mg Chitosan
(Novamatrix, Protasan up CL114) in 1ml miliQ water, and the solution was stirred for 24
hours at room temperature. Isopropanol solution was added to chitosan solution to
precipitate the mannosylated-chitosan and followed by repeated centrifugation and wash.
The collected precipitations were dried in high vacuum, and concentration of 200μg/ml
mannosylated-chitosan was prepared before siRNA synthesis (indicated as M-WSC).
Concentration of different chitosan solution at 200μg/ml was seperately prepared and
20μl of 20μM iNOS-siRNAs were added to 1ml chitosan solution while stirring and
remain at room temperature for 1 hour.
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5.2.2

Transmission Electron Microscopy

All samples were imaged using a FEI Tecnai T20 transmission electron microscope
operated at 200kV. One drop of chitosan Nps dispersed solution deposited onto a mesh
copper grid coated with amorphous carbon and allowed to settle at room temperature for
2 mins. Negative staining was subsequently performed by swishing through 2% uranyl
acetate droplet before imaging.

5.2.3

Size and Surface Charge of Nanoparticles

The size and zeta potential of the nanoparticles was analyzed using Zetasizer Nano ZS.
Both size and zeta potential were measured in triplicate. Measurements were set at 173
degree and a temperature of 25 degree. The sample solution was placed in disposable
cuvettes or zeta potential capillary cells respectively for size or zeta potential
measurements. The z-average hydrodynamic diameter indicated size of the nanoparticles
and calculated based on the viscosity and refractive index of water. The zeta potential
was quantified based on the principle of phase analysis light scattering.

5.2.4

Gel Retardation Assay

Poly(l-aspartic acid) (PAA) displacement assay was conducted to detect the integrity of
siRNA conjugated chitosan Nps. Polyanion PAA (Santa Cruz Biotechnology) were used
to displac negatively charged siRNA from positively charged chitosan. Nanoparticles
were incubated with or without PAA at concentration of 5mg/ml. A1 to 4 volumetric
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ratio between PAA and nanocomplexes was used, and then they were incubated at 37 oC
for 30mins. 50ul of sample solutions containing 0.532μg of siRNAs were placed into
each wells of 10% Mini-PROTEIN TBE poly-acrylamide gels. Electrophoresis was then
performed at 100V for approximatly100 mins. The gel was then transferred to SYBR
gold nucleic acid staining solution for 30 mins and visualized using GBox imager.

5.2.5

Toxicity Studies

Toxicity of siRNAs and different designed Chitosan Nps in macrophages cultures were
detected based on the morphology of the murine bone marrow-derived macrophages
(BMDM). Macrophages were cultured in 24-wells plate and maintained as described in
6.2.1 setion. They were incubated at both high concentration (5μl of 20μM siRNA with
6.5μl of Lipofectamine 2000 per well) and low concentration (2μl of 20μM siRNA with
2.5μl of Lipofectamine 2000 per well) of siRNAs and siRNAs without transfection
reagent, as well as different chitosan Nps for 4 hours. Macrophages were observed and
imaged using Olympus IX 81 inverted microscope.

5.3
5.3.1

Results

Chitosan Nanoparticles Morphology

To optimize siRNAs conjugated chitosan Nps, the molecular weight (MW), degree of
deacetylation (DD), pH, and N/P ratio (or weight ratio) as important criteria were
considered in the design of nanoparticles formation. Many successful siRNA conjugated
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chitosan Nps have shown that chitosan with MW at range of 60 to 170kDa and higher
DD value between 75%-90% would produce the Nps with reasonable size and surface
charge. It also remains the stability of siRNAs during the distribution in bio-environment
and allows the up-taking of different cell types without rapid degradation.

In our

experiment, all four chitosan nanocomplexes were formed using chitosan at the range
mentioned above. Additionally, an weight

ratio approximately at 37.5 was also

predetermined according to earlier publications and used in our study. [210] The
morphologies of four different chitosan Nps are illustrated in Figure 5.1.

Both

Chi/siRNAs Nps and M-WSC/siRNAs Nps showed a smooth surface of nanocomplexes
with spherical-like shapes. In the case of two Ab conjugated chitosan Nps, the Nps
predominantly exhibited a less smooth surface.
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Figure 5.1 Transmission electron microscopy images of different siRNAs conjugated
chitosan Nanoparticles. The scale bar for Chi/siRNA Nps and M-WSC/siRNA Nps is
0.5μm, and for Ab-Chi/siRNA Nps and Ab-WSC/siRNA Nps is 0.2μm.
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5.3.2

Particle Size and Surface Charge

Size distribution and surface charge analysis was performed by DLS and shown in Table
5.1. Mean particle size of Chi/siRNAs Nps were measured as 272.2+/- 8.13 nm, and
266.57+/-8.66 nm for M-WSC/siRNAs. The size of Ab conjugated chitosan Nps with
different Ab ratio were also tested and showed that 10% Ab-Chi/siRNAs Nps have an
average hydrodynamic diameter 295.53+/-6.47nm, 350.58+/-9.63nm for 20% AbChi/siRNAs Nps, and 385.73+/-4.78nm for 30% Ab-Chi/siRNAs Nps. A slightly
increased particle size was observed. A much larger size of Ab-WSC/siRNA Nps was
detected when using BS3 conjugation methods to link Ab with chitosan. Different Ab
ratios have also been performed and showed similar particle size, only 20% Ab displayed
here corresponding to later study results. Three nanoparticles (Chi/siRNAs Nps, MWSC/siRNAs Nps, Ab-Chi/siRNAs) have slightly different particle size, but no
detectable statistical difference. In addition, TEM images (Figure 5.1) shown the various
sizes of chitosan Nps, the smaller particle size was considered due to the lower molecular
weight of chitosan and larger particle size was formed by relatively higher molecular
weight chitosan.
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Table 5.1 Size distribution and surface charge of different siRNAs conjugated chitosan
Nps.

Name

Size (nm)

Zeta potential ζ(mV)

Chi/siRNA Nps

272.2+/- 8.13

23.63+/-0.18

M-WSC/siRNA Nps

266.57+/-8.66

35.13+/-2.19

10% Ab-Chi/siRNA Nps

295.53+/-6.47

24.33+/-0.73

20% Ab-Chi/siRNA Nps

350.58+/-9.63

21.93+/-0.61

30% Ab-Chi/siRNA Nps

385.73+/-4.78

17.77+/-0.18

20% Ab-WSC/siRNA Nps

580.73+/-18.37

11.27+/-0.81

During our studies, zeta potential analysis suggested that all nanocomplexes were
positively charged. M-WSC/siRNA Nps have a higher zeta potentials than other siRNA
loaded chitosan Nps, showing these Nps were more stable in suspension. In contrast, 20%
Ab-WSC/siRNA Nps had a very low zeta potential approximately at 11.27+/-0.81mv.
The synthesis procedures and/or instinct properties of these Nps needs further
optimization and investigation. Other chitosan Nps possess an approximately 25mV zeta
potentials. They are at a good stability conditions. Moreover, low zeta potential in AbChi/siRNA Nps with higher Ab ratio were also observed, indicating the poor stability of
30% Ab-Chi/siRNA Nps compared to 10% Ab-Chi/siRNA Nps.
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5.3.3

Binding Affinity Between SiRNAs and Chitosan Nanoparticles

Electrophoretic mobility tests were performed to evaluate the chitosan and siRNA
complexion efficiencies. siRNA must be stable in a bio-environment and can avoid
digestion or degradation by various nucleases in order to have maximal activity for
specific gene knockdown. The negatively charged siRNAs was synthesized with chitosan
and formed nanoparticles to protect the siRNAs from degration. Therefore, they would
not easily separate from the nanoparticles and migrated down during electrophoresis. Coadministration of polyanions PAA can be used as a competitor to displace the siRNA
from chitosan nanocomplexes. According to our results in Figure 5.2, the free siRNAs
without chitosan Nps protection migrated down and showed detectable bands. Moreover,
in all three chitosan nanocomplexes, the addition of PAA also results in the moving of
siRNAs, and the bands showed in the figure indicated that siRNAs were displaced and
move out the particle complexes as free siRNAs condition. All three chitosan
nanocomplexes without incubation of PAA show any sign of siRNAs bands and
demonstrating the fully protection of chitosan Nps to siRNAs and their stability.
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Figure 5.2 Gel retardation assay indicating the integrity of chitosan nanoparticles.

5.3.4

Low Cytotoxicity of Chitosan Nanoparticles

After 4 hours incubation at high concentration and low concentration of siRNAs and
different chitosan Nps, murine bone-marrow derivatived macrophages expressed
different morphology. The healthy status of macrophages without any treatment were
also inspected. There is obvious sign of detachment of the cells and dramatically decrease
of cell amount after high concentration of siRNAs incubation. For low concentration of
siRNAs treatment, some of cell cytoplasmic vacuolation and granularity were observed.
It is due to the slight toxin appeared in the present of lipid based reagents in the serum
contained medium during transfection. In the contrast, there is no sign of deterioration of
cells without transfection reagents. Very few granularities in the medium were also found
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in three different chitosan nanopartilces, but majority of the cells remain their shape and
appearance.

120

Figure 5.3 Morphology images of macrophages after treatment of siRNAs (at both high and low concentration) and different
120

siRNA conjugated chitosan Nanoparticles (including Chi/siRNA Nps, M-WSC/siRNA Nps, and Ab-Chi/siRNA Nps).
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5.4

Discussion

Due to the diverse nature of disease targets and bio-environments for siRNA gene
silencing, there is no single ideal nanocarrier that is universally applicable. In our study,
we tested the condition of SCI and developed a ligand conjugated natural polymer
mediated siRNA delivery system to reduce inflammation induced sendary injury and
promote the recovery of neural cells and tissues after SCI. We are searching for an
optimal delivery tool that can be systematically administered safely and repeatable to the
animal, and can deliver the siRNA specifically and efficiently to the targeted site. Unlike
M2 anti-inflammation macrophages, M1 macrophages are pro-inflammation, and it can
produce many pro-inflammatory molecules, especially a high level of NO production
which subsequently result in the cellular death and tissue damadge at spinal cord. Thus,
these M1 macrophages were considered as our cellular targets in this study. Since the
surface marker expressed differently in pro- and anti - inflammation macrophages after
SCI, we exploited an antibody strategy to target specific macrophages in order to enhance
the theraupeutic outcomes.
Natural polymer chitosan was used in this study especially due to its biocompatibility,
less cytotoxicity as well as convenient and reproducible synthesis procedures with
siRNAs. Many publications have shown its safe and successful outcomes when
delivering siRNAs. Our data has shown some observed toxic events when apply siRNA
with lipid based transfection agents, but rarely detected in the cells with chitosan Np
application.
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Most importantly, the various possibility of chitosan modification and conjugation can
avoid the intrinsic limitations of this polymer and improve its potential applications. We
first focused on conjugating antibodies with chitosan polymers for targeting and
considered two possible IgG incorporation methods in both acidic and neutral conditions.
One approach is using combination of EDC and sulfo-NHS to react the carboxyl group of
antibody with amine group of chitosan. In a whole antibody molecule, the Fr region
(amine group) of antibody usually present as the antigen binding sites in the common
applications. Thus, other approach we designed is using BS3 to conjugate amine group of
antibody with amine group of chitosan. EDC and NHS conjugation reaction requires a pH
conditions at range of 4.5~7.2 to be efficient, which is correspond to the acidic condition
during the dissolvation of the chitosan. On the other hand, the novel BS3 conjugation
method needs an almost neutral condition to react; therefore, we prepared water soluble
chitosan solutions for this case.
Although chitosan Nps with a higher Ab ratio showed gradually enlarged particle size
and reduced zeta potentials, this did not mean that there was a direct correlation between
size and zeta potentials. Zeta potentials depend on the level of electrolyte pH,
flocculation, instability, and temperature and so on. For example, the good dispersion
stability is usually with high positive (or negative) level zeta potential at very low pH or
high pH, the pH between 4 and 7.5 is the range has been indicated can initiate the
instability of suspension. The higher the zeta potential either negatively or positively, the
stronger the repulsion between colloids to overcome the van der waal attraction.
Therefore, they are more electrically stabilized. In contrast, the colloids in suspension
with low zeta potentials are susceptible to agglomerate or sediment so that they are easily
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to form a larger particle size. In our case, a larger particle size was observed in the
chitosan Nps with increased Ab portion as well as Ab linked chitosan Nps using BS3
conjugation method. This is most likely due to the less stable condition of nanoparticles.
The selection and volume of chitosan used during nanoparticle synthesis can lead to a
large structural and functional versatility for this material. During the synthesis process
with nucleic acids, many parameters were determent factors for the successful siRNAs
delivery by chitosan Nps. For example, body distribution of nanoparticles after IV
injection is highly influenced by their interaction with the biological environment, and
this especially dependent on the physicochemical properties, such as the surface charge
of the nanoparticle. The efficient delivery of siRNAs is also strongly depended on what
kind of bio-environment they are delivered to and the size of the nanoparticles. These are
closely related to the efficiency of cellular uptakes. Nanoparticles larger than 5nm in
diameter do not readily cross the capillary endothelium. On the other hand, the enhanced
vascular permeability in the liver, spleen, and some tumors permits the macromolecules
and nanoparticles up to approximately 200nm in diameter to cross, it is known as the
enhanced permeation and retention effect. The size of nanoparticles that is bigger than
500nm was reported easier for the recognizetion of macrophages and completion of
phagocytosis. The degree of polymerization of chitosan (DPn) as well as the fraction of
N-acetylated units (FA) were reported to be important associated with gene silencing
efficiency as well. For example, gene silencing is most efficient when chitosan with
intermediate chain lengths, that is, DP(n) approximate between100 and 300 were used.
[121]
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The size, zeta potentials and stability of siRNA/Chitosan Nps are critical during siRNAs
delivery and also depends on various parameters. Molecular weight of chitosan close
related to the size of chitosan Nps,

the size is decreased as the molecular weight

increased. 10kDa chitosan was proven to produce a 3500nm size of particles. A range
between 65 to 170kDa chitosan can produce 200 to 300nm diameter of nanoparticles.
[210] Our data are consistent with the results in these earlier studies. The nanoparticle
size of approximately 270~290nms were observed by TEM and analyzed using zetasizer
when chitosan with similar molecular weight were used. In contrast, zeta potentials will
slightly increase as molecular weight increases at a range of 65kDa to 170kDa. [210] In
the study of nanoparticle stability, lower molecular weight of 10kDa fail to complex and
compact siRNA into stable particles and a higer molecular weight (>60kDa) is required
to form a stable nanoparticles. [212]
The DD value designated as the percentage of deacetylated primary amine groups along
the molecular chain, which subsequently determines the positive charge density of the
chitosan. Higher DD results in increased positive charge enabling a greater siRNA
binding capacity. A relatively low DD value can decrease the charge of zeta potentials.
In our cases, no retardation effect or unstability of siRNA conjugated chitosan Nps were
observed during gel retardation study. It is because of the selected chitosan with MW
between 65 to 170kDa and DD value of 75-85% were used.
The N/P ratio between chitosan and siRNAs represented as the ratio of a mass per charge
of chitosan 167.88( when 84% DD is used) to a mass per phosphate of 325Da siRNAs,
this relationship can also be simply described as weight ratio.

They are also very
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important component to modulate the size, zeta potential, and stability of nanoparticles.
An w/w ratio of 37.5 ( approximately N/P ratio of 54 to 59) was considered in our study
based on previous successful protein silencing. [210] They showed that this range of N/P
ratio can balance the toxicity and stability of chitosan materials during siRNA delivery.
Chitosan mediated siRNAs delivery is in a charge density-dependent manner and charge
density strongly depends on the pH, or we can say a protonation level. The charge density
of the delivery vehicle significantly impacts its interaction with components of the
bloodstream and siRNA bindings. The comparative positive value of surface charge of
the chitosan/siRNA complexes increased with increasing concentration of chitosan at a
constant siRNA concentration. This net positive charge of the particles was desirable to
prevent particle aggregation and promote electrostatic interaction with the overall
negative charge of the cell membrane. It could probably explain why a higher Ab ratio,
such as 30% Ab-Chi/siRNA Nps propably with less charge level, showed a less stable
situation ( indicated by a lower level of zeta potential). In the study of macrophage
uptake, some findings also indicated that highly charged particles can lead to complement
activation of macrophages, whereas near-neutral particles show reduced phagocytic
uptake.
In summary, different parameters, such as molecular weight, DD value, N/P ratio, and pH
level, are tightly related to the size, charge density, and stability of siRNA conjugated
chitosan Nps. These characteristics of

the nanoparticles can further impact the

transfection and gene silencing efficiency. We successufully synthesized differnt chitosan
Nps with resonable size and zeta potentials value and minimized cytotoxicity based on
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the earlier results established by many researchers. Especially, we developed and
compared the properties of different ligands mediated chitosan Nps for macrophages
subsets targeting. Additionally, we are first introduce a new Ab conjugation method with
chitosan materials, in despite of the stability of Ab-WSC/siRNA Nps required further
improvment.
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CHAPTER SIX
PREVENTING CELL DEATH
AFTER SPINAL CORD INJURY VIA TARGETED SIRNAS DELIVERY

6.1
6.1.1

Introduction

Macropahges Polarization and Their Role in Spinal Cord Injury

Macrophages mediate a large scale of biological responses and play a key role in the
immune systems. Modulation of macrophages to achieve an optimal host response could
be crucial in the treatment of SCI. Recently, many groups reported the polarization of
macrophages can influence neural behavior after SCI. Macrophages can perform
distinctive functions by expressing either pro- or anti- inflammatory characteristics which
depended on the stimuli received by the micro-environment. Classically or proinflammatory-activated macrophages upregulate the level of pro-inflammatory cytokines
and designated as M1 macrophages. On the other hand, alternatively activated M2
macrophages, are associated with an anti-inflammatory profile and are crucial in tissue
remodeling after inflammation, especially for axonal regeneration. [213] Granulocytemacrophage colony-stimlating factor (GM-CSF) and macrophage colony-stimlating
factor (M-CSF) are commonly used for different phenotypic and functional changes in
macrophage lineage populations. Generally, the polarization of M1 macrophages
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can be activated by GM-CSF with combination of LPS and IFNγ, and M2 macrophages
can be primed by M-CSF with addition of interleukin-4 (IL-4) or IL-13 for M2a subset,
combination of immune complexes and LPS for M2b subset, and IL-10 or transforming
growth factor-β (TGF-β) for M2c subset of M2 macrophages. [214]
Many findings have been shown the phenomenon of macrophages polarization and its
presence after SCI, [213,215,216] with a long lasting expression of M1 macrophages at
damadged spinal cord tissue. The exacerbated secondary injury conditions after primary
injury might due to this high level residence of pro-inflammatory macrophages. The
hallmark of activated M1 macrophages is the upregulation of iNOS mRNA and its
proteins expression at the earlier stage of SCI. [213]
The detecting techniques of western blotting , polymerase chain reaction (PCR), and
immunohistochemical analysis are commonly used to trace the expression of iNOS.
Some studies reported that the iNOS mRNA occurred at 3-12 hours after SCI and
gradually decreased afterwards using PCR analysis. Immunohistochemcial study shown
the similar outcomes and suggested that iNOS positive cells peaked at 24 hours and
declined to none expression within 3 days after injury. [217] The sum of earlier
established study reveals that

the ideal determination and analysis time for iNOS

expression is between 12 and 24 hours after SCI, which will applied to our study.
Macrophages in the injured spinal cord origin from resident microglia and peripheral
monocytes derived infiltrating macrophages.

M1 macrophages trafficked through

adjacent arachnoid and pia mater of the spinal cord to the injured site while M2
macrophages infiltrated through the brain-ventricular choroid plexus. [218] Compare to
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the resident microglia, the infiltrated macrophages contributed to the phagocytosis, but
not efficiently phagocytosing damaged and degenerated cells and debris in CNS as
microglia in the early stage. However, they are the predominant cells associated with
chemokins and many pro-inflammatory cytokines production, and has been identified to
responding to the demyelination and axons degenerating, contributing to the secondary
injury in spinal cord. [219] Therefore, bone marrow-derived macrophages were selected
for our in vitro studies due to the nature of these macrophages and their susceptibility to
be polarized by stimuli.

6.1.2

Route of Administration for SiRNAs Delivery

Unfortunately, siRNAs associated delivery systems possessed some limitations during in
vivo applications, such as insufficient biodistribution. Therefore, the route of siRNA
administration is critical during the application and also responsible for the dosage of
siRNAs applied, the efficiency of tissue distribution, as well as the potential side effects.
The different routes of administration of siRNA were investigated by many research
groups to reveal the possible tissues that received siRNA corresponding to the
administration. Intravenous administration route results in the accumulation of siRNAs in
the kidney and pole/lumen of the proximal tubules, as well as urine due to the rapid
excretion. Shawn D. et. al also detected the siRNAs uptake in the liver, pancreas, spleen
and bone marrow using both hydrodynamic and standard IV. Intraperitoneal
administration resulted in the siRNAs expression occurred in the spleen, liver and bone
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marrow. Similar organs uptake, such as spleen, bone marrow as well as colon were also
observed following rectal administration. [220]
The drug delivery to CNS is more complicated than other organs due to the issue of
blood-brain or spinal cord barriers. The optimal administration to bypass this issue is
through direct intrathecal or intraventricular injection to CNS. To effectively detect the
biodistribution of siRNAs, dye-labeled siRNAs were often used through directly
visualizion of fluorescence signals in different tissues. Luo et. al has reported that
fluorescence signal can be detected in the spinal cord and dorsal root ganglia after
intrathecal delivery of siRNAs with transfection reagent. [221] The intrathecal injection
can prevent certain degree of siRNA degradation which frequently occurred in the blood
stream via serum protein. Even though the CNS environment contain less nuclease
compared to plasma and many other tissues, the assisted delivery strategies are still
critical for successful siRNAs delivery to CNS because it not only can improve
transfection efficiency, but also provide various functions by simply modification of the
carriers. For example, conjugating the targeting motif to drug carriers and deliverying
them to specific cell types or tissues for optimized siRNA uptakes in certain organs.
[222]

6.1.3

Nanoparticels Targeting Strategies to Macrophages via Fc Receptor

Recently, many reports indicated that the limitation of onsites of siRNAs delivery could
jeopardize its potential treatment. Therefore, our gear was directed to the development of
targeting strategies in order to achieve more efficient protein silencing.

Since the
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targeting strategies can be potentially applied to many disease-causing cells and tissues, a
various functional add-ons, such as antibodies, aptamers, and peptides were widely used
to guide its conjugated nanocomplexes to the desired cells or tissue sites. In addition,
these ligands can be characterized with therapeutic, diagnostic, or barrier-avoiding
properties to fulfill multivalent functionalities. Antibodies (Abs) have been commonly
and successfully used as escort molecules for the targeted delivery of nanoparticles, and
many are either proved by FDA or under development in clinical applications. This
antibody mediated targeting approach is based on the assoication of the ligands with the
receptors and receptor-mediated

endocytosis, which usually considered as active

targeting. In siRNAs studies, the targeted delivery provides the potential for efficient
siRNA transfection into specific type of cells and avoiding nonspecific binding.
Since mononuclear phagocyte was characterized of engulfing apoptotic cells, pathogens,
and even microparticels via phagocytosis and destroy them, the passive targeting
approaches can be used in the context of drug delivery to macrophages. It is close related
to the intrinsic physicochemical properties of the carrier. Sometimes, nanoparticles can
passively accumulate at inflamed sites because of the enhanced permeation and retention
(EPR) effect. [223] However, in order for macrophages to uptake the desired therapetuics
delivered by these nanoparticles, we can either use passive targeting approaches by
modulating the physical properties of the nanoparticles or use a ligand associated active
targeting strategies by selectively identify the surface marker of the macrophages. It has
been postulated that both anionic and cationic charged particle and nanoparticle with size
larger than 100nm are readily opsonized by the macrophages which is mainly resided in
the liver and spleen. [223] Schafer et al. studied different particles uptake including
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poly(methylmethacrylate), poly(alkylcyanoacrylate), and human serum albumin particle
in human macrophages. The results indicated that nanoparticles made from the same
material but of larger diameter were easiler for phagocytosis. [224] In phagocytes,
endocytosis can be initiated by small particulate complexes formation, and phagocytosis
can be initiated by a larger aggregates. Thus, the vital methodological tool to internalize
the nanoparticles to specific macrophages is to use the active targeting via specific
antibody-antigens reactions.
Active targeting are commonly accomplished by modificating of the surface of
nanoparticles via a targeting motif, a ligand with selective affinity, and can interact with
specific receptors in certain cell types. Nanoparticles used for macrophage-targeted
delivery can be associated with various receptors such as Fc receptors,

mannose,

galactose, and sialic acid specific lectin-based receptors, lipoprotein receptors, and
scavenger receptors. [223] The activation, recognition, endocytosis, secretion activities of
the macrophage depend on the surface receptors. Synthetic functionalized mannosyl
ligands has been revealed to conjugate with various drug carriers: liposomes, chitosan,
and gelatin nanoparticles in such way to increase the interaction with macrophages than
unmodified nanoparticles. The macrophages uptake via Fc Receptors provide key role in
active phagocytosis and endocytosis. Many studies reported that immunoglobulin and
monoclonal antibody or its Fc fragment incorporated nanocomplexes present much
higher binding and internalization by macrophages via Fc receptor-mediated endocytosis.
Nano-delivery small molecules therapeutics were widely use for macrophage targeting in
various pathologic conditions including mycobacterium tuberculosis, endotoxin-induced
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lung inflammation , parasitic infection, as well as HIV/AIDS. Many of them are mediated
through Fc receptors, and its associated drug delivery system is well developed. This
mechanism of macrophage uptake is called antibody dependent cellular phagocytosis
(ADCP). Briefly, IgG molecules that is specific for certain surface receptor of antigens
can bind to these pathogens with their fragment antigen binding region (Fab region)
which contains amine group, then their fragment crystallizable region (Fc regions)
exposed to phagocytes in order to induce phagocytosis. The low affinity properties of Fc
receptors can reduce the possible binding to antibody and agglutination when there is no
present of antigen. [225,226]
A detailed understanding of the functionality and property of these Fc receptors is critical
during the application. Subfamilies of Fc receptors can be classified according to variable
affinity and can also be classified based on the activating and inhibitory properties. It is
very important to balance the expression between activating and inhibitory Fc receptors
for normal immune responses. There are some similarities of FcγRs expression between
human and mouse species, but do exist many differences which can complicate the
clinical application. For example, mouse macrophages always express relative high levels
of FcγRI receptors at normal conditions, but the level of FcγRI receptors expressed low,
and high in inflamed human macrophages. The classification of similarity and difference
between human and mouse was summarized in Table 6.1.
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Table 6.1 Summary of Human and Mouse Fc Receptors.
Human

FcγRI

FcγRIIA

FcγRIIB

FcγRIIC

FcγRIIIA

Fc γRIIIB

(CD64)

(CD32A)

(CD32B)

(CD32C)

(CD16A)

(CD16B)

Mouse

Fc γRI

Fc γRIII

Fc γRIIB

Major

Activation

Activation

Inhibition

Fc γRIV
Activation Activation Activation?

Function

Although our study focused on murine macrophages, the terms associated for human Fc
receptors are used in the here.
Some experiment further indicated functionality of Fc receptors by blocking different
classes of FcRs. The results showed a significant reduction of ADCP when block all three
Fc Receptors with F(ab’)2 fragments.

Interestingly, the decreased ADCP was not

observed when only blocking FcRI receptors (CD64), indicating that Fc receptor
mediated phogocytosis only involved with Fc γRII and Fc γRIII (CD16 and CD32). [227]
Furthermore, some results also indicated that blockage of either FcRII or FcRIII receptor
didn’t remarkably influence the phagocytosis, but significant effected by the blockage of
both receptors. This suggested that either of these two low-affinity Fc receptors is capable
of functioning independently to initiate phagocytosis. [228] Therefore, the study of
nanoparticle uptake by macrophages through phagocytosis can focus on either Fc γRII or
Fc γRIII receptors, or both.
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6.1.4

Targeting Macrophages in Spinal Cord

The subsets of macrophages were revealed a markedly different biofunctional role in
immune system as mentioned earlier, there is no doubt that discrimination between M1
and M2 macrophages also strongly influence the targeting strategies to the macrophages.
Many researchers focused on targeting tumor-associated macrophages for cancer
treatment. These macrophages were favor the tumor growth via angiogenesis and
metastasis, and they are usually consider as a M2-similar macrophages which particularly
indicated by Arginase-1 and CD206-mannose receptor expression. However, the role of
M2 macrophages in different bioenvironment could results in a completely opposite
outcome.

In the case of spinal cord injury, the M2 macrophages can produce

neurotrophic factors and promote the nerve outgrowth in either developing or mature
neurons after SCI. [229] On the other hand, pro-inflammatory M1 macrophages can
produce various cytokine such as TNF- α and NO and play an pivotal role in secondary
injury. Therefore, the inhibitory molecules generated from M1 macrophages could be an
important target in drug delivery to treat neural trauma and disease.
The expression level of the receptors can be alternated depending on the changes in
bioenvironment. The differentially higher expression of Fc receptors on the surface of
macropahges was found in many rheumatoid arthritis studies, and also found in the case
of SCI. Since inflammatory macrophages at rheumatoid arthritis joint over-expressed
CD-64, CD64-directed immunotoxins has been reported to be useful for screening,
diogonose or even treatment for rheumatoid arthritis. [230]
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The surface markers after spinal cord injury were characterized as CD86, CD16/32
positive M1 macrophages and CD206 positive M2 macrophages. [213]In the case of
multiple sclerosis, surface marker CD40, CD86, CD64 and CD32 were overexpressed by
activated microglia and macrophages throughout demyelination. [231] There is a
significant increased M1 macrophages were observed at first day after SCI, however, the
M2 macrophages featured with IL-4 receptor α chain and CD206-mannose receptor
surface markers start upregulation from day 3 and significant increased at day 7. [218]
This timeline is cohesive with the results demonstrated by Kristina Kigerl et al and
Kyoung-Jin Min et al . [213,232] The expression of CD16, CD32, and CD64 in different
macrophage populations has also been indicated to correlated with phagocytic activity
and phagocytosis efficacy.[233]( Also see 6.1.3) Therefore, Fc receptors mediated M1
macrophage targeting can be a potential strategy in SCI study.

6.2

Materials and Methods
6.2.1

Cell Culture

Bone marrow-derived macrophages (BMDM) from C57BL/6 mice were purchased from
cell biologics LLD which purified by positive selecting CD11b using flow cytometry and
were maintained in cell medium with Dulbecco’s modified Eagle medium/F12, 10 mM Lglutamine, supplemented with 10% fetal bovine serum, 100 U/ml penicillin, and 100
μg/ml streptomycin in the presence of GM-CSF (5ng/ml) or M-CSF(2500U/ml). The
macrophage were seeded in 12- well or 24-well tissue culture plates and allowed to
adhere for 24 hour at 37oC in humidified atmosphere containing 5% CO2.
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6.2.2

Light Microscopic Studies on M1 and M2 Macrophages Morphology

Macrophages incubated with GM-CSF were polarized to M1 macrophages by
challenging with combination of LPS (Sigma) and IFNγ (B&D Research) at higher
concentration of 1μg/ml LPS+200 ng/ml IFNγ or at lower concentration of 100ng/ml
LPS+20ng/ml IFNγ for 12 hours. Also, macrophages incubated with M-CSF were treated
with IL-4 for 12 hours to activate M2 macrophages. The control group is prepared by
GM-CSF and without stimulation of any cytokines. The morphology of macrophages was
imaged using Olympus IX 81 inverted microscope.

6.2.3 In Vitro Experiment
For siRNA experiment, the siRNA was mixed with desired volume of Lipofectamine
2000 transfection reagent based on the instruction from the companies. Macrophages
cultured in serum free medium were then incubated with 2μl of 20μm siRNAs per well
for 48 hours (or 4 hours for comparision) before challenged with medium containing
100ng/ml LPS and 20ng/ml IFNγ for 12 hours. To screening most efficient iNOS
siRNAs, macrophages were also received the same siRNA treatment but stimulated with
higher concentration of insults, that is, 1μg/ml LPS with 200ng/ml IFNγ. The target
sequences

of

siRNA

as

GAAACGUUAUCAUGAAGAU
(siRNA2),

listed

here

(siRNA1),

were

(siRNA

4).

for

screening.

CAUGGGAGCCACAGCAAUA

GGAGAUGGUCCGCAAGAGA

GAUUUAGAGUCUUGGUGAA

used

(siRNA3)
In

addition,

three

and
different

siRNA/chitosan Nps were used as treatments during the experiment, which are
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Chi/siRNA Nps, M-WSC/siRNA Nps, and Ab-Chi/siRNA Nps. Pre-prepared siRNA
conjugated chitosan solution at concentration of 2μl of 20μm siRNAs was added to each
well containing serum free medium for 4 hours before low concentration of LPS/ IFNγ
challenge. For all experiment, cells were incubated in fresh medium for 12 hours between
treatment and challenge procedures. In negative control groups, scrambled siRNAs (will
not results in the specific degradation of iNOS mRNA) were synthesized with chitosan,
instead of iNOS targeted siRNAs.

6.2.4

Transfection Efficiency

Bone-marrow derivate macrophages were cultured in a 12-wells dish at density of 1*106.
Three different chitosan Nps were prepared as described 5.2.1section with exceptional of
DY547 conjugated siRNAs (customized by GE Dharmacon, CO) were used with sense
sequences

DY547-CAUGGGAGCCACAGCAAUAUU

and

antisense

5’-

PUAUUGCUGUGGCUCCCAUGUU siRNAs with transfection reagents or siRNA
conjugated chitosan Nps were incubated for 4 hours before imaging. The fluorescence
signals and macrophage morphology was imaged by Olympus IX 81 inverted
microscope. The overlapping of fluorescence and light microscopic images for each
groups also performed to indicate the level of macrophage uptake.

6.2.5

Western Blot Analysis of Gene Silencing

The cells were treated and challenged as described in 6.2.3 section. Subsequently, each
group of macrophages was incubated in ice-cold RIPA buffer (Pierce, Thermo Fisher
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Scientific Inc, IL) containing 25mM Tris-HCl (pH 7.6), 150mM NaCl, 1% NP-40, 1%
sodium deoxycholate, 0.1% SDS, and keep on ice for 5 mins. Macrophage lysate were
gently collected using cell mini scraper and centrifuged for 15mins at 14000rpm at 4oC.
Then supernatant were quantified by BCA protein assay kit (Pierce), and equal amount
of the proteins from different samples were loaded in 7.5% sodium dodecyl sulphate
(SDS)-polyacrylamide gels and transferred to a PVDF membrane. Membrane were
incubated in blocking buffer containing 1X Tris Buffered Saline with Tween® 20
(TBST, Cell Signaling Technology, Inc.) and 5% w/v nonfat dry milk for 1 hour at room
temperature. Immunoblotting was processed with incubating membrane with mouse
specific primary antibody iNOS (#2982, Cell Signaling Technology, Inc.) and β-Actin
Antibody (#4967, Cell Signaling Technology, Inc.) overnight at 4°C. Then, membrane
was gentle agitated in blocking buffer containing anti-rabbit IgG, HRP-linked Antibody
(#7074, Cell Signaling Technology, Inc.) for 1 hour at room temperature and developed
in LumiGLO solution for 1 min at room temperature. The bands of interest were detected
by Syngene GBox imager and the quantization of interest band was analyzed using Image
J software.

6.2.7

NO Assay

The macrophages were incubated with siRNA with or without transfection reagent for 48
hours. Also, all four siRNA/chitosan Nps were also performed as treatment groups and
incubated for 4 hours before LPS and IFNγ challenge. In two cases of Ab conjugated
chitosan nanocomplexes, different level of Ab (10%, 20%, and 30%) incorporated with
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chitosan were also analyzed.

Cells after received different treatments were then

incubated in fresh medium for 12 hours before stimulated by 1μg/ml LPS and 200ng/ml
IFNγ for 12 hours. Different samples were immediately collected and separately detect
the values of nitrate (NO3-) and nitrite (NO2-) levels based on Nitric Oxide Assay Kit
(Pierce).

6.2.8

In Vivo Experiment

All aspects of animal care and treatment were carried out according to the guidelines of
Purdue Animal Care and Use Committee (PACUC). Female BALB/c mice with weight
approximate 25g were used in this study. Spinal cord injury was induced similar to the
surgical procedures described at 4.2.3 section with exception that clip compression was
used to spinal cord instead of forcep compression. The prepared chitosan solution
described at 5.2.1section was centrifuged for 15 mins at 4 °C. The pellet was then diluted
using RNase free water and prepared as 10μg siRNAs in 10μl chitosan Nps suspension.
All siRNAs treatments were conducted by injecting 10μl solution to spinal cord via
hamlton syringe with 30 Gauge needles for 10 mins.

6.2.9

Western Blot Analysis for Spinal Cord Extracts.

Mouse were deeply anesthetized, euthanized, and kept on ice at 24 hours after SCI. The
injured spinal cord segments (0.5cm long) were rapidly removed and freeze in the dry
ice. Before use, the frozen tissue were weighted and placed into vial with Triple-Pure,
High Impact Zirconium Beads (1.5mm) and lysis buffer which containing RIPA buffer,
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1x Halt Protease and phosphatase Inhibitor Cocktail, and 1x EDTA (Pierce). The
samples were then homogenized using BeadBug Microtube Homogenizer (Benchmark).
The homogenate was centrifuged at 10,000 g for 5 mins at 4°C. The protein concentration
of tissue lysates was then determined with a BCA Protein Assay Kit (Pierce). 50ul
aliquots were subjected to 4–20% polyacrylamide gel, and the proteins were
electrophoretically transferred to PVDF membrane filters. The membrane then were
blocked with 5% nonfat milk in TBST for 1 hour at room temperature. After washing, the
membrane were incubated with primary antibody solution containing iNOS, α-tubulin
(1:1000, Cell signaling), Bcl-2 (1:200), and Bax (1:100) (Santa Cruz Biotechnology, Inc)
separately overnight at 4°C. Next day, the membrane were washed for 3 times with
TBST and probed with HRP conjugated secondary antibody for 1 hour at room
temperature. Then, it is followed by the incubation of LumiGLO solution for 1 min at
room temperature. The membrane was exposed to Syngene GBox imager and the density
of the immunoreactive bands was quantified using ImageJ software.

6.2.10

Statistical Analysis

All data are shown with standard error of the mean ( + SEM). The data was determined
as normal distribution based on the level of skew and kurtosis less than 2 and 9. Tukey's
HSC multiple comparisons tests were used. Significance was determined by a P-value <
0.05.
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6.3 Results
6.3.1

Divergent Morphologies of M1 and M2 Macrophages

In our results, we demonstrated that the activation of polarized macrophage is accompanied
with the alternation in macrophage morphology. According to our results in Figure 6.1, the
control group without any cytokine stimulation expressed a spindle-look or rounded shape
of cells, and the induction of IL-4 results in a more long elongated shape of M2
macrophages.

These extended shaped M2 macrophages also showed an enhanced

adherence properties compared to M1 macrophages. Moreover, the stimulation of
LPS+IFNγ results in more flattened round appearance as well as outspread cytoplasm in
M1 macrophages. In addition, a higher concentration of LPS+IFNγ is with similar but
more enhanced results.
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Figure 6.1 The macrophage morphology of inactivated macrophages (control), activated
M2 macrophages, and activated M1 macrophages. Control group did not receive any
cytokine activation. M2 macrophages were activated by IL-4 shown as M2(IL-4), and M1
macrophages were stimulated by either high concentration of LPS+IFNγ or low
concentration of LPS+IFNγ, indicating by M1 (LPS+IFNγ) (H) and M1 (LPS+IFNγ) (L)
respectively.

6.3.2

Efficient Transfection of SiRNAs Conjugated Chitosan Nanoparticles

The intracellular distribution of siRNA with transfection reagent, Chi/siRNA Nps, MWSC/siRNA Nps, and Ab-Chi/siRNA Nps in the murine BMDM were imaged using
fluorescence and light microscope. Customized DY547 dye conjugated with 5’end of
siRNA sense strand were used to visualize the cellular uptake. In figure 6.2, DY547 signals
were imaged using fluorescence microscope and expressed as the red fluorescence signals
displayed in the first row.(Figure 6.2 A and B) It demonstrates the quantity and distribution
of siRNAs or siRNA with chitosan complexes. The second row (Figure 6.2 C and D)

144
showed images of macrophages, and the third row (Figure 6.2 E and F) showed an
overlapping image of these two. The results showed a comparison of the transfection
efficiency between using transfection reagent (Figure 6.2 left column) and Ab conjugated
chitosan Np mediated (Figure 6.2 right column) siRNA delivery. The endocytosis of AbChi/siRNA Nps was dramatically higher than using transfection reagent during a 4 hours
incubation time. There is approximately 60~70% DY547-labled macrophages when using
Ab-Chi/siRNA Nps delivery, comparing to 10~20% using transfection agent. However,
there is no significant difference between Ab-Chi/siRNA complexes with either MWSC/siRNA or Chi/siRNA complexes (Data not shown here).
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Figure 6.2 Illustration of transfection efficiency of siRNAs and siRNA conjugated Abchitosan Nanoparticles. A and B are fluorescence images, indicating distribution of
siRNA and siRNA loaded chitosan Nps. C and D are macrophage images, and E and F
are overlapping images.
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6.3.3

Protein Knockdown

Following the confirmation of cellular uptake, the silencing effects of siRNA were
performed using western blotting methods. We used LPS+IFNγ to initiate the activation
of M1 macrophages and used IL-4 to induce M2 macrophages. The iNOS protein
expressions were evaluated at the condition of activated M1macrophages, activated M2
macropahges, and control group which is the macrophages without cytokine stimulation
applied. There is no iNOS expressions were observed in either control group or IL-4
activated M2 macrophages. In contrast, there was a significant increased level of iNOS
expression found after M1 macrophages activation (Figure 6.3 A), especially under the
simulation of a higher concentration of LPS+IFNγ (Figure 6.3 B). Four different siRNA
sequences were applied seperately for 48 hrs before LPS+IFNγ stimulation and were
screened for an optimized silencing of iNOS expression. Combining low and high level
of LPS+IFNγ stimulations, we conclude that the siRNA*2 showed a significant reduction
of iNOS expression with p<0.001 and p< 0.01respectively. Although the siRNA1 also
shown a dramatically reduction of iNOS protein level, the results are more variable
compare to the results of siRNA*2. Therefore, siRNA*2 were used in all following
experiments for further studies.
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Figure 6.3

Screening of siRNAs for silencing of iNOS mRNA expression. Protein

silencing efficiency of different sense and antisense strands of iNOS specific siRNAs.
Control group represents the macrophages without any cytokine stimulation. IL-4
represents M2 macrophages were activated by IL-4 cytokines for 12 hours. LPS+IFNγ
(H) indicated the activated M1macrophages stimulated by 1μg/ml LPS +200ng/ml IFNγ,
whereas LPS+IFNγ (L) indicated the activated M1macrophages stimulated by 100ng/ml
LPS +20ng/ml IFNγ for 12 hours. The target sequence of four differnt siRNAs was listed
in 6.2.3.
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As we mentioned earlier, siRNAs can be transfected into macrophages using transfection
reagent, but have very limited transfection efficiency in a shorter incubation time. Most
commercially available transfection reagents require days of incubation time for
optimized transfection. In our study, we compared the iNOS reduction level between a
48 hours incubation and a 4 hours incubation time. The data showed that a longer
incubation time results in a dramatically downregulation of iNOS expression after low
level of LPS+IFNγ stimulation to M1macrophages. Moreover, there is a significant
statistical difference of iNOS expression between without (Figure 6.4 LPS+IFNγ (L)) and
with pre-treatments using 48 hours incubation of siRNAs, 10%Ab-Chi/siRNA Nps, MWSC/siRNA

Nps,

and

Chi/siRNA

Nps

in

activated

M1

macrophages.

(p<0.001;p<0.001;p<0.01;p<0.01 respectively shown in Figure. 6.4) It is noteworthy that
there is no statistical differences were detected between siRNAs treatment for 48 hours
and treatment for 4 hours, although the mean value for 4 hours incubation of siRNAs
shows significant less reduction in protein silencing and showed no statistical difference
compared to without treatment. The statistical differences were also observed between
siRNAs treatment for 48 hours and scrambled siRNAs (N-siRNA)(p<0.001), and similar
statistical outcomes were also observed when compare targeted siRNA* with scrambled
siRNAs (N-siRNA) in different siRNA conjugated chitosan nanocomplexes including
10% Ab-Chi/siRNA Nps, M-WSC/siRNA Nps, and untargeted Chi/siRNA Nps.
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Figure 6.4 Knockdown of iNOS protein activity. All groups were challenged with low
concentration of LPS+IFNγ. SiRNA*2 (L) indicated using siRNA with transfection
reagent treatment for 48 hours, and a 4 hours incubation treatment time was also
performed. Different Ab combination ratio range from 10% to 30% in Ab-Chi/siRNA
Nps was also tested for iNOS expression. The outcomes of mannosylated chitosan and
untargeted chitosan mediated siRNA treatment were presented here as well. Last four
group demonstrate the same transfection reagent and chitosan Np based siRNA treatment
with exception of scrambled siRNA were applied. Label siRNA* indicated the siRNAs
used in all experiment was siRNA2 indicated in Figure 6.4. Label N-siRNA indicated
scrambled siRNA. * p<0.05; ** p< 0.01; *** p<0.001.
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6.3.4

NO Reduction

NO production, as a result of iNOS expression, is the direct detrimental molecules to
exacerbate the primary SCI and to sabotage the neural functional recovery. The level of
NO production was evaluated in a pattern as that in western blotting studies. The LPS and
IFNγ stimulation was applied to all groups except for control and IL-4 initiated M2
macrophages. The results showed that all treatment groups with targeted siRNAs
(siRNA*) showed a dramatically reduction of NO level. (p< 0.001 compare to without
treatment in figure 6.5) It confirmed the silencing efficiency of siRNA*2 addressed in
Figure 6.3. All the data are matching the results in protein expression study describe in
6.3.3 with exception of the similar outcomes of NO reduction for three different siRNA
conjugated chitosan complexes. We also tested NO production after the treatment of
siRNAs with transfection reagent and without transfection reagent. An increased NO
level was observed when there is no transfection reagent applied, suggesting that the poor
cellular membrane crossing of siRNA itself and failure of iNOS protein silencing. BS3
crosslinker mediated Ab conjugated chitosan Nps with a low zeta potential and larger
particle size were also tested. A slightly NO reduction indicate the this synthesis method
needs a further improvement in order to successfully delivery siRNA and silencing the
desired mRNA expression. (p<0.05)
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Figure 6.5 NO production of macrophages without cytokine stimulation, activated M2
macrophages stimulated by IL-4, and M1 macrophages challenged with LPS+IFNγ with
and without siRNA related gene silencing treatment.

Figure 6.6 NO production using scrambled siRNAs.

152
In contrast, we also performed all groups with scrambled siRNA (N-siRNA), and it fail to
prevent the NO production and showed no statistical difference.(See Figure 6.6)
The reduction ability of NO level using siRNA treatment with different sequences was
screened before apply the experiments described at Figure 6.5. These results confirmed
the knockdown ability of siRNA2 (siRNA*) as protein studies. The same NO assay also
applied to evaluate the reduction level produced by two different Ab conjugated
chitosan/siRNA Nps with various Ab ratio (from10%-30%).

There is no statistical

difference of NO level between different Ab ratio in each group. However, there is
significant statistical difference between with and without chitosan/siRNA Nps treatment.
(p<0.001) (Data not shown in here)

6.3.5

Inhibition of Apoptosis Pathway after Spinal Cord Injury

To exploit the functionality of targeted chitosan Nps in SCI conditions, we induced a
compression injury to spinal cord of the mice to initiate the upregulation of iNOS protein
expression and NO production. In our study, not only iNOS, but also Bax and Bcl-2
protein expression were also investigated using western blotting methods at 24 hours
after SCI. The upregulation of iNOS expression was observed after SCI (See Figure 6.7).
Pro-apoptosis Bax level were also appreciably increased, and anti-apoptosis Bcl-2 level,
in the contrary, were significantly decreased after SCI, indicating the apoptosis signaling
pathway was initiated or might be propagated after injury. Two treatment groups, AbChi/siRNA Nps and M-WSC/siRNA Nps, were performed to animal after SCI. Both
treatment groups showed a trend of elimination of iNOS and Bax expression and
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relatively increased Bcl-2 levels, especially in the case treated with Ab-Chi/siRNA Nps.
(*** p<0.001 for iNOS; ** p<0.01 for Bax and Bcl-2) These results suggest the
neuroprotective role of siRNA conjugated chitosan Nps by preventing cell apoptosis
signaling pathway after spinal cord trauma.

Figure 6.7 Different proteins expression level after SCI with and without treatment of
different chitosan nanoparticles carried siRNAs. Ab-Chi/siRNA Nps were originally
designed for M1 macrophages targeting, and M-WSC/siRNA Nps for M2 macrophages
targeting. *** p<0.001 ** p<0.01; * p<0.05.
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6.4

Discussion

Many approaches were developed to modulate the function and secretion of macrophages
to reduce the potential damage caused by secondary injury after SCI. The activation of
M1 macrophages triggered by traumatic injury can initiate many pro-inflammation. Thus,
preventing the proliferation of M1 macropahges or inibiting M1 associated proinflammatory signaling pathways can suppress the inflammation initiated secondary
injury. In our study, we targeted the hallmark expression of iNOS in M1 macrophages
using siRNA gene silencing strategies and nanoscaled drug delivery systems. This work
focused on targeting specific macrophages either to M1 or M2 macrophages using ligand
conjugated chitosan/siRNAs Nps in SCI study. This is first time in nanoparticle targeting
studies discriminating different subsets of macrophages. Since the overexpression of
CD16/32 in M1 macrophages was observed at the insulted state of spinal cord, we also
demonstrated the protential application of Fc receptor mediated M1 macrophages
targeting. Most importantly, we indicate that this M1 macrophage targeting strategy can
inhibited iNOS expression via delivery siRNAs and reduced cell damage and death after
apply chitosan/siRNAs Nps by detecting apotosis cell singling protein marker Bax and
Bcl-2 in vivo study.
There are many studies has suggested the successful chitosan nanoparticle mediated
siRNA delivery to macrophages, such as enhanced green fluorescent protein (EGFP) and
TNF-α knock down in murine peritoneal macrophages. [189,196]

A rabies virus

glycoprotein derived short peptide was designed as a AchR targeting ligand and it can
assist the delivery of TNF- α siRNA to both macrophages and microglia cells for
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neuroinflammation and neuronal apoptosis reduction. [234] Different administration
route of chitosan mediated nanoparticle has also been investigated for siRNA delivery to
achieve potential gene silencing, for example through IP injection to macrophages, [196]
and applied oral administration by

modificating chitosan to mannose-incorporated

trimethyl chitosan-cysteine (MTC). [235]
Due to the nature of chitosan polymers, there is no evidence of inflammatory reaction of
material itself in the clinical study. However, the purity, or we may say, the low degree
of acetylation of chitosan could results in a unexpected inflammation. Several
publications focused on the effects of chitosan materials towards macrophages culture.
The outcomes are various. Oliveira MI et al. indicated that chitosan significantly downregulated expression of proinflammatory cytokines in macrophages, more interestingly, it
also up-regulated anti-inflammatory cytokines and favors the M2 polarization. [236]
These results were supported by the suppression of chitinous materials to nitric oxide
production in the study of activated RAW 264.7 macrophages. [237] The mechanism of
this suppression was further evaluated in other publications, and they suggested that there
is a moderate activation of both iNOS and arginase in resident macropahges, but a strong
expression of arginase with no altered NO production in inflammatory macrophages
when treated with chitosan. Since arginase induction is responsible for proliferation of
many cell lines, it has the potentials to play a beneficial role in secondary injury
treatment. [238] However, one paper reported that chitosan can induce apoptosis of
macrophages through Fas signaling pathways. [239]
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Since the iNOS is preferentially produced by classically activated proinflammatory M1
macrophages, we focused on this subset of macrophages for targeting to attenuation the
iNOS expression and its consequent NO prodcution. In addition, M1 macrophages
upregulated the CD16/32, CD86, and MHCII expression after SCI. [213] Therefore, we
can be able to differentiate this from anti-inflammation M2 macrophages which are
designated by Arg1 and mannose receptor (CD206). The overexpression of receptors on
M1 macropahges can be used as the potential target for siRNAs delivery. The increased
iNOS expression starts few hours after SCI and dramatically reduced at day 3 after SCI,
therefore, a time-corresponding cell surface marker expression, such as CD16/32 in M1
macrophages can be considered as mediated receptors.
Although it is known that macrophage internalization can be influenced by particle size
and shape, as well as surface charge, it is still unclear about the mechanism of Nps uptake
of macrophages. In general, it is believed that increased particle size (especially for
nanoparticles size larger than 0.5um), higher zeta potentials, or long dimension of
particles can be uptaken more rapidly by macrophages compare to smaller and neutral
nanoparticles. Bone marrow and circulating blood derived monocytes and resident
macrophages in every organs are usually represented as Mononuclear Phagocyte System.
They are mainly responsible for pagocytosis. [240] The broad spectrum of extracellular
IgG molecules or IgG-coated partilces can bind and interact with Fc receptors
(FcRII/CD16 and or FcRIII/32) expressed on macrophage and initiate phogocytosis or Fc
receptor mediated endocytosis to enhance the activity of its uptake.
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Recent findings indicate that FcγRIIA is expressed primarily in phagocytic cells and also
present in natural killer (NK) cells. Inhibitory Fc Receptor FcγRIIB is constitutively
expressed in T and B lymphocytes as well as phagocytic cells. Macrophages and some
monocytes express FcγRIIIA, whereas FcγRIIIB is only expressed at neutrophils.
[241,242] More studies further exploit and suggested that macrophages and monocytederived dendritic cells and express high levels of activating FcγRs and moderated level of
inhibitory ones for IgG. In comparison, conventional and plasmacytoid dendritic cells
mainly express the inhibitory FcγR. [241]
In our in vitro study, the pre-treatment approaches of siRNAs or its related drug delivery
system were reported in majority of siRNAs gene silencing studies. In this bone-marrow
derived macrophages study, we apply either siRNAs or different chitosan/siRNA Nps to
the cells before LPS+IFNγ initiated M1 macrophage activation. Our flow cytometery
results addressed both expression of CD206 and CD16/32 before activation either M1or
M2 macrophages. These results were fit with data reported by Flora Rey-Giraud et al.
[243] The surface of the macrophages expressed both CD206 and CD16/32 receptors at
inactivated state could lead to the successful cellular uptake of both mannosylated
chitosan Nps and Ab conjugated chitosan Nps. A post-treatment was conducted during
the study, however, cell viability is relatively reduced (data not shown here). Untargeted
Chi/siRNA Nps also shown a significant reduction of iNOS, and it could due to the low
molecular weight chitosan binds to the mannose receptors and promotes the nanoparticles
internalization. [244]
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We need to emphasize again that the expression of cells bearing surface receptors can be
alternated, for example, accompanies with macrophage activation or spinal cord insults.
The overexpression of CD16/32 after spinal cord injury can be beneficial to perform Fc
receptor mediated phagocytosis and endocytosis as strategies using CD64-directed
immunotoxins targeting to inflammatory macrophages at rheumatoid arthritis joint. [230]
It is noteworthy that some studies also indicated that nanoparticle taken up via mannose
receptor, Fcγ receptor, or through complement receptor pathways elicit an inflammation
mediated immune response. It could due the phogocytosis process associated activation
of certain signaling pathway. It is not observed in our study based on the results in
Figure 6.4 and 6.6, there is no trace of increased iNOS level and NO production for MWSC/N-siRNA Nps and Ab-Chi/N-siRNA Nps treatment (using scrambled siRNAs)
compared to that without treatment after LPS + IFN γ challenge. However, other cytokine
production did not included in our studies. Interestingly, Ab-Chi/N-siRNA Nps treatment
showed visually but not statistically down regulation of iNOS expression. This
phenomenon can not be explained until very recent report (Oct,2014) published at
Santegoets K.C.M et al. The studies showed that macrophages cultured with GM-CSF
expressed a high level of inhibitory receptor, FcγRIIb, but a moderate level in the case of
M-CSF cultured macrophages. This inhibitory FcγRIIb plays a vital role in balancing the
induced inflammatory responses to prevent excessive tissue damage. More importantly,
they also demonstrated that the introduction of soluble IgG immune complexes to GMCSF macrophages can inhibited cytokine production mediated by various Toll like
receptors (such as 2,3,4, 7/8) via FcγRIIb signaling pathways. GM-CSF macrophages
challenged with LPS (trigger TLR4 signaling) can initiated high level of cytokines such
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as TNF-alpha. After co-stimulation with IgG immune complexes, dramatically reduced
level of TNFα was observed in GM-CSF macrophages whereas a slightly increase level
of IL-10 was occurred in M- CSF Macrophages. IgG immune complexes treatment alone
did not initiated any detectable cytokines in GM-CSF but initiate low level of cytokine in
the case of M-CSF macrophages. These results can be indicated due to the
overexpression of inhibitory FcγRIIb in GM-CSF, not in M-CSF. [245] The earlier study
from this research group also showed immune complexes binding to FcγRIIb prevent the
activation of TLR4 signaling, this study could explain the slight, but not statistical
significant, redcution in iNOS level, when Ab-Chi/siRNA Nps were applied in in vitro
experiment.
According to other earlier studies, the internalization by macrophages can be operated by
all Fc receptors no mater they have activation or inhibition functions, but the endocytosis
capacity and the route of oponized materials are different after internalization. One
investigation suggests that internalization through activating FcγRs results in antigen
degradation pathways and followed by the activation of T cells. On the other hand,
Inhibitory FcγRIIB mediated macrophage internalization can transport undegraded
antigen to B cells. [241] Also, it has been documented that large immune complexes or
antibody-coated particles are susceptible to be uptaken via phagocytosis whereas the
internalization of small immune complexes are through FcγR mediated endocytosis. This
FcγR mediated endocytosis, compare to phagocytosis, require much different signal
transduction mechanism which not involving Syk, SRTKs, and PI3K kinases initiated
cytokine production.[246]
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Moreover, our results indicated that an increased amount of Ab during nanoparticles
synthesis did not result in more efficient gene silencing. 20% and 30% of Ab
incorporated chitosan Nps has been shown an increased iNOS expression compare to the
case using 10% Ab. The undesired concentration of antibody could affect phagocytosis.
Some reports indicate that optimal phagocytosis occurred at antibody concentrations of
10-100ng/ml. A higher risk of coagulation of nanoparticles could also jeopardize the
reduction in iNOS expression because Nps with higher Ab ratios have a lower zeta
potentials. Most possible reason is a high Ab ratio have a lower ratio of encapturing
chitosan and limit synthesis of chitosan materials with desired amount of siRNAs.
Chitosan mediated siRNA delivery system has demonstrate the improved transfection
efficiency and gene silencing results, especially showed a shorter incubation time during
the treatment when compared to using lipid-based transfection reagent. The complete
depletion of iNOS expression is not set as our goal. But, in many situations, extremely
efficient blocking of the specific protein expression is required. The efficiency of
nanoparticle delivery usually can be effected by phagsome or phagolysosomal
entrapment for phagocytic cell studies or by endosome for other cells. It could be a
critical point in gene delivery to avoid degradation in the compartments of phagsome or
endosome. Some groups reported that TNF- α specific siRNA conjugated large
nanoparticles containing polyketal PK3 and chloroquine can significantly block targeted
gene expression. It is due to the characteristics of PK3 which not only protect the siRNA
from serum nucleases, but most importantly, it can cause osmotic disruption of the
phagosome. Therefore, the siRNA loaded nanocomplexes can be released to the
cytoplasm. [247] Endosomolytc agent modified with maleic anhydride generating a pH-
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sensitive maleamate bonds which can be cleaved under acidic endosome conditions in
order to expose positive charged amine group and destabilized the endosome membrane
for siRNAs to escape. [248,249] In addition, other agents, such as an amphipathic
poly(vinyl ether), were also well developed for this purpose of application. [250]
Therefore, agents used in endosome escape can also be considered to prevent phagosome
or phagolysosomal entrapment in the future studies to optimize silencing efficiency.
The macrophage morphology studies showed apparent elongation or extension of M2
macrophages, and it accompanied with no detectable iNOS expression and nearly same
amount of NO production when compared to control group. It matches the
neuroprotection properties of M2 macropahges reported in many earlier publications.
Some researchers has also confirmed our results and elaborated the shape of macrophages
correlated with the macrophages polarization and M2 macrophages are not associated
with the initiation of imflammation, such as M1-polarizing stimuli triggered iNOS
expression. [251]
In conclusion, we introduce a siRNAs based gene silencing strategies to reduce the iNOS
expression which usually triggered by activated pro-inflammatory macrophages after
SCI. We successfully synthesized different ligand conjugated chitosan nanoparticles
carring siRNAs. In vitro study, all siRNA loaded chitosan Nps showed significant iNOS
knockdown with low cytotoxicity and efficient transfection. We further evaluate the
targeting and gene silencing effects in animal studies. The results showed an alleviation
of iNOS and Bax expression which is the indicator for pro-apoptosis cell death whereas
an significant upregulation of anti-apoptosis marker Bcl-2 after Ab-Chi/siRNAs Nps
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treatmen, indicating the effient targeting and therapeutic effects after attenuation of iNOS
level by siRNAs application.
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CHAPTER SEVEN
FUTURE STUDIES
There are many potential improvements that can still be provided to Ppy platform or
chitosan nanoparticles mediated drug delivery system. Either polymer based drug carriers
have been shown their unique functionality during the drug delivery.
In this study, we focused on the structure, synthesis, and releasing profile for the Ppy
platform to optimize localized drug release in spinal cord bio-environment. A further
investigation on the 3D structure with increased drug loading capacitates would possibly
be a next step. The figure 7.1 shows the Ppy nanotubes that we have manufactured with a
larger surface area of polymers. It could enhance the drug release because there is less
possible drug entrapment due to larger areas exposure of materials. In figure 7.1, one PC12 cell was adhesived on the surface of Ppy matrix, indicating the small size of nanotube
diameter.
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Figure 7.1 SEM image of single cell on Ppy nanotube structure. Scale bar = 5μm.
Parameters of the EMF generator can also be modified, such as the frequency and the coil
size. We will start from a EMF stimulator with a low frequency instead of using current
radiofrequency frequency. So we can further explore the cell responses to the low
frequency stimulator (it has been well-established in the bio-electrical literatures) while
detect the potential drug release. It could acheive a dual treatment through one
application. Also, the penetration capacity of current induced by alternating
electromagnetic field generator (described in 3.4 section) can also be further studied with
a larger coil size and lower frequencies generator.
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Figure 7.2 SEM images for cell adhesion on flat Ppy and Ppy Nws. Scale bar A=100μm;
B=10μm; C and D=40μm.
Moreover, from tissue engineering perspectives, this Ppy NWs platform can be
potentially developed as biocompatible or even biodegradable substrates for cell adhesion
and connection. Collagen coated flat Ppy indicated the successful cell attachment see
figure 7.2 A and there is apparent neurite extension. (see lower magnification figure 7.2
B) However, there is no cell adhesion that was observed for the flat Ppy without collagen
substrate coating (See figure 7.2C). Interestingly, PC-12 cells successfully adhered to the
PpyNWs structured platform without substrate assistance (Figure 7.2D). A further and
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thoroughlly studies can be performed in the future as well. Meanwhile, different drugs
incorporation with this Ppy platform can also be discovered to improve neuronal recovery
after SCI.
For chitosan mediated siRNAs drug delivery system, co-polymerization and different
targeting motifs can be exploited as an add-on to improve the existing nanoparticles, such
as assisting nanoparticles cross spinal blood barriers. Thus, a simple IV injection instead
of intrathecal injection can be used. Also, the study on M1 and M2 macrophages shifting
through modulating various cytokines in bio-environment could lead to a new chapter of
therapeutic strategies for SCI.

167

BIBLIOGRAPHY

167

BIBLIOGRAPHY

1.

Dasari, V.R., K.K. Veeravalli, and D.H. Dinh, Mesenchymal stem cells in the
treatment of spinal cord injuries: A review. World J Stem Cells, 2014. 6(2): p.
120-33.

2.

Chen, J., et al., Experimental Spinal Cord Injury Models, in Animal Models of
Acute Neurological Injuries.

3.

Buki, A., et al., Cytochrome c release and caspase activation in traumatic
axonal injury. Journal of Neuroscience, 2000. 20(8): p. 2825-34.

4.

Shields, D.C., et al., Calpain activity and expression increased in activated
glial and inflammatory cells in penumbra of spinal cord injury lesion. J
Neurosci Res, 2000. 61(2): p. 146-50.

5.

Okonkwo, D.O. and J.T. Povlishock, An intrathecal bolus of cyclosporin A
before injury preserves mitochondrial integrity and attenuates axonal
disruption in traumatic brain injury. Journal of Cerebral Blood Flow &
Metabolism, 1999. 19(4): p. 443-51.

6.

Oyinbo, C.A., Secondary injury mechanisms in traumatic spinal cord injury:
a nugget of this multiply cascade. Acta Neurobiol Exp (Wars), 2011. 71(2): p.
281-99.

7.

Hulsebosch, C.E., Recent advances in pathophysiology and treatment of
spinal cord injury. Advances in Physiology Education, 2002. 26(4): p. 238255.

8.

Blight, A.R. and M.P. Zimber, Acute spinal cord injury: pharmacotherapy
and drug development perspectives. Current Opinion in Investigational Drugs.
2001. 2(6): p. 801-8.

168
9.

Wada, S., et al., Apoptosis following spinal cord injury in rats and
preventative effect of N-methyl-D-aspartate receptor antagonist.PG - 98-104.
J Neurosurg, 1999. 91(1 Suppl).

10.

Wrathall, J.R., Y.D. Teng, and D. Choiniere, Amelioration of functional
deficits from spinal cord trauma with systemically administered NBQX, an
antagonist of non-N-methyl-D-aspartate receptors. Exp Neurol, 1996. 137(1):
p. 119-126.

11.

Görgülü, A., et al., Superoxide dismutase activity and the effects of NBQX and
CPP on lipid peroxidation in experimental spinal cord injury. Research in
Experimental Medicine, 1999. 199(5): p. 285-293.

12.

Pointillart V., et al. Effects of nimodipineon post traumatic spinal cord
ischemia in baboons. J neurotrauma, 1993. 10(2): p.201-213.

13.

Hayes, K.C., et al., 4-Aminopyridine-sensitive neurologic deficits in patients
with spinal cord injury. Journal of Neurotrauma, 1994. 11: p. 433-446.

14.

Segal, J.L. and S.R. Brunnemann, 4-Aminopyridine alters gait characteristics
and enhances locomotion in spinal cord injured humans. J Spinal Cord Med,
1998. 21(3): p. 200-4.

15.

Grill, R., et al., Cellular delivery of neurotrophin-3 promotes corticospinal
axonal growth and partial functional recovery after spinal cord injury. J
Neurosci, 1997a. 17(14): p. 5560-72.

16.

Grill, R.J., A. Blesch, and M.H. Tuszynski, Robust growth of chronically
injured spinal cord axons induced by grafts of genetically modified NGFsecreting cells. Exp. Neurol., 1997b. 148: p. 444-452.

17.

Jin, Y., et al., Transplants of Fibroblasts Genetically Modified to Express
BDNF Promote Axonal Regeneration from Supraspinal Neurons Following
Chronic Spinal Cord Injury. Experimental Neurology, 2002. 177(1): p. 265275.

18.

Chico, L.K., L.J. Van Eldik, and D.M. Watterson, Targeting protein kinases
in central
892-909.

nervous system disorders. Nat Rev Drug Discov, 2009. 8(11): p.

169
19.

Kopp, M.A., et al., Small-molecule-induced Rho-inhibition: NSAIDs after
spinal cord injury. Cell Tissue Res, 2012. 349(1): p. 119-32.

20.

Silveira, M. and R. Linden, Neuroprotection by cAMP: Another brick in the
wall, in Brain Repair, M. Bähr, Editor. 2006, Springer US. p. 164-176.

21.

Hasko, G., M.V. Sitkovsky, and C. Szabo, Immunomodulatory and
neuroprotective effects of inosine. Trends Pharmacol Sci, 2004. 25(3): p. 152157.

22.

Tomaselli, B., et al., p42/44 MAPK is an essential effector for purine
nucleoside-mediated neuroprotection of hypoxic PC12 cells and primary
cerebellar granule neurons. Mol Cell Neurosci, 2008. 38(4): p. 559-68.

23.

Svirskis, D., et al., Electrochemically controlled drug delivery based on
intrinsically conducting polymers. Journal of Controlled Release, 2010.
146(1): p. 6-15.

24.

Straley, K.S., C.W. Foo, and S.C. Heilshorn, Biomaterial design strategies for
the treatment of spinal cord injuries. J Neurotrauma, 2010. 27(1): p. 1-19.

25.

Wu, W., et al., Neuroprotective ferulic acid (FA)-glycol chitosan (GC)
nanoparticles for functional restoration of traumatically injured spinal cord.
Biomaterials, 2014. 35(7): p. 2355-64.

26.

Wang, Y.C., et al., Sustained intraspinal delivery of neurotrophic factor
encapsulated in biodegradable nanoparticles following contusive spinal cord
injury. Biomaterials, 2008. 29(34): p. 4546-53.

27.

Shi, Y., et al., Effective repair of traumatically injured spinal cord by
nanoscale block copolymer micelles. Nat Nanotechnol, 2009. 5(1): p. 80-7

28.

Borgens, R.B., R. Shi, and D. Bohnert, Behavioral recovery from spinal cord
injury following delayed application of polyethylene glycol. J. Exp. Biol.,
2002. 205: p. 1-12.

29.

Ingram, M.D., H. Staeschea, and K.S. Ryderb, "Activated" polypyrrole
electrodes for high-power supercapacitor applications. Solid State Ionics,
2004. 169: p.51-57.

170
30.

Song, H.-K. and G. T. R. Palmore, Redox-Active Polypyrrole: Toward
Polymer-Based Batteries. Adv. Mater, 2006. 18: p.1764–1768.

31.

Yuan, X., et al., Use of polypyrrole in catalysts for low temperature fuel cells.
Energy Environ. Sci., 2013. 6: p. 1105-1124.

32.

Tüken, T., Zinc deposited polymer coatings for copper protection. Progress in
Organic Coatings, 2006. 55(1): p. 60-65.

33.

Yavuz, Ö., et al., Polypyrrole composites for shielding applications. Synthetic
Metals, 2005. 151(3): p. 211-217.

34.

Ramanaviciene, A., and A. Ramanavicius, Molecularly imprinted polypyrrolebased synthetic receptor for direct detection of bovine leukemia virus
glycoproteins. Biosens Bioelectron, 2004. 20(6): p. 1076-82.

35.

Schmidt, C.E., V.R. Shastri, and J.P. Vacanti, Stimulation of neurite
outgrowth using an electrically conducting polymer. . Proc. Natl. Acad. Sci.
U.S.A., 1997. 94: p. 8948-53.

36.

Brett Runge, M., et al., The development of electrically conductive
polycaprolactone fumarate–polypyrrole composite materials for nerve
regeneration. Biomaterials, 2010. 31(23): p. 5916-5926.

37.

Georgea, P.M., et al., Fabrication and biocompatibility of polypyrrole
implants suitable for neural prosthetics. Biomaterials, 2005. 26: p. 3511–
3519.

38.

Lee, J.Y., J.W. Lee, and C.E. Schmidt, Neuroactive conducting scaffolds:
nerve growth factor conjugation on active ester-functionalized polypyrrole. J
R Soc Interface, 2009. 6(38): p. 801-10.

39.

Nguyen, H.T., et al., Electric field stimulation through a biodegradable
polypyrrole-co-polycaprolactone substrate enhances neural cell growth. J
Biomed Mater Res A, 2014. 102(8): p. 2554-64.

40.

Forciniti, L., et al., Schwann cell response on polypyrrole substrates upon
electrical stimulation. Acta Biomater, 2014. 10(6): p. 2423-33.

171
41.

Olayo, R., et al., Tissue spinal cord response in rats after implants of
polypyrrole and polyethylene glycol obtained by plasma. J Mater Sci Mater
Med, 2008. 19(2): p. 817-26.

42.

Cruz, G.J., et al., Plasma polypyrrole implants recover motor function in rats
after spinal cord transection. J Mater Sci Mater Med, 2012. 23(10): p. 258392.

43.

Ateh, D.D., H.A. Navsaria, and P. Vadgama, Polypyrrole-based conducting
polymers and interactions with biological tissues. J R Soc Interface, 2006.
3(11): p. 741-52.

44.

Dai., L., Conducting polymer, in Intelligent Macromolecules for Smart
Devices: From Materials Synthesis to Device Applications.

45.

Bhattacharya, A., A. De, and S. Das, Electrochemical preparation and study
of transport properties of polypyrrole doped with unsaturated organic
sulfonates. Polymer, 1996. 37(19): p. 4375-4382.

46.

Wang, P.-C. and J.-Y. Yu, Dopant-dependent variation in the distribution of
polarons and bipolarons as charge-carriers in polypyrrole thin films
synthesized by oxidative chemical polymerization. Reactive and Functional
Polymers, 2012. 72(5): p. 311-316.

47.

Otero, T.F. and J.G. Martinez, Biomimetic intracellular matrix (ICM)
materials, properties and functions. Full integration of actuators and sensors.
Journal of Materials Chemistry B, 2013. 1(1): p. 26-38.

48.

Ansari, R., N.K. Fahim, and A.F. Delavar, Removal of Nitrite Ions from
Aqueous Solutions Using Conducting Electroactive Polymers. The Open
Process Chemistry Journal, 2009. 2(1): p. 1-5.

49.

Garfias-García, E., et al., Eletrochemical Nucleation of Polypyrrole onto
Different Substrates. Int. J. Electrochem. Sci., 2010. 5(6): p. 763-773.

50.

Hepel, M. and F. Mahdavi, Application of the Electrochemical Quartz Crystal
Microbalance for Electrochemically Controlled Binding and Release of
Chlorpromazine from Conductive Polymer Matrix. Microchemical Journal,
1997. 56(1): p. 54-64.

172
51.

Curtin, L.S., G.C. Komplin, and W.J. Pietro, Diffusive anion exchange in
polypyrrole films. The Journal of Physical Chemistry, 1988. 92(1): p. 12-13.

52.

Fattahi, P., et al., A Review of Organic and Inorganic Biomaterials for Neural
Interfaces. Advanced Materials, 2014. 26(12): p. 1846-1885.

53.

Bidan, G., et al., Incorporation of sulphonated cyclodextrins into polypyrrole:
an approach for the electro-controlled delivering of neutral drugs. Biosens
Bioelectron, 1995. 10(1-2): p. 219-29.

54.

Kopecka, J., et al., Polypyrrole nanotubes: mechanism of formation. RSC
Advances, 2014. 4(4): p. 1551-1558.

55.

Luo, X. and X.T. Cui, Sponge-like nanostructured conducting polymers for
electrically controlled drug release. Electrochem commun, 2009. 11(10): p.
1956.

56.

Kang, G., R.B. Borgens, and Y. Cho, Well-ordered porous conductive
polypyrrole as a new platform for neural interfaces. Langmuir, 2011. 27(10):
p. 6179-84.

57.

Sirivisoot, S., R. Pareta, and T.J. Webster, Electrically controlled drug release
from nanostructured polypyrrole coated on titanium. Nanotechnology, 2011.
22(8): p. 085101.

58.

Richardson, R.T., et al., The effect of polypyrrole with incorporated
neurotrophin-3 on the promotion of neurite outgrowth from auditory neurons.
Biomaterials, 2007. 28(3): p. 513-523.

59.

Evans, A.J., et al., Promoting neurite outgrowth from spiral ganglion neuron
explants using polypyrrole/BDNF-coated electrodes. J Biomed Mater Res A,
2009. 91(1): p. 241-50.

60.

Thompson, B.C., et al., Conducting polymers, dual neurotrophins and pulsed
electrical stimulation--dramatic effects on neurite outgrowth. J Control
Release, 2010. 141(2): p. 161-7.

61.

Weidlich, C., K.M. Mangold, and K. Jüttner, Conducting polymers as ionexchangers for water purification. Electrochimica Acta, 2001. 47(5): p. 741745.

173
62.

Kang, E.T., et al., XPS studies of proton modification and some anion
exchange processes in polypyrrole. Synthetic Metals, 1990. 39(1): p. 69-80.

63.

Pei, Q. and R. Qian, Protonation and deprotonation of polypyrrole chain in
aqueous solutions. Synthetic Metals, 1991. 45(1): p. 35-48.

64.

Moulton, S.E., et al., Galvanic coupling conducting polymers to
biodegradable Mg initiates autonomously powered drug release. Journal of
Materials Chemistry, 2008. 18(30): p. 3608-3613.

65.

Zinger, B. and L.L. Miller, Timed release of chemicals from polypyrrole films.
Journal of the American Chemical Society, 1984. 106(22): p. 6861-6863.

66.

Ge, D., et al., A polypyrrole-based microchip for controlled drug release.
Electrochimica Acta, 2009. 55(1): p. 271-275.

67.

Xiao, Y., et al., Preparation of nano-tentacle polypyrrole with pseudomolecular template for ATP incorporation. Journal of Biomedical Materials
Research Part A, 2007. 80A(4): p. 925-931.

68.

Arbizzani, C., et al., Polypyrrole: A drug-eluting membrane for coronary
stents. Electrochimica Acta, 2007. 52(9): p. 3274-3279.

69.

Orcajo,

O.,

et

al.,

A

new

reflection–transmission

bidimensional

spectroelectrochemistry cell: Electrically controlled release of chemicals from
a conducting polymer. Journal of Electroanalytical Chemistry, 2006. 596(2):
p. 95-100.
70.

Massoumi, B. and A. Entezami, Electrochemically Controlled Binding and
Release of Dexamethasone from Conducting Polymer Bilayer Films.Journal of
Bioactive and Compatible Polymers January, 2002. 17(1): p. 51-62.

71.

George, P.M., et al., Electrically controlled drug delivery from biotin-doped
conductive polypyrrole. Adv. Mater., 2006. 18: p. 577-581.

72.

Miller,

L.L.

and

X.Q.

Zhou,

Poly(N-methylpyrrolylium)

poly(styrenesulfonate) - a conductive, electrically switchable cation
exchanger that cathodically binds and anodically releases dopamine.
Macromolecules, 1987. 20(7): p. 1594-1597.

174
73.

Leprince, L.,et al., Dexamethasone electrically controlled release from
polypyrrole-coated nanostructured electrodes. J Mater Sci Mater Med, 2010.
21(3): p. 925-30.

74.

Wadhwa, R., L. Carl, and C. Xinyan, Electrochemically controlled release of
dexamethasone from conducting polymer polypyrrole coated electrode. J.
Control. Release, 2006. 110(3): p. 531-541.

75.

Pyo, M. and J.R. Reynolds, Poly(pyrrole adenosine 5′-triphosphate) (PPATP) and conducting polymer bilayers for transport of biologically active
ions. Synthetic Metals, 1995. 71(1–3): p. 2233-2236.

76.

Pyo, M. and J.R. Reynolds, Electrochemically Stimulated Adenosine 5‘Triphosphate (ATP) Release through Redox Switching of Conducting
Polypyrrole Films and Bilayers. Chemistry of Materials, 1996. 8(1): p. 128133.

77.

Creed, S., et al., Towards electrochemical analgesia: acetylsalicylate
delivered from polypyrrole by electroreduction. Journal of the Chemical
Society, Chemical Communications, 1994(19): p. 2291-2292.

78.

Thompson, B.C., et al., Optimising the incorporation and release of a
neurotrophic factor using conducting polypyrrole. J Control Release, 2006.
116(3): p. 285-94.

79.

Richardson, R.T., et al., Polypyrrole-coated electrodes for the delivery of
charge and neurotrophins to cochlear neurons. Biomaterials, 2009. 30(13): p.
2614-2624.

80.

Li, Y. and S. Dong, Electrochemically controlled release of adenosine
5[prime or minute]-triphosphate from polypyrrole film. Journal of the
Chemical Society, Chemical Communications, 1992(11): p. 827-828.

81.

Zhou, Q.-X., L.L. Miller, and J.R. Valentine, Electrochemically controlled
binding and release of protonated dimethyldopamine and other cations from
poly( N-methyl-pyrrole)/polyanion composite redox polymers. Journal of
Electroanalytical Chemistry and Interfacial Electrochemistry, 1989. 261(1): p.
147-164.

175
82.

Pilla, A.A., Mechanisms and therapeutic applications of time varying and
static magnetic fields., in Biological and medical aspects of electromagnetic
fields, F. Barnes and B. Greenebaum, Editors. 2006, CRC: Boca Raton, FL. p.
351-411.

83.

Ganesan, K., et al., Low frequency pulsed electromagnetic field — A viable
alternative therapy for arthritis. Indian Journal of Experimental Biology
(IJEB) 2009. 47(12): p. 939-948.

84.

Wu, C.-H., et al., Trojan-Horse Nanotube On-Command Intracellular Drug
Delivery. Nano Letters, 2012. 12(11): p. 5475-5480.

85.

Ding, G.R., et al., Extremely low frequency magnetic fields and the promotion
of H2O2‐induced cell death in HL‐60 cells. International Journal of Radiation
Biology, 2004. 80(4): p. 317-324.

86.

Zmyślony, M., et al., Effects of in vitro exposure to power frequency magnetic
fields on UV-induced DNA damage of rat lymphocytes. Bioelectromagnetics,
2004. 25(7): p. 560-562.

87.

Jajte, J., et al., Effect of 7 mT static magnetic field and iron ions on rat
lymphocytes:

apoptosis,

necrosis

and

free

radical

processes.

Bioelectrochemistry, 2002. 57(2): p. 107-111.
88.

Zmyślony, M., et al., Acute exposure to 930 MHz CW electromagnetic
radiation in vitro affects reactive oxygen species level in rat lymphocytes
treated by iron ions. Bioelectromagnetics, 2004. 25(5): p. 324-328.

89.

Kirtman, B., et al., Polarization of one-dimensional periodic systems in a
static electric field: Sawtooth potential treatment revisited. The Journal of
Chemical Physics, 2009. 131(4).

90.

Bishop, A. and J.E. Anderson, NO signaling in the CNS: from the
physiological to the pathological. Toxicology, 2005. 208(2): p. 193-205.

91.

Radi, R., Nitric oxide, oxidants, and protein tyrosine nitration. Proc Natl Acad
Sci U S A, 2004. 101(12): p. 4003-8.

176
92.

Liu, D., et al., The role of reactive nitrogen species in secondary spinal cord
injury: formation of nitric oxide, peroxynitrite, and nitrated protein. J
Neurochem, 2000. 75(5): p. 2144-54.

93.

Liu, D., et al., Peroxynitrite generated at the level produced by spinal cord
injury induces peroxidation of membrane phospholipids in normal rat cord:
Reduction by a metalloporphyrin. J. Neurotrauma, 2005. 22(10): p. 11231133.

94.

Scott, G.S., C. Szabó, and D.C. Hooper, Poly(ADP-ribose) polymerase
activity contributes to peroxynitrite-induced spinal cord neuronal cell death in
vitro. J Neurotrauma 2004. 21(9): p. 1255-1263.

95.

Xiong, Y., A.G. Rabchevsky, and E.D. Hall, Role of peroxynitrite in
secondary oxidative

damage after

spinal cord

injury. Journal

of

Neurochemistry, 2007. 100(3): p. 639-649.
96.

Genovese, T., et al., Evidence for the Role of Mitogen-Activated Protein
Kinase Signaling Pathways in the Development of Spinal Cord Injury. Journal
of Pharmacology and Experimental Therapeutics, 2008. 325(1): p. 100-114.

97.

Bhat, N.R., et al., Extracellular Signal-Regulated Kinase and p38 Subgroups
of Mitogen-Activated Protein Kinases Regulate Inducible Nitric Oxide
Synthase and Tumor Necrosis Factor-α Gene Expression in EndotoxinStimulated Primary Glial Cultures. The Journal of Neuroscience, 1998. 18(5):
p. 1633-1641.

98.

Wang, M.-J., et al., c-Jun N-terminal kinase and, to a lesser extent, p38
mitogen-activated protein kinase regulate inducible nitric oxide synthase
expression in hyaluronan fragments-stimulated BV-2 microglia. Journal of
Neuroimmunology, 2004. 146(1–2): p. 50-62.

99.

Xu, Z., et al., ERK1/2 and p38 mitogen-activated protein kinase mediate
iNOS-induced spinal neuron degeneration after acute traumatic spinal cord
injury. Life Sciences, 2006. 79(20): p. 1895-1905.

177
100.

Xie, Z., C.J. Smith, and L.J. Van Eldik, Activated glia induce neuron death
via MAP kinase signaling pathways involving JNK and p38. Glia, 2004. 45(2):
p. 170-179.

101.

Torres, M. and H.J. Forman, Redox signaling and the MAP kinase pathways.
BioFactors, 2003. 17(1-4): p. 287-296.

102.

McCubrey, J.A., M.M. LaHair, and R.A. Franklin, Reactive oxygen speciesinduced activation of the MAP kinase signaling pathways. Antioxidants and
Redox Signaling, 2006. 8(9-10): p. 1775-1789.

103.

Guyton, K.Z., et al., Activation of mitogen-activated protein kinase by H2O2.
Role in cell survival following oxidant injury. J Biol Chem, 1996. 271(8): p.
4138-42.

104.

Tobiume, K., et al., ASK1 is required for sustained activations of JNK/p38
MAP kinases and apoptosis. EMBO reports, 2001. 2(3): p. 222-228.

105.

Kamata, H., et al., Reactive Oxygen Species Promote TNFα-Induced Death
and Sustained JNK Activation by Inhibiting MAP Kinase Phosphatases. Cell,
2005. 120(5): p. 649-661.

106.

Hou, N., et al., Reactive Oxygen Species-Mediated Pancreatic {beta}-Cell
Death Is Regulated by Interactions between Stress-Activated Protein Kinases,
p38 and c-Jun N-Terminal Kinase, and Mitogen-Activated Protein Kinase
Phosphatases. Endocrinology, 2008. 149(4): p. 1654-1665.

107.

Choi, B.H., et al., Protein kinase Cδ-mediated proteasomal degradation of
MAP kinase phosphatase-1 contributes to glutamate-induced neuronal cell
death. J Cell Sci 2006. 119: p. 1329-1340.

108.

Chan, E.D. and D.W. Riches, Potential role of the JNK/SAPK signal
transduction pathway in the induction of iNOS by TNF-alpha. Biochem
Biophys Res Commun, 1998. 253(3): p. 790-6.

109.

Chan, E.D., et al., Evaluation of the role of mitogen-activated protein kinases
in the expression of inducible nitric oxide synthase by IFN-gamma and TNFalpha in mouse macrophages. J Immunol, 1999. 162(1): p. 415-22.

178
110.

Chan, E.D. and D.W. Riches, IFN-gamma + LPS induction of iNOS is
modulated by ERK, JNK/SAPK, and p38(mapk) in a mouse macrophage cell
line. Am J Physiol Cell Physiol, 2001. 280(3): p. C441-50.

111.

Swantek, J.L., M.H. Cobb, and T.D. Geppert, Jun N-terminal kinase/stressactivated protein kinase (JNK/SAPK) is required for lipopolysaccharide
stimulation of tumor necrosis factor alpha (TNF-alpha) translation:
glucocorticoids inhibit TNF-alpha translation by blocking JNK/SAPK. Mol
Cell Biol, 1997. 17(11): p. 6274-82.

112.

Lasa, M., et al., Dexamethasone Causes Sustained Expression of MitogenActivated Protein Kinase (MAPK) Phosphatase 1 and Phosphatase-Mediated
Inhibition of MAPK p38. Mol Cell Biol, 2002. 22(22): p. 7802-7811.

113.

Medeiros, R., et al., Connecting TNF-alpha signaling pathways to iNOS
expression in a mouse model of Alzheimer's disease: relevance for the
behavioral and synaptic deficits induced by amyloid beta protein. J Neurosci,
2007. 27(20): p. 5394-404.

114.

Huo, Y., et al., Dexamethasone inhibits the Nox-dependent ROS production
via suppression of MKP-1-dependent MAPK pathways in activated microglia.
BMC Neurosci, 2011. 12: p. 49.

115.

Ozaki, T., et al., Dexamethasone inhibits the induction of iNOS gene
expression through destabilization of its mRNA in proinflammatory cytokinestimulated hepatocytes. Shock, 2010. 33(1): p. 64-9.

116.

Matsumura, M., et al., Dexamethasone suppresses iNOS gene expression by
inhibiting NF-κB in vascular smooth muscle cells. Life Sciences, 2001. 69(9):
p. 1067-1077.

117.

Korhonen, R., et al., Dexamethasone Inhibits Inducible Nitric-Oxide Synthase
Expression and Nitric Oxide Production by Destabilizing mRNA in
Lipopolysaccharide-Treated Macrophages. Molecular Pharmacology, 2002.
62(3): p. 698-704.

179
118.

Walker, G., J. Pfeilschifter, and D. Kunz, Mechanisms of suppression of
inducible nitric-oxide synthase (iNOS) expression in interferon (IFN)-gammastimulated RAW 264.7 cells by dexamethasone. Evidence for glucocorticoidinduced degradation of iNOS protein by calpain as a key step in posttranscriptional regulation. J Biol Chem, 1997. 272(26): p. 16679-87.

119.

Golde, S., et al., Decreased iNOS synthesis mediates dexamethasone-induced
protection of neurons from inflammatory injury in vitro. European Journal of
Neuroscience, 2003. 18(9): p. 2527-2537.

120.

Xu, W., et al., Increased production of reactive oxygen species contributes to
motor neuron death in a compression mouse model of spinal cord injury.
Spinal Cord, 2005. 43(4): p. 204-13.

121.

Hassler, S.N., K.M. Johnson, and C.E. Hulsebosch, Reactive oxygen species
and lipid peroxidation inhibitors reduce mechanical sensitivity in a chronic
neuropathic pain model of spinal cord injury in rats. J Neurochem, 2014.
131(4): p. 413-7.

122.

Diaz-Ruiz, A., et al., Cyclosporin-A inhibits inducible nitric oxide synthase
activity and expression after spinal cord injury in rats. Neurosci Lett, 2004.
357(1): p. 49-52.

123.

Chatzipanteli, K., et al., Temporal and segmental distribution of constitutive
and inducible nitric oxide synthases after traumatic spinal cord injury: effect
of aminoguanidine treatment. J Neurotrauma, 2002. 19(5): p. 639-51.

124.

Kwon, D.-J., et al., Suppression of iNOS and COX-2 expression by
flavokawain A via blockade of NF-κB and AP-1 activation in RAW 264.7
macrophages. Food and Chemical Toxicology, 2013. 58(0): p. 479-486.

125.

Satake, K., et al., Nitric oxide via macrophage iNOS induces apoptosis
following traumatic spinal cord injury. Brain Res Mol Brain Res, 2000. 85(12): p. 114-122.

126.

Mukherjee, P., et al., Development of nitric oxide synthase inhibitors for
neurodegeneration and neuropathic pain. Chemical Society Reviews, 2014.
43(19): p. 6814-6838.

180
127.

Hirakawa, A., et al., Pyrroloquinoline quinone attenuates iNOS gene
expression in the injured spinal cord. Biochemical and Biophysical Research
Communications, 2009. 378(2): p. 308-312.

128.

Isaksson, J., M. Farooque, and Y. Olsson, Improved functional outcome after
spinal cord injury in iNOS-deficient mice. Spinal Cord, 2004. 43(3): p. 167170.

129.

Pearse, D.D., et al., Comparison of iNOS inhibition by antisense and
pharmacological inhibitors after spinal cord injury. J Neuropathol Exp
Neurol, 2003. 62(11): p. 1096-107.

130.

Maggio, D.M., et al., Acute molecular perturbation of inducible nitric oxide
synthase with an antisense approach enhances neuronal preservation and
functional recovery after contusive spinal cord injury. J Neurotrauma, 2012.
29(12): p. 2244-9.

131.

Mertas, A., et al., N-[3-(Aminomethyl)benzyl]acetamidine (1400W) as a
Potential Immunomodulatory Agent. Oxidative Medicine and Cellular
Longevity, 2014. 2014: p. 6.

132.

Gwak, Y.S., et al., Spatial and temporal activation of spinal glial cells: role of
gliopathy in central neuropathic pain following spinal cord injury in rats. Exp
Neurol, 2012. 234(2): p. 362-72.

133.

Baldwin, S.A., et al., Alterations in temporal/spatial distribution of GFAPand vimentin-positive astrocytes after spinal cord contusion with the New
York University spinal cord injury device. J Neurotrauma, 1998. 15(12): p.
1015-26.

134.

Nesic, O., et al., Transcriptional profiling of spinal cord injury-induced
central neuropathic pain. J Neurochem, 2005. 95(4): p. 998-1014.

135.

Wu, D., et al., Co-expression of radial glial marker in macrophages/microglia
in rat spinal cord contusion injury model. Brain Res, 2005. 1051(1-2): p. 1838.

181
136.

Li, Z., E.L. Hogan, and N.L. Banik, Role of calpain in spinal cord injury:
increased mcalpain immunoreactivity in spinal cord after compression injury
in the rat. Neurochemistry International, 1995. 27(4–5): p. 425-432.

137.

Jung, K., et al., Upregulation of phospholipase D1 in the spinal cords of rats
with clip compression injury. Neurosci Lett, 2003. 336(2): p. 126-30.

138.

Chen, J., S.-Y. Leong, and M. Schachner, Differential expression of cell fate
determinants in neurons and glial cells of adult mouse spinal cord after
compression injury. European Journal of Neuroscience, 2005. 22(8): p. 18951906.

139.

Chadi, G., et al., Experimental Models of Partial Lesion of Rat Spinal Cord to
Investigate Neurodegeneration, Glial Activation, and Behavior Impairments.
International Journal of Neuroscience, 2001. 111(3-4): p. 137-165.

140.

Tian, D.S., et al., Attenuation of astrogliosis by suppressing of microglial
proliferation with the cell cycle inhibitor olomoucine in rat spinal cord injury
model. Brain Res, 2007. 1154: p. 206-14.

141.

Baloui, H., et al., Upregulation in rat spinal cord microglia of the nonintegrin
laminin receptor 37 kDa-LRP following activation by a traumatic lesion or
peripheral injury. J Neurotrauma, 2009. 26(2): p. 195-207.

142.

Koshinaga, M. and S.R. Whittemore, The temporal and spatial activation of
microglia in fiber tracts undergoing anterograde and retrograde degeneration
following spinal cord lesion. J Neurotrauma, 1995. 12(2): p. 209-22.

143.

Verdú, E., et al., Olfactory ensheathing cells transplanted in lesioned spinal
cord prevent loss of spinal cord parenchyma and promote functional
recovery. Glia, 2003. 42(3): p. 275-286.

144.

Matsumoto, S., et al., The temporal profile of the reaction of microglia,
astrocytes, and macrophages in the delayed onset paraplegia after transient
spinal cord ischemia in rabbits. Anesth Analg, 2003. 96(6): p. 1777-84, table
of contents.

182
145.

Gomes-Leal, W., et al., Astrocytosis, microglia activation, oligodendrocyte
degeneration, and pyknosis following acute spinal cord injury. Exp Neurol,
2004. 190(2): p. 456-67.

146.

Dihne, M., et al., Time course of glial proliferation and glial apoptosis
following excitotoxic CNS injury. Brain Res, 2001. 902(2): p. 178-89.

147.

Zhong, Y. and R.V. Bellamkonda, Dexamethasone-coated neural probes elicit
attenuated inflammatory response and neuronal loss compared to uncoated
neural probes. Brain Res, 2007. 1148: p. 15-27.

148.

Fitch, M.T. and J. Silver, Activated macrophages and the blood-brain barrier:
Inflammation after CNS injury leads to increases in putative inhibitory
molecules. Exp. Neurol., 1997. 148: p. 587-603.

149.

Busch, S.A. and J. Silver, The role of extracellular matrix in CNS
regeneration. Curr Opin Neurobiol, 2007. 17(1): p. 120-7.

150.

Fitch, M.T. and J. Silver, Inflammation and the glial scar: Factors at the site
of injury that influence regeneration in the central nervous system., in
Degeneration and regeneration in the nervous system., N.R. Saunders and
K.M. Dziegielewska, Editors. 2000, Harwood Academic Press. p. 77-92.

151.

Fitch, M.T. and J. Silver, CNS injury, glial scars, and inflammation:
Inhibitory extracellular matrices and regeneration failure. Exp Neurol, 2008.
209(2): p. 294-301.

152.

Fujita, K., et al., Increase of glial fibrillary acidic protein fragments in the
spinal cord of motor neuron degeneration mutant mouse. Brain Res, 1998.
785(1): p. 31-40.

153.

Bracchi-Ricard, V., et al., Inhibition of astroglial NF-kappaB enhances
oligodendrogenesis following spinal cord injury. J Neuroinflammation, 2013.
10(1): p. 92.

154.

Liedtke, W., et al., GFAP is necessary for the integrity of CNS white matter
architecture and long-term maintenance of myelination. Neuron, 1996. 17(4):
p. 607-615.

183
155.

Brenner, M., Role of GFAP in CNS injuries. Neurosci Lett, 2014. 565: p. 713.

156.

Jung, K., et al., Upregulation of phospholipase D1 in the spinal cords of rats
with clip compression injury. Neurosci Lett, 2003. 336(2): p. 126-30.

157.

Li, Z., E.L. Hogan, and N.L. Banik, Role of calapin in spinal cord injury:
increased mcalpain immunoreactivity in spinal cord after compression injury
in the rat. Neurochem. Int., 1995. 27: p. 425–432.

158.

Xu, M., Y.K. Ng, and S.K. Leong, Neuroprotective and neurodestructive
functions of nitric oxide after spinal cord hemisection. Exp Neurol, 2000.
161(2): p. 472-80.

159.

Friday, E., J. Ledet, and F. Turturro, Response to dexamethasone is glucosesensitive in multiple myeloma cell lines. J Exp Clin Cancer Res, 2011. 30: p.
81.

160.

Kitajima, T., et al., A novel mechanism of glucocorticoid-induced immune
suppression: the inhibiton of T cell-mediated terminal maturation of a murine
dendritic cell line. J Clin Invest, 1996. 98(1): p. 142-7.

161.

Murray, C.L., D.T. Skelly, and C. Cunningham, Exacerbation of CNS
inflammation and neurodegeneration by systemic LPS treatment is
independent of circulating IL-1beta and IL-6. J Neuroinflammation, 2011. 8:
p. 50.

162.

Ruiz, L.M., et al., Dexamethasone Inhibits Apoptosis of Human Neutrophils
Induced by Reactive Oxygen Species. Inflammation, 2002. 26(5): p. 215-222.

163.

Sanner, B.M., et al., Effects of glucocorticoids on generation of reactive
oxygen species in platelets. Steroids, 2002. 67(8): p. 715-9.

164.

Lingaiah, H.B., R. Thamaraiselvan, and B. Periyasamy, Dexamethasone
induced alterations in lipid peroxidation, antioxidants, membrane bound
ATPase in wistar albino rats. International Journal of Pharmacy &
Pharmaceutical Sciences, 2012. 4.

184
165.

Kraaij, M.D., et al., Dexamethasone increases ROS production and T cell
suppressive

capacity

by

anti-inflammatory

macrophages.

Molecular

Immunology, 2011. 49(3): p. 549-557.
166.

Wang, L., K.J. Colodner, and M.B. Feany, Protein Misfolding and Oxidative
Stress Promote Glial-Mediated Neurodegeneration in an Alexander Disease
Model. The Journal of Neuroscience, 2011. 31(8): p. 2868-2877.

167.

Muntane, G., et al., Glial fibrillary acidic protein is a major target of
glycoxidative and lipoxidative damage in Pick's disease. J Neurochem, 2006.
99(1): p. 177-85.

168.

Morgan, T.E., et al., Increased transcription of the astrocyte gene GFAP
during middle-age is attenuated by food restriction: implications for the role
of oxidative stress. Free Radic Biol Med, 1997. 23(3): p. 524-8.

169.

Theriault, E., et al., Connexin43 and astrocytic gap junctions in the rat spinal
cord after acute compression injury. J Comp Neurol, 1997. 382(2): p. 199214.

170.

Yang, P., et al., Expression of nestin and glial fibrillary acidic protein in
injured spinal cord of adult rats at different time]. Zhongguo Xiu Fu Chong
Jian Wai Ke Za Zhi, 2005. 19(6): p. 411-5.

171.

Fitch, M.T. and J. Silver, Glial Cells, Inflammation, and CNS Trauma:
Modulation of the Inflammatory Environment After Injury Can Lead to LongDistance Regeneration Beyond the Glial Scar, in CNS Regeneration (Second
Edition), J.H.K.H. Tuszynski, Editor. 2008, Academic Press: San Diego. p.
59-94

172.

Myer, D.J., et al., Essential protective roles of reactive astrocytes in traumatic
brain injury. Brain, 2006. 129(Pt 10): p. 2761-72.

173.

George, E.R., et al., Failure of methylprednisolone to improve the outcome of
spinal cord injuries. Am Surg, 1995. 61(8): p. 659-63; discussion 663-4.

174.

Lee, H.C., et al., Pitfalls in treatment of acute cervical spinal cord injury
using high-dose methylprednisolone: a retrospect audit of 111 patients. Surg
Neurol, 2007. 68 Suppl 1: p. S37-41; discussion S41-2.

185
175.

Pointillart, V., et al., Pharmacological therapy of spinal cord injury during the
acute phase. Spinal Cord, 2000. 38(2): p. 71-6.

176.

Bracken, M.B., High dose methylprednisolone must be given for 24 or 48
hours after acute spinal cord injury. Bmj, 2001. 322(7290): p. 862-3.

177.

Bracken, M.B., Steroids for acute spinal cord injury. Cochrane Database Syst
Rev, 2012. 1: p. Cd001046.

178.

Kuchner, E.F., R.R. Hansebout, and H.M. Pappius, Effects of dexamethasone
and of local hypothermia on early and late tissue electrolyte changes in
experimental spinal cord injury. J Spinal Disord, 2000. 13(5): p. 391-8.

179.

Lewin, M.G., R.R. Hansebout, and H.M. Pappius, Chemical characteristics of
traumatic spinal cord edema in cats. Effects of steroids on potassium
depletion. J Neurosurg, 1974. 40(1): p. 65-75.

180.

Dorsett, Y. and T. Tuschl, siRNAs: applications in functional genomics and
potential as therapeutics. Nat Rev Drug Discov, 2004. 3(4): p. 318-29.

181.

Reischl, D. and A. Zimmer, Drug delivery of siRNA therapeutics: potentials
and limits of nanosystems. Nanomedicine, 2009. 5(1): p. 8-20.

182.

Kilic, E., et al., Role of Nogo-A in neuronal survival in the reperfused
ischemic brain. J Cereb Blood Flow Metab, 2010. 30(5): p. 969-984.

183.

Otsuka, S., et al., Delayed intrathecal delivery of RhoA siRNA to the contused
spinal cord inhibits allodynia, preserves white matter, and increases
serotonergic fiber growth. J Neurotrauma, 2011. 28(6): p. 1063-76.

184.

Qu, Y., et al., Silencing ephrinB3 improves functional recovery following
spinal cord injury. Mol Med Rep, 2014. 9(5): p. 1761-6.

185.

Ando, T., et al., Photomechanical wave-driven delivery of siRNAs targeting
intermediate filament proteins promotes functional recovery after spinal cord
injury in rats. PLoS One, 2012. 7(12): p. e51744.

186.

Tao, X., et al., Role of telomerase reverse transcriptase in glial scar formation
after spinal cord injury in rats. Neurochem Res, 2013. 38(9): p. 1914-20.

187.

Wong, J.W.J., Knocking Down Glycosaminoglycan Synthesis. The Journal of
Neuroscience, 2008. 28(11): p. 2688-2689.

186
188.

Lee, J.Y., et al., Matrix Metalloproteinase-3 Promotes Early Blood-Spinal
Cord Barrier Disruption and Hemorrhage and Impairs Long-Term
Neurological Recovery after Spinal Cord Injury. Am J Pathol, 2014.

189.

Howard, K.A., et al., RNA interference in vitro and in vivo using a novel
chitosan/siRNA nanoparticle system. Mol Ther, 2006. 14(4): p. 476-84.

190.

Koping-Hoggard, M., et al., Chitosan as a nonviral gene delivery system.
Structure-property

relationships

and

characteristics

compared

with

polyethylenimine in vitro and after lung administration in vivo. Gene Ther,
2001. 8(14): p. 1108-21.
191.

Ruan, G.X., et al., Hepatic-targeted gene delivery using cationic mannan
vehicle. Mol Pharm, 2014. 11(10): p. 3322-9.

192.

Ji, A.M., et al., Functional gene silencing mediated by chitosan/siRNA
nanocomplexes. Nanotechnology, 2009. 20(40): p. 405103.

193.

Fernandes, J.C., et al., Low molecular weight chitosan conjugated with folate
for siRNA delivery in vitro: optimization studies. Int J Nanomedicine, 2012. 7:
p. 5833-45.

194.

Kong, F., et al., Phosphorylatable short peptide conjugated low molecular
weight chitosan for efficient siRNA delivery and target gene silencing. Int J
Pharm, 2012. 422(1-2): p. 445-53.

195.

Lee, J., et al., T cell-specific siRNA delivery using antibody-conjugated
chitosan nanoparticles. Bioconjug Chem, 2012. 23(6): p. 1174-80.

196.

Howard, K.A., et al., Chitosan/siRNA nanoparticle-mediated TNF-alpha
knockdown in peritoneal macrophages for anti-inflammatory treatment in a
murine arthritis model. Mol Ther, 2009. 17(1): p. 162-8.

197.

Malmo J, et al., Nanoparticle Mediated P-Glycoprotein Silencing for
Improved Drug Delivery across the Blood-Brain Barrier: A siRNA-Chitosan
Approach. PLoS ONE, 2013. 8(1): p. e54182.

198.

Mittnacht, U., et al., Chitosan/siRNA nanoparticles biofunctionalize nerve
implants and enable neurite outgrowth. Nano Lett, 2010. 10(10): p. 3933-9.

187
199.

Cho, Y., R. Shi, and R.B. Borgens, Chitosan produces potent neuroprotection
and physiological recovery following traumatic spinal cord injury. J Exp Biol,
2010. 213(9): p. 1513-1520.

200.

Zhang, J., C. Tang, and C. Yin, Galactosylated trimethyl chitosan-cysteine
nanoparticles

loaded

with

Map4k4

siRNA

for

targeting

activated

macrophages. Biomaterials, 2013. 34(14): p. 3667-77.
201.

Gao, J.-Q., et al., Gene-carried chitosan-linked-PEI induced high gene
transfection efficiency with low toxicity and significant tumor-suppressive
activity. International Journal of Pharmaceutics, 2010. 387(1–2): p. 286-294.

202.

Gaspar, V.M., et al., Biofunctionalized nanoparticles with pH-responsive and
cell penetrating blocks for gene delivery. Nanotechnology, 2013. 24(27): p.
275101.

203.

Dehousse,

V.,

et

al.,

Comparison

of

chitosan/siRNA

and

trimethylchitosan/siRNA complexes behaviour in vitro. Int J Biol Macromol,
2010. 46(3): p. 342-9.
204.

Katas, H. and H.O. Alpar, Development and characterisation of chitosan
nanoparticles for siRNA delivery. Journal of Controlled Release, 2006.
115(2): p. 216-225.

205.

Sato, T. and Y. Matsuda, Macromolecular Assemblies in Solution:
Characterization by Light Scattering. Polym. J, 2009. 41(4): p. 241-251.

206.

Andersen, M.O., et al., Delivery of siRNA from lyophilized polymeric
surfaces. Biomaterials, 2008. 29(4): p. 506-12.

207.

Mao, H., et al., Chitosan-DNA nanoparticles as gene carriers: synthesis,
characterization and transfection efficiency. J Controlled Release, 2001.
70(3): p. 399-421.

208.

Techaarpornkul, S., et al., Chitosan-Mediated siRNA Delivery In Vitro: Effect
of Polymer Molecular Weight, Concentration and Salt Forms. AAPS
PharmSciTech, 2010. 11(1): p. 64-72.

188
209.

Kim, T.H., et al., Mannosylated chitosan nanoparticle-based cytokine gene
therapy suppressed cancer growth in BALB/c mice bearing CT-26 carcinoma
cells. Mol Cancer Ther. , 2006. 5(7): p. 1723-32.

210.

Liu, X., et al., The influence of polymeric properties on chitosan/siRNA
nanoparticle formulation and gene silencing. Biomaterials, 2007. 28(6): p.
1280-8.

211.

Malmo, J., et al., siRNA delivery with chitosan nanoparticles: Molecular
properties favoring efficient gene silencing. J Control Release, 2012. 158(2):
p. 261-8.

212.

Koping-Hoggard, M., et al., Improved chitosan-mediated gene delivery based
on easily dissociated chitosan polyplexes of highly defined chitosan
oligomers. Gene Ther, 2004. 11(19): p. 1441-52.

213.

Kigerl, K.A., et al., Identification of two distinct macrophage subsets with
divergent effects causing either neurotoxicity or regeneration in the injured
mouse spinal cord. J Neurosci, 2009. 29(43): p. 13435-44.

214.

Wu, A.C., et al., Unraveling macrophage contributions to bone repair.
BoneKEy Rep, 2013. 2.

215.

David, S. and A. Kroner, Repertoire of microglial and macrophage responses
after spinal cord injury. Nat Rev Neurosci, 2011. 12(7): p. 388-99.

216.

Kuo, H.-S., et al., Acid Fibroblast Growth Factor and Peripheral Nerve
Grafts Regulate Th2 Cytokine Expression, Macrophage Activation, Polyamine
Synthesis, and Neurotrophin Expression in Transected Rat Spinal Cords. The
Journal of Neuroscience, 2011. 31(11): p. 4137-4147.

217.

Satake, K., et al., Nitric oxide via macrophage iNOS induces apoptosis
following traumatic spinal cord injury. Brain Res Mol Brain Res, 2000. 85(12): p. 114-22.

218.

Shechter, R., et al., Recruitment of Beneficial M2 Macrophages to Injured
Spinal Cord Is Orchestrated by Remote Brain Choroid Plexus. Immunity,
2013. 38(3): p. 555-569.

189
219.

Greenhalgh, A.D. and S. David, Differences in the Phagocytic Response of
Microglia and Peripheral Macrophages after Spinal Cord Injury and Its
Effects on Cell Death. The Journal of Neuroscience, 2014. 34(18): p. 63166322.

220.

Larson, S.D., et al., Effectiveness of siRNA uptake in target tissues by various
delivery methods. Journal of Surgical Research, 2007. 137(2): p. 189-190.

221.

Luo, M.C., et al., An efficient intrathecal delivery of small interfering RNA to
the spinal cord and peripheral neurons. Mol Pain, 2005. 1: p. 29.

222.

Santel, A., et al., A novel siRNA-lipoplex technology for RNA interference in
the mouse vascular endothelium. Gene Ther, 2006. 13(16): p. 1222-34.

223.

Jain, S. and M.M. Amiji, Macrophage-Targeted Nanoparticle Delivery
Systems, in Multifunctional nanoparticles for drug delivery applications:
imaging, targeting, and delivery nanoparticles for drug delivery applications:
imaging, targeting, and delivery.

224.

Schäfer, V., et al., Phagocytosis of nanoparticles by human immunodeficiency
virus (HIV)-infected macrophages: a possibility for antiviral drug targeting.
Pharm Res, 1992. 9(4): p. 541-546.

225.

Ahsan, F., et al., Targeting to macrophages: role of physicochemical
properties of particulate carriers—liposomes and microspheres—on the
phagocytosis by macrophages. Journal of Controlled Release, 2002. 79(1–3):
p. 29-40.

226.

Angyal, A., et al., CD16/32-specific biotinylated 2.4G2 single-chain Fv
complexed with avidin–FITC enhances FITC-specific humoral immune
response in vivo in a CD16-dependent manner. International Immunology,
2010. 22(2): p. 71-80.

227.

Ashraf, S.Q., et al., Humanised IgG1 antibody variants targeting membranebound carcinoembryonic antigen by antibody-dependent cellular cytotoxicity
and phagocytosis. Br J Cancer, 2009. 101(10): p. 1758-1768.

190
228.

Munn, D.H., M. McBride, and N.K. Cheung, Role of low-affinity Fc receptors
in antibody-dependent tumor cell phagocytosis by human monocyte-derived
macrophages. Cancer Res, 1991. 51(4): p. 1117-23.

229.

Hirai,

T.,

et

al.,

The

prevalence

and

phenotype

of

activated

microglia/macrophages within the spinal cord of the hyperostotic mouse
(twy/twy) changes in response to chronic progressive spinal cord
compression: implications for human cervical compressive myelopathy. PLoS
One, 2013. 8(5): p. e64528.
230.

Van Vuuren, A.J., et al., CD64-directed immunotoxin inhibits arthritis in a
novel CD64 transgenic rat model. J Immunol, 2006. 176(10): p. 5833-8.

231.

Vogel, D.Y., et al., Macrophages in inflammatory multiple sclerosislesions
have an intermediate activation status. Journal of Neuroinflammation, 2013.
10: p. 35-46.

232.

Min, K.-J., et al., Spatial and temporal correlation in progressive
degeneration of neurons and astrocytes in contusion-induced spinal cord
injury. Journal of Neuroinflammation, 2012. 9(1): p. 1-13.

233.

Leidi, M., et al., M2 macrophages phagocytose rituximab-opsonized leukemic
targets more efficiently than m1 cells in vitro. J Immunol, 2009. 182(7): p.
4415-22.

234.

Kim, S.S., et al., Targeted delivery of siRNA to macrophages for antiinflammatory treatment. Mol Ther, 2010. 18(5): p. 993-1001.

235.

He, C., et al., Multifunctional polymeric nanoparticles for oral delivery of
TNF-alpha siRNA to macrophages. Biomaterials, 2013. 34(11): p. 2843-54.

236.

Oliveira, M.I., et al., Chitosan drives anti-inflammatory macrophage
polarisation and pro-inflammatory dendritic cell stimulation. Eur Cell Mater,
2012. 24: p. 136-52; discussion 152-3.

237.

Hwang, S.M., et al., Chitinous materials inhibit nitric oxide production by
activated RAW 264.7 macrophages. Biochem Biophys Res Commun, 2000.
271(1): p. 229-33.

191
238.

Porporatto, C., et al., Chitosan induces different l-arginine metabolic
pathways in resting and inflammatory macrophages. Biochemical and
Biophysical Research Communications, 2003. 304(2): p. 266-272.

239.

Mori, T., et al., Mechanism of macrophage activation by chitin derivatives. J
Vet Med Sci, 2005. 67(1): p. 51-6.

240.

Murray, P.J. and T.A. Wynn, Protective and pathogenic functions of
macrophage subsets. Nat Rev Immunol, 2011. 11(11): p. 723-37.

241.

Guilliams, M., et al., The function of Fc[gamma] receptors in dendritic cells
and macrophages. Nat Rev Immunol, 2014. 14(2): p. 94-108.

242.

Rosales, C. and E. Uribe-Querol, Fc receptors: Cell activators of antibody
functions. Advances in Bioscience and Biotechnology, 2013. 4: p. 21-33.

243.

Rey-Giraud, F., M. Hafner, and C.H. Ries, In Vitro Generation of MonocyteDerived Macrophages under Serum-Free Conditions Improves Their Tumor
Promoting Functions. PLoS ONE, 2012. 7(8): e42656.

244.

Shibata, Y., W.J. Metzger, and Q.N. Myrvik, Chitin particle-induced cellmediated immunity is inhibited by soluble mannan: mannose receptormediated phagocytosis initiates IL-12 production. J Immunol, 1997. 159(5): p.
2462-7.

245.

Santegoets, K.C.M., et al., Fc Gamma Receptor IIb on GM-CSF Macrophages
Controls Immune Complex Mediated Inhibition of Inflammatory Signals.
PLoS ONE, 2014. 9(10): e110966.

246.

Huang, Z.Y., et al., Differential kinase requirements in human and mouse Fcgamma receptor phagocytosis and endocytosis. J Leukoc Biol, 2006. 80(6): p.
1553-62.

247.

Lee, S., et al., Solid polymeric microparticles enhance the delivery of siRNA
to macrophages in vivo. Nucleic Acids Res, 2009. 37(22): p. e145.

248.

Kirby, A.J. and P.W. Lancaster, Structure and efficiency in intramolecular
and enzymic catalysis. Catalysis of amide hydrolysis by the carboxy-group of
substituted maleamic acids. Journal of the Chemical Society, Perkin
Transactions 2, 1972(9): p. 1206-1214.

192
249.

Rozema, D.B., et al., Endosomolysis by Masking of a Membrane-Active Agent
(EMMA) for Cytoplasmic Release of Macromolecules. Bioconjugate
Chemistry, 2002. 14(1): p. 51-57.

250.

Wakefield, D.H., et al., Membrane Activity and Transfection Ability of
Amphipathic Polycations as a Function of Alkyl Group Size. Bioconjugate
Chemistry, 2005. 16(5): p. 1204-1208.

251.

McWhorter, F.Y., et al., Modulation of macrophage phenotype by cell shape.
Proceedings of the National Academy of Sciences, 2013. 110(43): p. 1725317258.

193

VITA

193

VITA

Wen Gao was born and raised in Beijing, China. W en completed her undergraduate in
Xian International Studies University in 2006. After graduate, she was employed as
Project Assistant for Exhibitions and Conventions. In 2009, She came to United State
and pursue her study in science. She enrolled in the graduate program in Department of
Basic Medical Sciences at Purdue University and joined to Dr. Richard Borgens lab in
Center for Paralysis Research. Her research concentration is on nanotechnology and
polymer science in drug delivery for spinal cord injury treatment. Up to this date, Wen is
working together with her advisor and colleagues on several patent disclosures based on
her research of interest. She expects to graduate at Purdue and earn her Ph.D degree in
Basic Medical Science in December 2014.

